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ABSTRACT 
 
DIETARY OLIGOSACCHARIDES ARE DIFFERENTIALLY METABOLIZED 
BY COMMENSAL MICROBIOTA WITHIN IN VITRO MODEL SYSTEMS 
 
SEPTEMBER 2019 
 
EZGI ÖZCAN 
B.S., MIDDLE EAST TECHNICAL UNIVERSITY, TURKEY 
M.S., YEDITEPE UNIVERSITY, TURKEY 
Ph.D., UNIVERSITY OF MASSACHUSETTS, AMHERST, MA 
Directed by: Professor David A. Sela 
 
Our diet contains indigestible carbohydrates that are available for microbial 
metabolism within the gastrointestinal tract. These carbohydrate sources are 
oligosaccharides found in plants and human milk. Oligosaccharide utilization phenotypes 
are often consistent with the ecological niche that microbes occupy (e.g. adult gut, infant 
gut, plants). This study represents an in-depth metabolic analysis for utilization of human 
milk oligosaccharides (HMOs) including lacto-N-tetraose (LNT) and lacto-N-neotetraose 
(LNnT), and cranberry oligosaccharides (i.e. xyloglucans) within in vitro modeled systems. 
These model systems include microplate systems for pure cultures as well as an adapted 
bioreactor system to mimic microbial interactions within the gut.  
Infant-colonizing Bifidobacterium longum subsp. infantis (B. infantis) metabolized 
both LNT and LNnT that vary by a single glycosidic linkage with inefficient metabolism 
 vii 
 
 
resulting in increased formate production. The utilization of LNT and LNnT varied by 
strain. The strain-variant metabolism was also observed during pooled HMO utilization.  
The differential HMO metabolism of B. infantis is of interest in terms of microbe-
microbe interactions within in the infant gut. A modeled microbe-microbe interaction was 
conducted by supplementing B. infantis to the infant fecal derived modeled microbiomes. 
Depending on the microbial composition to be used for modeled microbiomes, LNT and 
LNnT metabolism differed. Moreover, B. infantis addition to the modeled microbiomes 
shifted complex microbial metabolism during LNnT towards formate production and 
transformed microbial structure towards Clostridium spp. as well as butyrate producers.  
Plant-based foods also contain bioactive compounds that are impervious to host 
digestion but modulate the gut microbiome. Xyloglucans are oligosaccharides found in 
plant cell walls in cranberries. The phylogenetic near-neighbor B. longum subsp. longum 
(B. longum), isolated from the infant gut, was capable of utilizing xyloglucans, resulting in 
formate production. Probiotic Lactobacillus plantarum also utilized cranberry xyloglucans 
to a greater extent than bifidobacterial strains. Interestingly, crude cranberry extracts that 
contain additional molecules stimulated bacterial growth. Thus, we hypothesized that 
secondary products, e.g. polyphenols from cranberries, with oligosaccharides might 
synergistically impact on L. plantarum physiology. This strain deployed differential 
metabolic response to proanthocyanidins (PACs) from cranberries depending on the 
carbohydrate source. In summary, this study characterizes the structure-function 
relationships between dietary oligosaccharides and bifidobacteria, lactobacilli, and within 
the microbiome. 
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CHAPTER 1 
IN VITRO MODELS OF HOST-MICROBIAL INTERACTIONS WITHIN THE 
GASTROINTESTINAL TRACT 
 
Ezgi Özcan1, Rachel Levantovsky1,2, and David A. Sela1,3 
 
1Department of Food Science, University of Massachusetts, USA 
2Commonwealth Honors College, University of Massachusetts, USA 
3Department of Microbiology & Physiological Systems and Center for Microbiome 
Research, University of Massachusetts Medical School, Worcester, MA. 
 
1.1 The human gastrointestinal tract  
The human gastrointestinal tract (GIT) refers to the anatomical features and organs 
that are linked sequentially and participate in the digestion and absorption of nutrients and 
water. The adult GIT is approximately 1.5 m in length and supports a volume of 500 mL, 
and often contains 200 g of solid content [1]. Beginning with the oral cavity and esophagus, 
the GIT progresses through the stomach and into the small and large intestine, ending at 
the rectum. The term “gut” is often used colloquially to describe the entire GIT, and 
particularly the colon proper. Food moves through the colon more slowly compared to the 
upper GIT, which is aided by peristaltic movements [1]. Colonic digesta consists of 
exogenous dietary molecules in addition to microbial cells which are estimated to 
contribute to 50% of the total mass [1]. Therefore, microbial metabolic processes that occur 
within the gut contribute to host homeostasis in a significant fashion. On the average, the 
 2 
nutrient content that reaches the colon from the small intestine is about 20-60 g/day 
carbohydrates (i.e. polysaccharides) and 5-20 g protein [2]. 
The human colon is segregated into three primary anatomical sites, termed the 
proximal, transverse, and distal colon. In the proximal region, saccharolytic fermentation 
proceeds due to high concentrations of non-digestible carbohydrates that colonizing 
microbiota utilize. As a result, short chain fatty acids (SCFA) are secreted by microbes 
which decreases the local pH to 5-6 and promotes rapid bacterial growth [3]. As the digesta 
transits to the transverse colon, fermentable carbohydrates decrease to coincide with less 
microbial acid production to promote an environment that approaches neutral pH [4]. In 
the distal colon, microbial proteolysis rapidly results in the production of ammonia, amines, 
phenols, thiols, and indoles in addition to other metabolites including SCFAs [5, 6]. As 
available substrates change across the length of the colon, the microbial communities and 
their inherent metabolic function are somewhat distinct in these environments [5, 7]. 
The human gut is colonized by bacteria and archaea in quantities of up to 1012 cells 
per gram [2, 3, 8]. The development or microbial succession within the mammalian gut 
shares an evolutionary relationship with milk and soluble factors delivered within [9]. In 
newborn infants that are breastfed, bifidobacterial populations often dominate the 
microbiome due their ability to utilize human milk oligosaccharides [10–12]. Post-
weaning, gut microbial community diversity is influenced by their host’s nutrition and 
genotype [8, 13–15]. This is in addition to environmental factors such as antibiotic and 
other exposures. The impact of diet on guiding the microbial community has been studied 
in comparing children from Europe and Burkina Faso [16] as well as other human and 
animal studies  [17–22]. 
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The human gut may host up to 1200 microbial species within the microbiome [23, 
24], with several bacterial phyla that are consistently represented including Actinobacteria, 
Firmicutes, Bacteroidetes, Proteobacteria, Fusobacteria, and Verrucomicrobia. Of these, 
Bacteroidetes and Firmicutes are typically dominant and comprise up to 90% of the GIT 
microbiota [25–28]. The diversity within microbial communities is influenced by host diet 
and genotype among other host-microbial interactions and microbe-microbe interactions 
[19, 25, 29]. Microbial species that colonize the mature human gut are facultative 
anaerobes or strict anaerobes [30]. In addition to maintaining an anaerobic environment, 
studying GIT microbial ecosystems often requires culture-dependent approaches.  
Accordingly, some bacteria require complex cultivation requirements that are not 
well understood or are impossible to recapitulate in the laboratory. For example, some 
bacteria require the metabolic activities of heterologous species or hosts to provide 
essential molecules [31]. Since culturing-based approaches require optimal viability within 
the growth media of choice, it often underestimates bacterial diversity or biases the 
representation. This is often referred to as the “great plate count anomaly”[32]. In response, 
culture-independent approaches are often deployed to determine the phylogenetic diversity 
present in the gut from fecal community extracts [28, 33–35]. This includes massively 
parallel sequencing of the small subunit ribosomal RNA (16s) gene to enable the 
identification of uncultivable species. Accordingly, the community composition could be 
characterized in previously unprecedented resolution [36, 37]. Shotgun metagenomics of 
total community DNA allows the classification of the genetic functional capacity of the 
microbiome. This is coupled with other system-level approaches such as 
metatranscriptomics to infer the gene expression profile of the community, as well as 
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metabolomics to characterize metabolite production within the gut [38–41]. These methods 
have been used in large consortium-level collaborations such as the European 
Metagenomics of Human Intestinal Tract (MetaHIT) and the US Human Microbiome 
Project (HMP) [42–44]. Regardless of taxonomic diversity within one’s microbiome, the 
core functions of their community remains similar in healthy subjects [27, 41]. This 
functional redundancy is a consistent theme that has emerged in the study of the human 
microbiome. 
The gut microbiota extract energy and nutritive molecules from dietary components 
that are otherwise impervious to host digestion. This leads to the production of metabolites 
such as SCFAs, vitamins and amino acids to be utilized in host metabolism. Microbial 
metabolic activity is influenced by both endogenous factors (e.g. secreted mucins, bile, 
enzymes, immune cells) and exogenous factors (e.g. diet, xenobiotics, environmental 
exposures). Specific carbohydrates that are encountered by the gut microbiota include 
resistant starch, non-starch polysaccharides, milk oligosaccharides, plant cell wall 
oligosaccharides, non-digestible oligosaccharides (fructo-oligosaccharides (FOS), 
galactooligosaccharides (GOS) and inulin) [45–54]. In addition to carbohydrates, proteins 
and peptides released during digestion could also interact with microbial communities 
established along the length of the GIT [55–57]. Phenolic-based compounds participate in 
reciprocal interactions with the microbiota, as they are transformed by the community 
metabolism [58]. The interactions of phenolics with the gut microbiota may dictate the 
function of these dietary molecules as well as their bioavailability. Often these phenolic 
compounds are transformed in vivo and may modulate the gut microbiota to promote health 
benefits for the host [59–64]. Several studies have been performed to elucidate the complex 
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interactions between dietary polyphenolics and gut microbiota [65–69]. In order to utilize 
these dietary molecules, microbes have evolved an assortment of enzyme systems to 
degrade molecules both extracellularly and within intracellular compartments following 
transport [70–73]. 
Microbial metabolism in the gut is not restricted to linear pathways, or bound by 
the cellular envelope. Microbes compete for substrates, with metabolites secreted by one 
member often utilized by a secondary taxon [74]. Syntrophic metabolism is extended 
towards interactions with their host. Among other activities, microbial SCFAs (i.e. acetate, 
propionate, butyrate, formate) provide an energy source for specific host tissues including 
butyrate utilization by gut enterocytes [75, 76]. In addition, SCFAs interact with the 
immune cells that further regulates the microbiome [77, 78]. Along these lines, dietary 
phenolic derivatives may have local or systemic anti-inflammatory activity in the host [79–
81]. Moreover, proteolytic catabolism may lead to the formation of toxic compounds such 
as ammonia and amines, both of which have been linked to colon cancer [82].  
Since the gut microbiome is composed of both commensal and potentially 
opportunistic pathogens, analysis of microbial ecosystems in aggregate is required to test 
scientific hypotheses to ultimately be applied in maintaining a healthy gut state. Thus in 
vitro systems to model complex community interactions have been innovated to study 
associated scientific questions. 
1.2 The current state of in vitro model systems to model gut ecosystems 
In vitro systems enable the investigation of microbial communities and their 
respective functions by modeling microbial ecology and the interface with host physiology. 
This could include single or multiple bioreactors that are seeded by fecal inocula or defined 
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communities (e.g. 8 bacterial species) [3]. Parameters are manipulated to reflect GIT 
physiology and include temperature, pH, oxygen tension, and substrates introduced to the 
system at defined intervals and flow rates. These systems vary by experimental approach 
and differ by inoculation, transit/resident time, and the specific bioreactors.  
In vitro models are preferred in many instances, as in vivo studies are expensive 
and require special facilities to maintain animals or interact with human subjects in an 
ethical manner. For the latter, access to the internal anatomy of human subjects is 
prohibitively restricted, thus most studies focus on analyzing fecal excreta [3]. This is a 
limitation for investigations of other GIT sites beyond the distal colon. Moreover, 
nutritional interventions require a controlled diet over extended time intervals, and 
sufficient participants who must comply with inconvenient study parameters. In contrast, 
in vitro studies are not restricted by similar ethical constraints, are often cost effective, and 
enable mechanistic studies. A strong argument for their use is to allow pre-clinical 
hypothesis testing prior to in vivo trials with human and animal subjects. 
Other advantages for in vitro models include facile sampling across time with strict 
control of variables. Some models allow parallel experiments to account for inter-
community variation while measuring several outcomes simultaneously. The accumulation 
of microbial metabolites allows for cross-sectional and time course studies and access to 
molecular markers that would otherwise be rapidly sequestered in vivo.   
There are, however, limitations to in vitro experimental systems in comparison to 
in vivo approaches. Fecal inocula does not fully model the spatial complexity of microbial 
ecosystems along the GIT [83]. Moreover, reproducibility and stability is a challenge to 
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establishing an informative in vitro model. The priority lies in managing the inoculation 
and colonization efficiency of fecal microbiota, both qualitatively and quantitatively.  
The reproducibility and stability of modeled microbiomes has been evaluated using 
various approaches [83–92]. The HITChip microarray analysis and next-generation 
sequencing (NGS) has been employed to test the stability of in vitro microbiomes [83, 89]. 
These approaches enable characterization of microbial succession with great precision. As 
sequencing technologies improve, taxonomic discrimination is enhanced with NGS 
approaches rapidly ascending to the tool of choice [83].  
Experimental reproducibility is a concern often cited with these approaches. There 
is evidence that the initial fecal inocula must be fresh to reduce errors in composition due 
to freeze-induced bias [93]. Another approach is to pool fecal specimens from multiple 
donors to approximate a stable microbial community, albeit theoretical or otherwise ideal 
[83]. This approach may inadvertently lead to artifacts resulting from inter-microbial 
interactions that do not occur in vivo [3]. Inoculation with recently acquired of fecal 
samples is generally preferred for batch culture systems used in short-term studies [94]. 
1.3 Batch culture systems to model the gut microbial consortium 
Batch culture typically involves small reactor vessels (i.e. 70-1000 ml) inoculated 
with either axenic cultures or a mixed community that is allowed to grow in a medium for 
a short period of time (e.g. 72 hours) with regular sampling [3, 94]. These are either closed 
or fed-batch bioreactor systems that are maintained under anaerobic conditions by sparging 
with oxygen-free gas (usually nitrogen). Closed systems are used to model a single 
component of the human gut, such as the distal colon but other sites have been developed 
as well [3, 94]. A common use of batch models is to measure the response to a given 
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treatment or perturbation to dominant populations maintained within the simple system [3, 
94, 95]. Although this may not represent the full functional potential of the community it 
permits investigation of simplified mechanistic relationships. In general, batch systems are 
seeded with fecal inocula perform well for initial characterizations of inter-individual 
variation in community metabolism [96]. These systems are tractable for many research 
groups, cost-effective, and operate well when large amounts of substrates and seed 
microorganisms are available [3, 94]. Batch models are typically stirred continuously to 
promote homogeneity, sparged with nitrogen to reduce oxygen tension, with pH and 
temperature controlled throughout the experimental cycle.  
Batch culture systems to represent the GIT are made up small volume of reactor 
vessels in order to represent the typical volumetric space of GIT. It also points out a 
scientific shift from commonly used fermentation experiments to in vitro gut model 
systems. Additionally, it is important to validate the usage of model systems. 
Batch culture systems have been developed to investigate carbohydrate catabolism 
and the interactions of modeled GIT communities with other exogenous factors [97, 98]. 
This includes both prebiotics and probiotics that are believed to influence host physiology 
by influencing endogenous microbiota [99–103]. In 1992, Macfarlane and colleagues 
investigated the fermentation within different regions of the GIT using contents harvested 
from sudden death victims [5]. In vitro fermentations were conducted in 70 ml capacity 
serum bottles gassed with argon and incubated at 37°C anaerobically in an orbital shaker 
using 10 % (w/v) fecal slurries. Interestingly, the secretion of fermentative end products 
correlated with variations in the donors. Although in general, SCFAs, lactate, and ethanol 
concentrations were higher in the ascending colon whereas protein fermentation products 
 9 
such as ammonia and phenolic compounds increased in the descending colon. In 1993, 
Wang and Gibson [104] investigated oligofructose and inulin utilization in an in vitro 
fermentation by Bifidobacterium and Clostridium spp. in a 280 ml volume fermentation 
vessels which were run for 48 h at 37°C and pH of 7.0. They were sparged with oxygen-
free nitrogen and continuously stirred using 5% fecal slurries collected from 6 individuals. 
These were prepared freshly by homogenizing in anaerobic phosphate buffer. Thus it was 
determined that oligofructose and inulin are utilized by intestinal commensals as SCFA 
coincides with the increase in specific beneficial populations and reduces Escherichia coli 
and Clostridium perfringens. This Gibson model has been replicated in several additional 
studies to be discussed in subsequent sections.  
Phenolic biotransformation within the human gut has been modeled in batch culture 
systems. Microbial metabolism of anthocyanins and quercetin were conducted either in 
head-space bottles or large-scale fermenters under controlled temperature, pH, and oxygen 
concentration [105, 106]. In 2008, Tzounis and colleagues [107] developed a batch culture 
model similar to the Gibson system with 300 mL vessels under expected conditions within 
the gut. Afterward, this model was used in several studies of flavanol and anthocyanin 
metabolism transformed by colonic microbiota and assessed by metabolite and microbial 
profiling using liquid chromatography (HPLC) and fluorescent in situ hybridization 
(FISH), respectively [108–110]. Flavanol and anthocyanin phenolics are degraded by gut 
microbiota, with products increasing the populations of Bifidobacterium and Eubacterium 
reflecting the potential enriching activity of precursor phenolics. Several static batch 
colonic fermentation models were developed to investigate flavonol and phenolic acid 
degradative pathways [96, 111–113].  
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Two batch systems were prepared with phosphate-buffered saline (PBS, 
oligotrophic) and basal culture medium (BCM, eutrophic) and seeded with fecal inoculum 
to characterize the response of the modeled community to a prebiotic formulation of GOS 
and guar gum [114]. As a result, significant shifts within specific populations receiving 
treatment were observed in the pyrosequencing community analysis.  
Despite frequent use of batch culture fermentation systems, models have limitations 
related to over-simplification of the ecosystem being modeled in the absence of the host 
physiology. Moreover, accumulation of toxic compounds and substrate diminishment may 
restrict microbial activity as the system will not achieve steady-state equilibrium [115]. A 
simple in vitro batch culture fermentation study conducted in multiple labs illustrates 
limitations of the batch culture systems [99]. Accordingly, dietary fiber was fermented 
within several laboratories with outcomes varying in terms of the rate of substrate 
degradation as well as the amount of SCFAs produced. It was concluded that the most 
significant potential source of variation is the fecal inoculum in in vitro models. Thus batch 
systems are typically appropriate for short-term resident times with continuous, semi-
continuous, and dynamic model systems used in more complex models.  
1.4 Continuous systems to model the human GIT 
Continuous model systems contain multiple chemostats used in long-term studies 
with constant provision of substrates and removal of toxic compounds under defined 
parameters. In general, optimal conditions for microbial growth may be achieved at steady-
state conditions unless experimental goals dictate otherwise. Chemostat conditions reflect 
distinct parts of the human GIT and often consist of the proximal, transverse, and distal 
colon [3]. Environmental conditions are simulated including substrate retention time and 
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may involve modeling peristaltic movements. Continuous model systems are appropriate 
for studies that require longer response measurements to a given treatment or perturbation. 
Important considerations in designing these experimental schemes include maintaining 
physiological concentrations of metabolites and relative concentrations of microbial 
populations to reflect fermentation rates of substrates and interactions between microbes 
[86]. Often in vitro models are constrained by maintaining stable communities of microbes 
to model in vivo states. Stabilization requires a period of adaptation to the simulated 
environment that involves microbial interactions within this unique environment. This is 
often not considered in batch culture models due to shorter resident times. However, in 
continuous models the adaptation period must be addressed. The validation of the stability 
of these systems was tested using culture-independent techniques [87, 89].    
An early semi-continuous system was developed by Miller and Wolin in a glass 
vessel to maintain 500 ml of stirred anaerobic culture over 81 days [116]. Fermentation 
was initiated with 156 g of freshly collected feces diluted in 200 ml of solution containing 
sodium bicarbonate, urea, hemin, casein and a vitamin mixture. The microbial community 
was left to stabilize for 18 days before a suspension of dietary material was added derived 
from various fruits and vegetables. Sodium deoxycholate represented bile salts and mixed 
with nutrient suspensions to be pumped into the fermentation vessels once or twice daily. 
In the same year, Veillux and Rowland developed a 2 stage continuous reactor to simulate 
the distal part of the rat intestine [117]. Two-stage cultures were connected in series with 
sterile media added to the first stage. The continuous system was run in a volume of 600 
ml in an agitated, temperature, and pH-controled fermenter and continuously flushed at a 
rate of 0.5 l/min. The medium reservoir was held under anaerobic conditions and agitated 
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to ensure a homogenous distribution of the components and pumped continuously. Fecal 
suspensions were homogenized shortly after acquisition and allowed to stabilize for 12 h 
before culture medium addition. These model systems were developed based on a number 
of assumptions. The first is that most microbial growth and metabolism occurs immediately 
after ileal fluid entry into the colon and prior to water removal that concentrates substrates. 
Another assumption is the use of fecal communities is representative of the colonic 
microbial community. Furthermore, the high concentration of insoluble carbohydrates in 
dietary substrates in the study is predicted to evade digestion in the stomach and small 
intestine. These assumptions are necessary in order to simplify the system in these in vitro 
systems. Regardless, the metabolite and microbiological profile was found to be consistent 
between the model and in vivo systems. 
A three stage continuous system was developed by the Gibson group to investigate 
the influence of mucin on sulfate reduction and methanogenesis by mixed populations of 
human gut microbiota [118]. This three-stage continuous culture system was inoculated 
with 20 % (w/v) of feces in an anaerobic sodium buffer and maintained under controlled 
conditions for 120 days. A mixture of polysaccharides and proteins were added as carbon 
and nitrogen sources respectively. The vessels operating volumes (0.3, 0.5, and 0.8 liter) 
and pH (6.0, 6.5 and 7.0) reflected the physiological characteristics of the colon. Porcine 
gastric mucin was added to the first vessel after 48 days, with microbial degradation 
allowed to proceed for 22 days until the mucin was replaced by distilled water. As a result, 
the mucin was extensively hydrolyzed which stimulated volatile fatty acid production. 
Mucin participated in sulfate-reduction, however methanogenesis was the major route for 
the disposal of electrons in the absence of mucin. Of primary interest, this study modeled 
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competition between sulfate-reducers bacteria and methanogens over a limited nutrient 
source.  
In another approach, a three-stage continuous system was developed to test the 
effects of retention time of various organic carbon and nitrogen sources on the community 
ecology and metabolism of gut microbes [7]. This system consisted of three vessels 
simulating the ascending, transverse, and distal colon by judiciously dictating pH, 
temperature, operating volumes, and retention time. Since fecal extracts do not reflect the 
community structure in the proximal colon, the researchers used content harvested from 
four sudden death victims. Operating volumes of the three vessels were set as 0.22, 0.32 
and 0.32 L and pH was maintained at 5.5, 6.2, and 6.8 under automated control. The 
environmental conditions sought to recapitulate the spatial, temporal, nutritional, and 
physicochemical characteristics encountered by gut microbiota. The first vessel (V1) was 
fed with culture media containing polysaccharides, proteins, vitamins, and salts under 
anaerobic conditions. The three stages were continuously linked, and the vessels were 
inoculated with 100 ml of 20% (w/v) fecal slurry. The system was equilibrated overnight 
and allowed to achieve steady state after at least 336 h assessed by monitoring SCFA 
production. The retention time for each vessel was determined as the reciprocal of dilution 
rate and evaluated by comparing the chemical and biological characteristics of the fecal 
suspensions from donors.  
Further advances to the development of the 3 stage in vitro model were made to 
investigate fermentation of dextran, oligodextran, and maltodextrin by human gut 
microbiota [4]. In this approach, a cascade of three fermenters inoculated with 10 % (w/v) 
freshly collected and homogenized fecal slurry were linked in series, with operating 
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volumes of 250, 250 and 300 ml, and pH values of 5.5, 6.2 and 7.1 under continuous stirring 
and anaerobic conditions. Vessel 1 simulated the acidic conditions and rapid bacterial 
growth in response to high substrate availability that are experienced in the proximal colon. 
In contrast, vessel 3 was maintained at a neutral pH and with limited substrates to model 
conditions in the distal colon. In total the retention time was 60 hours which was selected 
according to previous three stage continuous models validated for retention time [7]. 
Oligodextran IV was shown to enrich for bifidobacteria and lactobacilli with steady-state 
populations achieving higher densities in all three vessels. However, substrate utilization 
varied among the three stages of the colonic model. Whereas dextran is a suitable growth 
substrate for bifidobacteria and lactobacilli in the proximal colon (Vessel 1), maltodextrin 
was used as the carbohydrate source for both bacterial groups in Vessel 3. Recently, a 
similar system was used to model the effects of the antibiotic rifaximin on the colonic 
microbiota of patients with Crohn’s disease [119]. Interestingly, rifaximin promoted the 
relative abundance of Bifidobacterium, Atopobium, and Faecalibacterium prausnitzi that 
was confirmed using fluorescent in situ hybridization (FISH), quantitative PCR, and other 
culture-independent methods. The coinciding shift in microbial metabolism was observed 
with 1H-NMR and solid phase microextraction coupled with gas chromatography/mass 
spectrometry. Accordingly, SCFAs, propanol, decanol, nonanone, and aromatic organic 
compounds were increased, and ethanol, methanol and glutamate were decreased. In 
addition, wheat dextrin soluble fiber influenced the composition and metabolic activity of 
the gut microbiota in this model as measured by 16S rRNA-based FISH and gas 
chromatography [120]. Wheat dextrin fermentation significantly increased production of 
acetate (vessels 2 and 3) and propionate (vessel 3), coinciding with a significant increase 
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in key butyrate-producing bacteria assigned to clostridial cluster XIVa and the genus 
Roseburia.  
Another three stage continuous model was developed and termed GIS2 
(gastrointestinal simulation) to study the effects of a probiotic product (i.e. PROEXO) on 
the modeled infant gut microbiota [121]. This three-stage system consists of three Duran 
bottles (1,000 ml capacity) and maintained at pH values of 5.5, 6.2 and 6.3. Culture media 
and the substrate which functions as both a probiotic and prebiotic were introduced to the 
first vessel to be pumped to vessel 2 and 3. The model was seeded by fecal samples 
obtained from healthy infants of 6 months and stabilized after an initial period of 10 days 
assessed by culture-dependent quantification. In this system, polysaccharides present in the 
tested product enriched the lactic acid bacteria in the modeled ascending colon.  
A four stage, semi-continuous colonic model system (i.e. EnteroMix human colon 
simulator) was developed to model the effects of lactose on the growth and fermentation 
dynamics of colonic microbiota [122]. This system contains four glass vessels connected 
in sequence, with conditions adjusted to represent each compartment of the human colon 
under anaerobic conditions. pH values were maintained at 5.5, 6.0, 6.5 and 7.0 from the 
ascending colon towards the distal colon. The system was run in parallel with six treatment 
and three baseline simulations using the same fecal inoculum preconditioned at 37°C for 
24 h, anaerobically. The microbial density was adjusted from vessel 1 to vessel 4. Lactose 
was initially dissolved in sterile simulator medium, which mimics the contents of the 
human ileum and was semi continuously fed to the first vessel. Microbial populations and 
metabolite (SCFA) profiling were monitored by flow cytometry and HPLC. In a 
subsequent study, the effects of polydextrose and xylitol were investigated in the 
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EnteroMix four-stage colon model [123].  While polydextrose degradation leads to higher 
concentrations of all SCFA, especially acetate and propionate, xylitol degradation 
increased the concentration of butyrate in the medium. This was attributed to population 
shifts of Bifidobacterium and Lactobacillus. In addition, this model was used to study the 
effects of xylo-oligosaccharides on bifidobacteria in the human colon [124]. Interestingly, 
xylo-oligosaccharides were preferred by Bifidobacterium lactis strains and lactitol by 
lactobacilli in this four stage in vitro model, whereas galacto-oligosaccharides, fructo-
oligosaccharides and gentiobiose were preferred by a larger group of microbes. 
Molly and colleagues developed a novel model that was termed the simulated 
human intestinal microbial system (SHIME) [125]. This is a five-stage bioreactor system 
consisting of a large intestine phase that encompasses three bioreactors, and is fed by a 
small intestine reactor 1 and 2 (duodenum/jejunum and ileum) simulated by a two-step fill 
and draw system. This system was based on the presence of indicator bacterial groups, 
volatile fatty acids, enzymatic activities (e.g. α- galactosidase β-galactosidase, α-
glucosidase, β-glucosidase, β -xylosidase), and headspace gases. The first substrates tested 
in the SHIME system included dietary carbohydrates such as arabinogalactan, xylan, 
pectin, dextrin and starch. In addition, SHIME has been deployed to model microbial 
activity in the GIT in separate operations [126]. Each reactor vessel was designed with 
eight ports for medium transfer, sampling of the liquid phase and headspace gases, pH-
electrode, pH-control (acid and base) and for flushing of the headspace. Pumps were used 
to transfer the reactor contents between the successive vessels. Media containing 
polysaccharides were introduced to the first vessel semi-continuously (3 times a day) and 
two hours after first feeding, pancreatic juice supplemented with bile (pancreas acetone 
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powder dissolved in NaHCO) was added to reactor vessel 1 to simulate the conditions in 
dueodenum/jejunum. In order to model the GIT, stool specimens (10 % w/v) from eight 
healthy individuals were fed into reactor vessels 3-4-5 (caecum and ascending colon, 
transverse colon, descending colon) [126]. Validation of the SHIME system was performed 
by analyzing a number of microbial activities, degradation of four polysaccharides and 
direct enumeration of bacteria by plate count [125, 126]. A validation of a model system is 
generally performed on the available data in literature by comparing the outcomes with in 
vivo clinical trials. Additionally, validation also requires the reproducibility, stability and 
consistency within the same system. Not much sufficient information is available in 
literature for every model system validation that is used in vitro experiments. From 
scientific perspective, it was assumed that the validation of a system had done before the 
related outcomes for the treatment were established.  
SHIME has been employed in several applications since its initial development. In 
1999, Alander and colleagues tested six stages of SHIME for screening and selection of 
five probiotic strains (Lactobacillus plantarum, two strains of Lactobacillus paracasei 
subsp. paracasei, Lactobacillus rhamnosus and Bifidobacterium sp.) [127]. In this study, 
they developed a SHIME reactor consisting of five closed vessels in series to which a sixth 
reactor was added (simulating the stomach). Stabilization of probiotic strains required a 7-
day pre-treatment period, followed by a 7-day inoculation period during which the 
supplement was added daily. A 2-week post-treatment washout period was included. The 
impact of the strains on the composition of modeled gut microbiota and its metabolic 
activities (production of lactic acid and SCFA) were measured by plate count enumeration 
and gas chromatography coupled with flame ionization detector. Accordingly, lactic acid 
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increased in the SHIME probiotics were added as well as the relative increase in lactobacilli 
and bifidobacteria. Interestingly, SCFA profile remained somewhat static. Members of the 
enterobacteriaceae and clostridia decreased markedly during the intervention, while 
enterococci tended to increase post-treatment. This suggests that the positive effects 
attributed to probiotic treatment are reversible.  
The effects of a synbiotic mixture of Lactobacillus acidophilus and fructo-
oligosaccharides (FOS) were also tested in a six stage version of SHIME [128]. Alterations 
to the microbial community structure and their metabolic activity were monitored by 
culture-dependent methods and assayed for β-galactosidase and β-glucuronidase activity. 
These experimental conditions were similar to those performed by Alander and colleagues 
including pretreatment (10 days), treatment (addition of probiotic strains and FOS; 17 days) 
and post-treatment (10 days) [127].  To avoid the deleterious effects of stomach acid on 
the integrity of the synbiotics, the treatment feeding started from the second set of vessels. 
The addition of the synbiotic product increased the bifidobacterial population and 
production of butyric and propionic acid. 
A synbiotic mixture of Lactobacillus GG and fermented oat bran was introduced to 
a modeled gut microbiome in a six-stage SHIME system [129]. This system diverges from 
the canonical SHIME model [128] as the model stomach and small intestine vessels were 
fed semi-continuously. Accordingly, pre-feeding occurred for 8-10 days, feeding totaled 
12 days, and post-feeding lasted for 19 days. Lactic acid bacteria, bifidobacteria, 
enterobacteria and clostridia were enumerated by culture-dependent methods. It was 
concluded that Lactobacillus GG may colonize in the human gut for several weeks with 
the fermented oat bran enriching bifidobacteria and the production of several desirable 
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metabolites. However, one limitation of the SHIME model is that lack of absorption led to 
an overestimation of digesta constituents that reached the colon [128, 129].  
Possemiers and colleagues [87] employed 5-stage SHIME (stomach, small 
intestine, and three colonic phases) to produce a stable bacterial community for 27 days. 
The microbiome members were quantified by enumeration of total aerobes and anaerobes, 
total coliforms, and other targeted groups by culture-dependent methods and PCR-DGGE. 
SCFAs and ammonium in the reaction vessels were monitored by gas chromatography 
coupled with flame ionization and as a released of ammonia to determine the metabolic 
activity of the microbial community. Microbiome stability was achieved after two weeks, 
while metabolic activity required three weeks to achieve stead-state.  
In another application of the five-stage SHIME system, the prebiotic potential of 
inulin that varied by degrees of polymerization was evaluated [90, 130]. Moreover, the 
SHIME system was used to screen for prebiotic sources from soy germ and to model 
potential alterations in the microbial ecology of the human colon [131, 132]. In 2009, the 
prebiotic potential of arabinoxylan oligosaccharides and inulin was evaluated in a TWIN-
SHIME system which is two systems run in parallel to compare treatments simultaneously 
[133]. This enables real time inline monitoring of oligosaccharide hydrolysis and the 
production of marker metabolites in parallel. Microbial colonization was developed in 
TWIN-SHIME that was simultaneously inoculated with the same human fecal seed. The 
microbial diversity was assessed with a high-resolution phylogenetic microarray: the 
human intestinal tract chip (HITChip) [134]. This model was found to be reproducible in 
SHIME units and resulted in highly diverse microbial communities that were colon region 
specific, with the proximal regions harboring saccharolytic microbes (e.g., Bacteroides 
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spp. and Eubacterium spp.) and the distal regions harboring mucin-degrading microbes 
(e.g., Akkermansia spp.). Subsequently, the TWIN-SHIME system was used to evaluate 
the microbial metabolism of red wine and black tea extracts [65].  
In another effort to model an interaction between food constituents and gut 
microbiota, the TWIN-SHIME system was used in conjunction with key dietary 
polyphenols [135]. Ingestion of polyphenols might influence health through absorption, as 
well as interactions with resident gut microbiota. Accordingly, black tea and a red wine 
grape extract (RWGE), both contain complex dietary polyphenols and influence the 
microbiome structure and function. This was measured by both culture-independent and –
dependent methods and gas chromatography. Pyrosequencing of community phylogenetic 
markers indicated that the Firmicutes:Bacteroidetes ratio was altered in the presence of 
polyphenolic extracts. Moreover, black tea stimulated Klebsiella, enterococci and 
Akkermansia and reduced bifidobacteria, B. coccoides, Anaeroglobus and Victivallis. 
Likewise, RWGE promoted growth of Klebsiella, Alistipes, Cloacibacillus, Victivallis and 
Akkermansia while bifidobacteria, B. coccoides, Anaeroglobus, Subdoligranulum and 
Bacteroides were decreased. In addition, the effects of cranberry and grape seed 
polyphenols were tested on a similarly modeled microbial community in SHIME [136]. 
Finally, a single strain of Lactobacillus plantarum IFPL935 was evaluated for their ability 
to metabolize a polyphenolic red wine extract by monitoring phenolic derivatives using 
UPLC−ESI-MS/MS and community changes using qRT-PCR [137].  
Currently, next-generation sequencing (NGS) beyond pyrosequencing is 
commonly used to determine to measure phylogenetic diversity of modeled gut microbiota. 
These techniques have been particularly valuable in prebiotic studies [138]. As an example, 
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fructo-oligosaccharides and inulin were introduced to a model community in SHIME and 
the microbial communities assessed by Illumina sequencing [139].  
In addition to simulations of the GIT, a multi-compartmental dynamic computer-
controlled system for the stomach and small intestine (TIM-1, TNO intestinal model) was 
developed [140]. A similar system to simulate the large intestine with peristaltic mixing, 
and the dynamic absorption of fermentation products and water (TIM-2) was developed as 
well [86]. The TIM-2 was engineered to host the relatively high concentrations of microbes 
to model in vivo conditions. Moreover, hollow-fiber membranes were included inside the 
reactor compartments to simulate absorption of water and dialysis of metabolites. In this 
system, a dense chyme model is mixed and transported to the tubular loop-shaped segment 
with movement to mimic peristalsis where the colonic fermentation occurs. Water and 
SCFAs were removed from the system to obtain the desired cell density, which provides 
an advantage over batch culture systems. The TIM-2 system contains four glass units, all 
connected and each with flexible inner walls to permit peristaltic movements by controlling 
the hydraulic pressure to circulate the chyme through the loop-shaped system. The tubular 
shape of the model lumen prevents blockage or obstipation. The water activity of the 
luminal content is maintained via absorption controlled by a level sensor, and the system 
is kept anaerobic reflecting conditions in the proximal part of the large intestine. In addition 
to metabolite removal, the TIM-2 system also maintains metabolite concentrations through 
controlling the dilution rate and providing a limited amount of substrates. In addition, TIM-
2 models the proximal colon, as most carbohydrate fermentation occurs in this region 
allowing for the mechanistic study of the transformation and bioactivity of exogenous 
molecules [92]. Accordingly, the TIM-2 system was used to model the effects of lactulose 
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on the composition of anaerobic bacterial groups within an intestinal microbial community 
by plate counting and SCFA production by gas chromatography [92]. The TIM-2 model 
has been used in a variety of experiments to model host-microbial interactions and diet-
microbial interactions This includes investigating bacterial metabolism of black tea 
polyphenols [141], the diversity of glucose fermenting microbiota [142], phylogenetic 
analysis of starch fermenting bacteria [143], and the effects of inulin (degree of 
polymerization = 3-25) on the metabolic activity of modeled gut microbiota in the presence 
of Clostridium difficile [144].  
In an effort to benchmark the performance of the SHIME and TIM-2 systems, the 
models were compared in parallel characterizations of the fermentation patterns of 
arabinoxylan and inulin [145]. This revealed similar effects for arabinoxylan and inulin on 
structure and function of the modeled microbiome in both models. In the TIM-2 model, ten 
fecal samples were pooled and stabilized for 16 h prior to the addition of either inulin or 
arabinoxylan in three days. In contrast, the microbial ecosystem in the SHIME model was 
derived from a single fecal suspension that was stabilized for 14 days with inulin or 
arabinoxylan introduced for 21 days. Both in vitro systems exhibited an increase in 
propionate and butyrate in response to a given substrate. Furthermore, arabinoxylan 
enriched Bifidobacterium longum in the modeled community, whereas inulin stimulated 
populations of Bifidobacterium adolescentis.  
In addition to previously described models, the dynamic SIMulator of the 
GastroIntestinal tract (SIMGI) was innovated to simulate operations of digestion and 
fermentation [146]. This system incorporates three-stage culture reactors to model the 
ascending, transverse, and descending colon. In addition, the SIMGI model includes a 
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gastric compartment that simulates peristaltic mixing and a dedicated reactor to simulate 
the small intestine. Most in vitro gut model systems were engineered to simulate either the 
upper GIT or the colon [86, 125, 140, 145]. Thus the SIMGI model represents an advance 
compared to previous models as this fully computer-controlled, multi-compartmental 
system allows joint or independent simulation of gastric and colonic processes. The 
stomach compartment is comprised of two transparent, rigid, methacrylate plastic modules 
covering a reservoir of flexible silicone walls. The gastric content is mixed by peristaltic 
movements created by pumping thermostated water into a jacket between the plastic 
modules and the flexible reservoir. Beyond mimicking peristalsis, water movement is used 
to maintain temperature of the gastric compartment. The initial food intake is mixed with 
gastric electrolytes and enzymes in the stomach compartment. The other four vessels, 
representing the small intestine and the three distinct colonic regions, are magnetically 
stirred, continuous flushed by nitrogen and pH and temperature controlled, and connected 
sequentially through pipes and peristaltic pumps. The succession and stability of the 
microbial community was evaluated by PCR-DGGE and quantitative PCR in this particular 
study.  
Recently, a high-throughput continuous-flow system was developed to allow 
microbial community dynamics to be examined in minibioreactor arrays (MBRA) [83, 
147]. The MBRA was designed in continuously stirred six reactors, with a working volume 
of 15 ml to operate under an atmosphere of 5% CO2 -5% H2 -90% N2 at 37°C in a heated 
anaerobic chamber. To simulate microbial community, pooled fresh fecal samples were 
mixed in anaerobic phosphate buffer, inoculated in 5 % (w/v) in each bioreactor and 
stabilized for 72 h. This MBRA system was used to describe community differences 
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between epidemic and non-epidemic Clostridium difficile infections which is a common 
cause of severe cases of antibiotic-associated diarrhea (AAD) [147]. In this study, the tcdA 
gene was used to quantify C. difficile invasion and 16S rRNA amplicon sequencing was 
used to profile microbiome diversity in the presence of C. difficile and antibiotic treatment. 
Interestingly, clinical strains outcompeted the other strains in the presence of complex 
microbiota.  
1.5 Mucus-immobilized models of the gut 
Mucosal microbiota are difficult to study in vivo as human intervention studies are 
typically restricted to observations on fecal samples. Microbes do not typically interact 
with the host epithelia and are instead found within the mucin layer secreted by goblet cells 
[148–151]. Bacteria that reside in the mucosal gel layer contribute to inhibiting pathogenic 
epithelial invasion, either by excreting antimicrobial molecules or competing for adhesion 
sites [148]. Model systems that incorporate mucosal immobilization are used to study 
interactions between luminal and mucosal microbiota. Models that simulate dynamic 
interactions that occur with long-term residence times typically do not address the mucosal 
environment and may restrict their predictive power.  
Immobilized mucus systems utilizing cell immobilization in anaerobic continuous-
flow cultures for modeling the GIT were first established in the Lacroix model [152]. 
Thereafter, the model was used for the immobilization of infant fecal microbiota in in vitro 
gut fermentation model system by Cinquin et al [153]. The system is predicated on a three-
stage bioreactor that models immobilization of mucosal microbiota with xanthan-gellan 
gum beads to simulate bacterial cells entrapped in fibrous particles or forming biofilms on 
the intestine epithelium [152]. Bacteria isolated from infant feces were immobilized in 
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xanthan-gellan gum beads using a two-phase dispersion process previously described for 
the immobilization of lactic acid bacteria in kappa-carrageenan/locust bean gum gel beads 
[154]. This is done in order to study the compositional changes in the microbial ecosystem 
over a long time period of fermentation. The medium was formulated to approximate the 
carbohydrate:nitrogen ratio present in infant chyme, with the bile salt concentrations 
reduced to the levels of secretion observed in infants. This model has several improvements 
including growing bacteria within biofilm structures, achieving high cell density in gel 
beads, maintaining community stability, protection of sensitive bacterial taxa from shear 
stress, prevention of washout and loss of less competitive bacteria. Based on these 
characteristics, a model with immobilized fecal bacteria was developed to simulate 
intestinal Salmonella infections and long-term shedding in children was developed [155].  
In order to model sessile gut bacteria populations, a single stage chemostat could 
house mucin beads to encourage microbial adhesion encased within a dialysis membrane 
[88]. Water and metabolites are removed by osmosis and diffusion respectively using 
polyethylene glycol (PEG) and the media is maintained under anaerobic conditions. This 
model system supports the growth of bacteria associated with mucin beads and planktonic 
bacteria in the culture medium. Distinct differences were observed between the biofilm 
fermenter system and traditional chemostats including microbial populations and their 
secreted metabolites. 
Recently, a chemostat gut model was developed and validated to model planktonic 
and sessile states of colonic bacteria in biofilm formation associated with Clostridium 
difficile infections (CDI), [156]. In this model, macroscopic biofilms were facilitated with 
18 glass rods inserted into the biofilm vessel, positioned to ensure the sampling portion of 
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the rod extended across the liquid/gas interface to simulate CDI. Rods were affixed to the 
lid under an anaerobic environment with the vessel modified to encourage an even 
distribution of gas flow across the rods. The continuous chemostat model was inoculated 
with a pooled human fecal emulsion. Planktonic and sessile bacterial populations were 
enumerated culturing methods and C. difficile toxin production was monitored using a Vera 
cell cytotoxicity assay Interestingly, C. difficile spores preferentially persisted within 
biofilm structures.  
The SHIME model has been adapted to simulate surface attached mucosal microbes 
(M-SHIME) [157]. Two SHIME units used in parallel (i.e. Twin-SHIME) were inoculated 
with luminal microbes (i.e. luminal-SHIME or L-SHIME), along with mucin-enveloped 
microcosms to the ascending colon model vessel for a mucosal environment (i.e. mucosal-
SHIME or M-SHIME). In order to achieve a representative mucosal surface in the M-
SHIME, microcosms were created with mucin-encapsulated suspensions. Mucin-adhesion 
assays were performed to track the succession of the community in addition to typical 
microbiological assays. The study reported Lactobacillus mucosae and Pediococcus 
acidilactici were both present in the modeled lumen, though L. mucosa was strongly 
enriched in the mucosal phase due to a specific mucus binding (mub) protein. In addition, 
Lactobacillus rhamnosus GG specifically colonized mucus upon inoculation.  
The Polyfermentor Intestinal Model (PolyFermS) was developed to study the 
ecological distribution of intestinal microbiota [158]. In this model, the proximal colon is 
simulated in the primary reactor containing fecal microbiota from healthy children 
immobilized in gel beads. The reactor continuously inoculates a set of parallel second stage 
reactors referred to as an inoculum reactor (IR). This is to enhance reproducibility, by 
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allowing testing of the same complex microbiota in parallel reactions. A single reactor 
serves as intra-model control for assessing system stability. The PolyFermS system favors 
stable microbial compositions and metabolite production consistent with bacterial activity 
reported in vivo. The intestinal communities were validated as stable communities using 
HITChip microarray analysis and metabolic activity over a 38-day culture were observed 
at ratios similar feces of healthy donors. Enhanced butyrate production at the expense of 
acetate in inoculum reactors were detected, which was accompanied by a donor-specific 
reorganization of the reactor community. This suggests a metabolic adaptation and 
induction of community-specific lactate or acetate cross-feeding pathways in response to 
varying pH conditions. In addition, the PolyFermS was used to model fermentation that 
occurs in the gut of elderly individuals [159]. Three platforms were deployed to conduct 
this study. The first vessel system was in three-stages to emulate the proximal, transverse, 
and distal colon similar to adult gut microbiota previously validated in infant and child 
microbiota fermentation in the Lacroix model. Vessel systems two and three were based 
on the PolyFermS composed of an IR that was seeded with immobilized fecal microbiota 
and used to continuously inoculate second-stage reactors in parallel. The modeled gut 
microbial diversity and metabolite production was monitored using qRT-PCR, 
pyrosequencing, and HPLC [159].  
In addition to human GIT models, PolyFermS was utilized to simulate the 
conditions of the porcine proximal colon [160]. This was composed of a first-stage IR 
seeded with immobilized fecal porcine microbiota and used to inoculate (10% v/v) five 
second-stage reactors, with all reactors fed fresh media with carbohydrate and protein 
concentrations to closely mimic the ileal chyme found in pigs. First, the IR was operated 
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in batch mode to colonize the fecal beads and the nutritive medium was replaced by fresh 
medium every 12 hours. After colonization, continuous operation in IR was initiated, 
followed by a stabilization period of 5 days before connection to CR (control reactor) and 
TR1-4 (treatment reactors). The entire two-stage system was then stabilized for another 5 
days. Thus, the model provides a tool for efficient, reproducible and cost- effective 
screening of environmental factors, such as dietary additives, on colonic fermentation.  
1.6 Models to simulate complex host-microbial interactions  
Canonical bioreactor systems such as those described previously are ideal for 
studying single microbial species and inter-microbial interactions. However, they do not 
fully account for all features of the human GIT that add complexity to host-microbial 
interactions. While iterations of these models have been developed in order to achieve 
accurate simulations of the human GIT, in vitro bioreactor modeling systems typically do 
not account for the three-dimensional architecture of the colon. The colonic walls present 
intricate patterns of epithelial invaginations. Whereas conventional bioreactors mimic 
luminal conditions, including pH, gas content, and temperature, direct microbial-epithelial 
interactions cannot be simulated in such systems. Furthermore, it is difficult to model the 
planktonic and sessile phases, as they exist in vivo, despite development of mucosal 
systems. This is not representative of the complex interplay between the host epithelia and 
commensal microbes that reciprocally interact. 
As in vitro model systems have evolved to include peristaltic movement and fluid 
flow under constant parameters, there have been efforts to develop systems to bridge the 
three-dimensional gap. One solution to this concern is the recent development of an 
approach referred to as “gut-on-a-chip” [161]. The general setup of the gut-on-a-chip is a 
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small chamber made of a flexible polymer with several microchannels traversing its length. 
Upper and lower channels of the same dimensions, 150 µm high by 1000 µm wide, are 
separated by a porous layer of the same flexible polymer, and this membrane is then coated 
with an extracellular matrix solution, typically containing collagen of mammalian origin. 
The channels are connected to both a vacuum source and a source of fluid medium, both 
of which can be manipulated to achieve the desired flow rate and peristaltic simulation. A 
common epithelial cell line such as Caco-2 are deposited on the top surface of the polymer 
membrane using a syringe and maintained in culture. The cells are deposited at a density 
of 1.5x105 cells/cm2, and have been observed to adhere to the membrane in 30 minutes, 
and form inter-cellular adhesions in one hour. Once the Caco-2 cells have formed 
attachments, culture medium is perfused through the channels with enough shear stress to 
ensure that any superimposed cells or cell aggregates are washed away, and only a 
monolayer remains. 
Prior to the development of gut-on-a-chip, complex host-microbial interactions 
were best performed in animal studies. Not only these studies are costly, they may also 
require dedicated resources, such as gnotobiotic centers, and come with ethical concerns 
inherent to working with live animals. Gut-on-a-chip does not present any ethical concerns, 
as human cell lines are a widely distributed and available. Also, interactions between 
human gut microbiota and the cells may better reflect in vivo interactions over time. 
Microbial viability under these experimental conditions was determined through assays of 
enzymatic activity, and the level of activity remained comparable to those observed in vivo 
[161]. 
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Most significantly, however, is how accurately the gut-on-a-chip model emulates 
intestinal physiology, including response to laminar flow, peristalsis, and cell morphology. 
While other models of planar epithelium have been previously utilized, the gut-on-a-chip 
promotes the three-dimensional arrangement of epithelium observed in vivo. Multiple 
factors of the model’s design work in conjunction to shape the cells in villus-like structures. 
These influences include the shear stress of laminar fluid flow, mechanical strain, and 
cyclic strain.  
In the static system, the Caco-2 monolayer lies flat, and does not undergo any 
dynamic changes in cell structure or arrangement regardless of shear stress or mechanical 
strain. On the contrary, when cells on the gut-on-a-chip membrane were exposed to a shear 
stress of 0.02 dyne/cm2 an obvious directionality was observed. The cells grew to a 
columnar shape and height of 30-40 µm, the expected characteristics of epithelium in a 
healthy human large intestine [161]. Forces of laminar flow that epithelial cells experience 
in vivo are effectively represented in this system, and results indicate their important role 
in cellular morphology. In addition to the spontaneous formation of a columnar cell shape, 
when the same levels of laminar flow are maintained for a longer period of time, in the 
presence of cyclic strain, the monolayer also began to spontaneously fold. Through 
histology, the folds were confirmed to mimic the natural villi, comprised of columnar 
epithelium, that line the colon, thus achieving a model of the barrier environment that much 
of the gut microbiome inhabits. 
The effects of mechanical stress and cyclic stress were also experimentally 
determined, and while the phenomena did not directly affect the formation of villi from the 
cellular monolayer, both of these stressors are critical to simulate peristaltic motion that 
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occurs in vivo. Peristalsis is also involved with dictating whether a model system could 
withstand strain similar to the host organism, and how this may interact with microbial 
commensals. Classic static epithelial monolayers do not mimic the degree of permeability 
observed in the human gut. However, the introduction of peristaltic, cyclic strain to the gut-
on-a-chip system led to a four-fold increase of monolayer permeability, without 
compromising the integrity of the tight junctions [161]. Barrier integrity continued to be 
measured in the presence of bacteria, and was determined to increase over time as the 
epithelial and microbial cells interacted. This supports previously reported findings that 
“probiotic” strains promote the health of intestinal epithelium and enhance its barrier 
function [161, 162]. 
Gut-on-a-chip performs well in studies of complex microbial communities, such as 
those derived from human fecal samples. Specific analytical platforms have been created 
in conjunction with microarray technologies to assess mass quantities of phylogenetic 
information [162]. In addition, massively parallel sequencing could now be applied 
towards analyzing data from 454-pyrosequening of a variable region of the 16srRNA gene 
[162].  
Overall, the gut-on-a-chip in vitro model holds a great deal of promise for studying 
host-microbial interactions that take place in the human colon. Due to their representation 
of colonic forces, including strain and flow, epithelial cell morphology, and barrier strength 
and permeability, these models provide a degree of accurate mimicking of colonic 
physiology and microbial interactions at the epithelial barrier.  
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1.7 Gastric-small intestine model systems 
Although the majority of microbes colonize the large intestine, other GIT segments 
are relevant to health outcomes. Accordingly, modeling the colon in the absence of the 
upper GIT does not represent the harsh barriers experienced by food and microbes once 
consumed or delivered.  
Modeling the stomach and small intestine requires maintenance of proper pH in 
both simulated organs (2 in the stomach, 6-7.4 in the small intestine) [140, 163]. Besides 
pH, modeling the proper composition of gastric juice is imperative in the correct sequence 
and concentration [140, 163] . Pepsin and hydrochloric acid are encountered in the 
stomach. In contrast, bile, bicarbonate, and pancreatic enzymes are found in the small 
intestine, particularly in the duodenum. Modeling upper GIT enzyme secretions pose 
another challenge in these systems. In the stomach, acid and enzymes are secreted evenly 
throughout directly from the stomach lining [164]. Thus, the direct addition of 
physiological concentrations of enzymes and hydrochloric acid to a model system may not 
emulate digestion in vivo.  
In addition to modeling biochemical aspects of the upper GIT, there are many 
mechanical forces to be considered to achieve a representative simulation. The secretions 
themselves, whether from the stomach walls or duodenum, exert forces of flow onto the 
digesta present [163, 164]. These hydrodynamic forces and waves cause shear stress. As 
food progresses through the GIT, its own viscosity contributes to a decreased rate of 
diffusion of nutritive food components to their site of absorption in the small intestine[165]. 
The stomach possesses active churning, and an accurate model must mimic the peristaltic 
contractions that cause churning [140, 163, 164]. Churning is necessary for the appropriate 
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mixing and production of chyme. The small intestine experience peristalsis as well, as it 
pushes chyme along its length, the duodenum, jejunum, and ileum, so nutrient absorption 
can occur. 
At the junction of the stomach and small intestine lies the pyloric sphincter, which 
selectively allows digested material through, to control the rate of stomach emptying [166]. 
Liquids pass through the pyloric sphincter with relative ease, while larger particulates will 
be forced back into the stomach for further breakdown [140, 167]. Without a model 
sphincter with the proper pressure in place, this critical function cannot be simulated [163]. 
Indirectly, this affects the modeling of transit time through the GI tract as well [140]. Each 
of these parameters has been included based the results of on studies done on human 
subjects and animal in vivo studies [140] . 
The role of the nervous and endocrine systems in digestion, such as stimulation by 
the vagus nerve, has yet to be emulated in an in vitro GIT model [168]. Pancreatic enzymes 
and bile can be accurately added to a duodenal approximation, but the hormones that act 
upon the pancreas and gallbladder are not typically considered. Feedback mechanisms that 
occur in the stomach and small intestine digestion and absorption have not been factored 
in either.  
With these challenges in mind, a successful gastric and upper intestinal simulator 
can encompass the dynamic nature of these organs’ physiology. One of the earliest 
dynamic models, and one that is widely used and highly regarded today, is the TNO in 
vitro Gastrointestinal Model (TIM), by Minekus et al [140]. The first model, TIM-1 was 
created in 1995, followed by TIM-2 in 1999 [86]. This model is significant because it was 
the first of its kind to be both dynamic and multi-compartmental [140, 168]. At its core, 
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the system consists of four compartments, representing the stomach, duodenum, jejunum, 
and ileum. Comprising each region is a glass vessel with an internal compartment, with 
flexible walls. The space between the glass container and the inner compartment is filled 
with water controlled by a rotary pump. A separate three part valve pumps connects each 
discrete region and emulates the forces of peristalsis, contracting 3 times per minute in the 
stomach compartment, and 9 times per minute in the models of the small intestine. Dialysis 
was performed after digestion was completed with an added glucose load to simulate 
absorption by the small intestine, and it was reported that 96% of the glucose was found in 
the dialysis, demonstrating successful absorption. The pressure exerted on the walls inside 
also allow the system to simulate churning and mixing of the meal [140].  
Although the mechanical forces that are exerted in the stomach and small intestine 
are accounted for, some of the more sophisticated aspects of contraction and peristalsis 
may be improved. The regular contractions that TIM-1 exerts through the pumping of water 
are not entirely representative, as within a single peristaltic contraction, there is gradient in 
the force felt by the stomach, increasing as the contraction approaches the antrum, the 
lower, fuller portion of the stomach [167] . Antral grinding is a critical component of the 
mechanical digestion that occurs in the stomach, as particulate matter is turned into chyme. 
Sufficient decrease in size of digested food is necessary for entry into the duodenum. If 
larger pieces of digesta within the stomach are not broken down, the human pylorus is 
responsible for the phenomenon of retropulsion. Liquids and sufficiently small particles 
pass through the pyloric sphincter with ease, all the while preventing the entry of large 
constituents, forcing them back into the stomach for further mechanical breakdown with 
almost elastic properties [167] .  
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One model created to meet these needs is the Human Gastric Simulator (HGS) from 
University of California Davis [167] . In practice, this model is similar to TIM, but contains 
only a stomach chamber, and addressed the concern specific to gastric simulation that the 
former system lacked. The stomach itself is modeled with a latex chamber, held up with 
clamps and supports at a height of 13 inches. Rather than enclosing the “stomach” in a 
solid vessel and using water to simulate pressure and contraction, this system uses a series 
of 12 rollers on belts that apply force directly to the latex walls. Three rollers are connected 
via pulley system on each of the four sides of the vessel such that peristalsis is experience 
evenly throughout the model. A motor drives each of the four belts to operate 
simultaneously. This model also uses a rate of 3 contractions per minute to mimic in vivo 
observations [167]. In contrast to the previous models, the roller and pulley system is more 
sophisticated because they can be adjusted to simulate the pressure differential that occurs 
in one single peristaltic contraction. The stomach experiences stronger contractions at the 
antrum, and as such food used in an in vitro gastric modeling system should feel the greatest 
contraction force in the bottom portion of the chamber simulating the stomach. The HGS 
accomplished this by tapering the latex vessel, indirectly decreasing the area over which 
the four sets of rollers exert their force, thus increasing the force of the contraction [167]. 
The latex of the vessel combined with the intricate application of mechanical force make 
the HGS better for modeling specific parameters of peristalsis, such as frequency, 
amplitude, and intensity [168]. 
Gastric secretions are delivered to the chamber via variable flow mini peristaltic 
pump. The pump flows into a piece of tubing that splits into 5 equivalent tubes, ensuring 
that the simulated juice is distributed evenly throughout the vessel, as occurs in the human 
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stomach [167].The pyloric function of selective filtration and retropulsion that is observed 
in vivo is achieved with the addition of a polythene mesh bag inside of the latex vessel, 
with an average pore size of 1.5 mm. Particles less than 2 mm in diameter are able to 
continuously pass through the pore for emptying, as is true of liquids and small particles 
through the pyloric sphincter. However, larges particles are retained in the chamber, 
exposing them to further digestive action. As such, the “sieving” function of the pyloric 
sphincter is retained in the HGS [167]. 
The success of this model was determined based on properties of the experimentally 
digested food, in this case apples and rice. The criteria they hoped to fill were particle size 
distribution, pH profile, and desired content remaining in the stomach compared to what 
was emptied [167] . Experiments performed comparing the HGS to older shaking bath 
techniques of food disintegration showed that particle size was significantly reduced in the 
HGS, meaning that it better approximates in vivo gastric digestion due to its additional 
mechanical forces. Smaller particle size confers a greater surface area to the digested food. 
As a result, it is implied that this in vitro system is able to simulate the kinetics of nutrient 
release for absorption in vivo, as surface area plays an outsized role in increasing 
absorption. 
An in vitro upper GI tract simulator that has been commonly used in 
pharmacological studies is the Dynamic Gastric Model (DGM) [164]. While similar in 
design to other models of its kind, there are differences in how mechanical forces are 
applied. The DGM consists of inner and outer compartments, like HGS and TIM, but food 
is exposed to mechanical digestion is found in between the two chambers, as the inner 
compartment is mobile and acts to crush the food against the walls of the outer chamber 
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[167]. Contractions, at 3 times per minute, are achieved through water pressure, as in the 
TIM system [164] . Gastric juice, including enzymes, is also carefully distributed such that 
it is delivered evenly, but rather than through a system of tubes, the mixture is released 
from a dispenser floating atop the contents of the vessel. Overall, the DGM was designed 
to account for many of the considerations mentioned previously, including dynamic pH 
change, shear stress, churning, and transit time. As this particular study was concerned with 
the absorption of pharmacological agents in the presence of different meals, the success of 
the model was determined by the measure of mean breaking time of agar beads, used to 
represent ingested tablets or capsules [164] . 
This model places particular emphasis on simulating antral grinding forces, as 
discussed with the HGS [164, 167]. A piston is used to achieve shearing in the antrum of 
the model, and the sieving of the pyloric sphincter is mimicked using an elastic ring [164]. 
However, it has been claimed that the mechanical forces applied in the DGM do not 
accurately reflect the forces of peristalsis [167, 168]. 
All three models – TIM, HGS, and DGM – are dynamic representations of gastric 
digestion, but each comes with its own strengths and attributes. Only TIM is multi-
compartmental, which is useful for whole-system studies, but its approximations of gastric 
mechanical forces are weakest. Both the HGS and DGM attempt to recreate forces in the 
stomach, considering both peristalsis and the gradient of force exerted along the stomach. 
The HGS arguably accomplishes this task with more accuracy, using the system of rollers 
at different applied pressures, while the DGM uses a water based pressure simulation like 
TIM. However, TIM is also a better model with which to observe absorption after digestion 
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is complete. HGS allows for the approximation of nutrient absorption, but this phenomenon 
cannot be directly measured in this model. 
In vitro models of the stomach and small intestine are most representative of in vivo 
conditions when a meal or food matrix is incorporated along with the bacteria of interest. 
Since some strains have been demonstrated to be resistant to harsh conditions in vivo it is 
important to be able to distinguish between the success of the model and a particular 
microbe simple exhibiting resilience. For example, sporulating bacteria are known to 
withstand the conditions of the upper GI tract [166].  
In conventional testing of microbes in highly acidic conditions, 100% of strains 
exposed to hydrochloric acid did not survive. However, food itself has significant buffering 
capabilities that can protect microbes from pH profiles that would otherwise render them 
inviable [169]. It is not enough to consider the effects of acid or bile, which is thought to 
be antibacterial, on their own [170]. Rather, the combination of acid exposure with a 
buffering meal and subsequent exposure to bile and enzymatic action must be considered 
as is in vivo. Studies using TIM but with these additional considerations, namely a kefir 
based meal, demonstrated that more bacterial strains survive when in a dynamic model 
rather than static, and the survival is significantly greater than when on media incorporating 
acid or bile alone [169] .  
Another difference from the conventional TIM set-up is that this study only used 
the stomach and duodenal compartments. The duodenum is the site of most of the digestion 
in the small intestine and is considered to be the threshold between the upper and lower 
gastrointestinal tract. If viability is determined upon emptying into the duodenum, it is 
likely that the microorganisms will successfully pass through to the colon.  Survival rates 
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of microbes in the duodenum were shown to be more uniform than those of the stomach, 
likely due to the higher pH [169] . Five strains of lactic acid bacteria were found to have 
survival rates of over 72%, implying likelihood of a significant number of them remaining 
viable and reaching the colon [169]. Known genera of beneficial microbes are lactic acid 
bacteria, including Lactobacillus and Bifidobacteria, so this is a promising result. 
Though each model discussed is best fit for certain types of studies, at large these 
models represent a comprehensive arsenal of methods for approximating the human 
gastrointestinal tract, especially in relation to commensal microbiota. Although the 
majority of the human gut microbiome resides in the large intestine, it is important to 
consider the effects of the upper GIT on digested food, and how this affects the nutrients 
that become available to the microbiome. Future directions for improvement of these 
studies is to emulate mucosal interactions more accurately, such as gut-on-a-chip strives to 
do, as well as continue to improve the dynamics of multi-compartmental models. Current 
studies have also begun to look at the effects of non-nutritive bioactive components in in 
vitro models, which can also have some bearing on the interactions between 
microorganisms, their human hosts, and the food we digest.  
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2.1 Abstract 
Human milk contains a high concentration of indigestible oligosaccharides, which 
likely mediated the coevolution of the nursing infant with its gut microbiome. 
Specifically, Bifidobacterium longum subsp. infantis (B. infantis) often colonizes the 
infant gut and utilizes these human milk oligosaccharides (HMOs) to enrich their 
abundance. In this study, the physiology and mechanisms underlying B. infantis utilization 
of two HMO isomers lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT) was 
investigated in addition to their carbohydrate constituents. Both LNT and LNnT utilization 
induced a significant shift in the ratio of secreted acetate to lactate (1.7–2.0) in contrast to 
the catabolism of their component carbohydrates (~1.5). Inefficient metabolism of LNnT 
prompts B. infantis to shunt carbon toward formic acid and ethanol secretion. The global 
 41 
transcriptome presents genomic features differentially expressed to catabolize these two 
HMO species that vary by a single glycosidic linkage. Furthermore, a measure of strain-
level variation exists between B. infantis isolates. Regardless of strain, inefficient HMO 
metabolism induces the metabolic shift toward formic acid and ethanol production. 
Furthermore, bifidobacterial metabolites reduced LPS-induced inflammation in a cell 
culture model. Thus, differential metabolism of milk glycans potentially drives the 
emergent physiology of host-microbial interactions to impact infant health. 
2.2 Introduction 
Breastfeeding is critical for infant development and health in the absence of formula 
milk substitutes. Human milk contains a high concentration of indigestible 
oligosaccharides, as well as other nutritive molecules that promote growth experienced 
early in life [171–175]. Human milk oligosaccharides (HMOs), are indigestible 
carbohydrates soluble in human milk, and are composed of five monosaccharides: D-
glucose (Glc), D-galactose (Gal), N-acetylglucosamine (GlcNAc), L-fucose (Fuc) and N-
acetylneuraminic acid (Neu5Ac or sialic acid) with a varying degree of polymerization and 
branching [176–179]. These oligosaccharides are not directly metabolized by the infant; 
however, commensal bifidobacteria have coevolved within the nursing infant gut to utilize 
HMO [11, 180]. 
Bifidobacterium longum subsp. infantis (B. infantis) colonizes the nursing infant 
and is typically overrepresented within the infant gut microbiome [10, 181–183]. The B. 
infantis genome encodes an array of glycosyl hydrolases, oligosaccharide transporters, and 
catabolic enzymes that enable HMO utilization [11, 184–187]. Both glycosyl hydrolases 
and membrane-spanning transporters feed milk oligosaccharides and their derivatives into 
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the bifidobacterial fructose-6-phosphate phosphoketolase (F6PPK) central fermentative 
pathway. The F6PPK is believed to be unique to the genus Bifidobacterium, which 
generates ATP from hexoses via substrate-level phosphorylation resulting in the secretion 
of endproducts that recycle co-factors [188–191]. Bifidobacteria initially converts one 
mole of fructose-6-phosphate to one mole of erythrose 4-phosphate and one mole of acetyl-
phosphate via F6PPK (EC 4.1.2.22). A transaldolase (EC 2.2.1.2) and transketolase (EC 
2.2.1.1) converts erythrose 4-phosphate and one mole of fructose-6-phostphate to two 
moles of xylulose-5-phosphate, which are converted into two moles of acetyl-phosphate 
and of glyceraldsehyde 3-phosphate via xylulose-5-phosphate phosphoketolase activity 
(EC 4.1.2.9). Acetyl-phosphate is dephosphorylated into acetate by an acetate kinase (EC 
2.7.2.1), accompanied by a single ATP per acetyl-phosphate [192]. In addition, 
glyceraldehyde 3-phosphate is oxidized to pyruvate accompanied by the production of a 
single ATP. Pyruvate is converted to lactate by lactate dehydrogenase (EC 1.1.1.27) along 
with recycling NAD+ from NADH [193]. For every 2 moles of hexose entering the F6PPK 
pathway, 3 moles of acetate and 2 moles of lactate are produced (i.e. ratio of 1.5). Based 
on transcriptomic evidence, it is likely that B. infantis catabolizes HMO derived 
monosaccharides through the F6PPK pathway to generate ATP [45]. This potentially links 
bifidobacterial physiology (i.e. flux through the F6PPK pathway) with infant nutritional 
and health outcomes as B. infantis benefits their developing host [194, 195]. 
In general, all B. infantis strains examined to date efficiently utilizes HMOs pooled 
from several donor mothers with the exception of one [12, 196–200]. The tetrasaccharides 
lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT) are highly abundant 
oligosaccharides secreted in breast milk [172, 176]. LNT (Galβ1-3GlcNAcβ1-3Galβ1-
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4Glc) is classified as a type I HMO, which incorporates lactosyl coupled to a lacto-N-biose 
(LNB) (Galβ1-3GlcNAc) residue. In contrast, LNnT (Galβ1-4GlcNAcβ1-3Galβ1-4Glc) is 
an isomer of LNT and classified as a type II oligosaccharide, linking the terminal lactosyl 
with N-acetyllactosamine (LacNAc) (Galβ1-4GlcNAc). These isomers are identical aside 
from a sole glycosidic linkage (i.e. β1-3 vs. β1-4) thus leading to the hypothesis that this 
structural variation is responsible for differential phenotypes in bifidobacterial utilization 
of these major HMOs.  
2.3 Materials and Methods 
2.3.1 Bacterial strains and propagation 
Bacterial strains used in this study are summarized in Table 2.1. Bifidobacterial 
strains were propagated in De Man Rogosa Sharp (MRS, Oxoid, Hampshire, England) 
medium supplemented with 0.05 % (wt/v) L-cysteine hydrochloride (Sigma-Aldrich, St. 
Louis, MO)[201] at 37° C under anaerobic conditions (Coy Laboratory Products, Grass 
Lake, MI). Bacterial strains were routinely verified using the bifidobacterial-specific 
phosphoketolase assay [202] and bifidobacterial-specific PCR targeting the 16S rRNA 
gene sequence using the previously developed Bif164-F (5¢-
GGGTGGTAATGCCGGATG-3¢) and Bif662-R 5¢-CCACCGTTACACCGGGAA-
3¢)[203]. In addition, the PCR-based Bifidobacterium longum/infantis ratio analysis 
(BLIR) was performed to verify subspecies as previously described [204]. 
2.3.2 Microplate growth assay  
In order to evaluate growth phenotypes in a 96-well format, overnight cultures were 
inoculated 1% (v/v) to modified MRS media (mMRS; a defined carbohydrate substrate and 
no acetate). Carbohydrate substrates used in this study include glucose (Sigma-Aldrich Co. 
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St. Louis, MO), galactose (Sigma-Aldrich Co. St. Louis, MO), lactose (Sigma-Aldrich Co. 
St. Louis, MO), L-fucose (Sigma-Aldrich Co. St. Louis, MO), N-acetylglucosamine 
(GlcNAc) (Tokyo Chemical Industry Co, Tokyo Japan), lacto-N-tetraose (LNT) (Elicityl-
oligotech, Crolles, France) and lacto-N-neotetraose (LNnT) (Elicityl-oligotech, Crolles, 
France) at a final concentration of 2 % (wt/v) as the sole carbon source. Carbohydrate 
sources were incorporated into culture media in non-limiting concentrations. The growth 
assay was conducted anaerobically at 37° C for 48 h by assessing optical density at 600 nm 
(OD600nm) in an automated PowerWave HT microplate spectrophotometer (BioTek 
Instruments, Inc. Winooski, VT) placed within the anaerobic chamber. Each strain was 
evaluated in biological triplicates with three technical replicates. Inoculated mMRS media 
in the absence of carbohydrate substrates served as the negative control. Bacterial growth 
kinetics were calculated using Wolfram Mathematica 10.3 Student Edition with the 
equation below as described in Dai et al [205].  
!"#(%) = !"#()*+{ 11 + exp[3%4 − %] − 11 + exp[3%4]} 
 
ΔODasym is the growth level at stationary phase with k representing the growth rate and tc 
is the inflection point indicating the time to reach the highest growth rate. 
2.3.3 Characterization of microbial metabolic endproducts 
Endproducts from bacterial fermentation were quantitated by HPLC. Bacterial 
strains were initially propagated as described above. Cell-free supernatants from 
microplate growths were obtained at early stationary phase and filtered through a 0.22 µm 
filter (Sartorius Corp, Bohemia, NY) following centrifugation and stored at -20° C until 
further analysis. Organic acids were quantified using a Schimadzu HPLC system equipped 
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with a Refractive Index Detector 20A, (Schimadzu Corp., Kyoto, Japan). Separation was 
carried out using an Aminex HPX-87H column (7.8 mm ID x 300 mm, Bio Rad 
Laboratories, Hercules, CA) at 30° C in a mobile phase of 5 mM H2SO4 at flow rate of 0.6 
ml/min with 20 µl of injection volume. Standards including organic acids (i.e. acetic acid, 
lactic acid, formic acid), ethanol, and carbohydrates (i.e. glucose, galactose, lactose, and 
GlcNAc) were acquired from Sigma-Aldrich Co. (St. Louis, MO). Metabolite 
concentrations were calculated from standard curves derived from external standards for 
six concentrations (0.5, 1, 5, 10, 20 and 50 mM). Metabolite profiling was carried out in 
triplicate and each measurement was performed in duplicate. The metabolite profiling for 
each strain subsisting on the panel of carbohydrates were analyzed using MetaboAnalyst 
3.0 (http://www.metaboanalyst.ca) [206]. The sugar consumption in percentages was 
calculated by dividing the amount of mono- and di-saccharide expected after fermentation 
by the concentration of carbohydrate source prior to fermentation. The carbon recovery in 
percentages was calculated by dividing the total amount of carbon recovered in the 
metabolites by the total amount of carbon present in pre-fermentation minus total carbon 
after fermentation. 
2.3.4 Quantitative real-time PCR analysis 
B. infantis gene expression was performed by quantitative real-time PCR (qRT-
PCR) on a relative basis. One mL samples were harvested at mid-exponential phase 
(OD600nm ~ 0.4-0.6 varied depending on carbohydrate source), pelleted at 12,000 x g for 
2 min, and stored in 1 ml Ambion RNAlater (Life Technologies, Carlsbad, CA). RNA 
extraction and cDNA conversion was performed as previously described [45]. Briefly, 
samples were centrifuged at 12,000 x g for 2 min to collect the cell pellet. The pellet was 
 46 
washed twice with PBS buffer to remove residual RNAlater and centrifuged at 12,000 x g 
for 2 min. Total RNA was extracted using Ambion RNAqeous-Mini kit (LifeTechnologies, 
Carlsbad, CA) according to the manufacturer’s instructions. Cells suspended in lysis buffer 
were transferred to the Lysing Matrix E tubes (MP Biomedicals LLC, Solon, Ohio) to 
disrupt cell walls through beadbeating at 5.5 m/seconds for 30 seconds twice using 
FastPrep 24 bead beader (MP Biomedicals, Santa Ana, CA). Total RNA was eluted in 50 
µl of EB solution and immediately subjected to DNase treatment with the Ambion Turbo 
DNA-free (Life Technologies, Carlsbad, CA) using 1 µl of DNase I for 30 min. 
Subsequently, total RNA was converted to cDNA using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Carlsbad, CA) according to the manufacturer's 
instructions. The resultant cDNA was quantified by a Nanodrop 2000 Spectrophotometer 
(Thermo Fisher Scientific Inc., Agawam, MA). The qRT-PCR was performed on a 7500 
Fast Real-Time PCR System (Applied Biosystems, Singapore) with PowerUP SYBR 
Green Master Mix (Applied Biosystems, Foster City, CA) using 200ng of input cDNA. 
The reaction conditions were informed by manufacturer recommendations and optimized 
for the specific target locus. qRT-PCR primers were designed using the Primer3 software 
(Table A2.1; http:// frodo.wi.mit.edu). The gene Blon_0393, encoding a cysteinyl-tRNA 
synthetase was used as an endogenous control as previously [184, 207]. Growth on lactose 
(2 % wt/v) served as the reference condition for gene expression. Results were expressed 
as fold change relative to the reference. These experiments were conducted in triplicates 
and triplicate technical measurements were performed. Following DNase treatment, the 
absence of genomic DNA was confirmed using total RNA as template by qRT-PCR (i.e. 
endogenous control reaction).  
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2.3.5 Statistical analyses 
The relationships between asymptotic OD600nm, growth rates and metabolites were 
characterized with principal components analysis (PCA) and hierarchal clustering with 
Ward’s method and Euclidean distances using R (R.3.4.0). The outliers were determined 
according to their distance to the average within biological replicates were omitted to 
maintain at least biological triplicates. When no growth was observed in sugars, the values 
were assigned as “0” for PCA function(prcomp) analysis and PCA plots were drawn using 
ggbiplot in R. Growth kinetics, metabolite concentrations, fold change in gene expressions 
of cell culture for B. infantis ATCC 15697 were subjected to one-way analysis of variance 
(ANOVA) and Tukey’s HSD test for multiple comparisons between carbohydrate source. 
The fold change in gene expression for B. infantis, growth kinetics, and metabolites 
between strains were analyzed with two-way analysis of ANOVA. The simple effects and 
main factor effects were determined with Tukey’s HSD test for multiple comparisons of 
carbohydrate sources for the same strain and between strains for a defined carbohydrate 
source.  
2.3.6 Bioinformatic analysis of transcriptome data  
Transcriptomic data (i.e. raw reads) of B. infantis ATCC 15697 while growing on 
lactose, LNT, and LNnT was retrieved from a previously performed RNA-seq study [45] 
publically deposited in the NCBI Gene Expression Omnibus database 
(http://www.ncbi.nlm.nih.gov/geo/) under the accession number GSE58773 (and personal 
communication with Danielle Lemay). This data was uploaded to the Massachusetts Green 
High Performance Computing Cluster (MGHPCC) that was used for all 
computational/statistical analyses unless specifically noted. The RNA-seq reads were 
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aligned to the reference B. longum subsp. infantis ATCC 15697 genome (NC_011593.1). 
Coding regions of the ATCC 15697 genome were subjected to this analysis. Total and 
unique gene reads aligning to a specific genomic locus (i.e. locus tag), as well as calculated 
raw counts was obtained for differential expression analysis.  
2.3.7 Differential gene expression 
In order to identify and quantify the magnitude of differentially expressed genes, 
the R package DESeq2 was used to analyze the raw count data [208]. Genes with a mean 
count < 200 was removed from analysis by pre-filtering. DESeq2 applies the Wald test for 
statistical analysis. Adjusted p-values ≤ 0.05 were defined as statistically significant.  
2.3.8 Anti-inflammation assay performed in a cell culture model 
Caco-2 cells (ATCC HTB 37) lines were routinely cultured in High Glucose 
Dulbecco’s Modified Eagle Medium (DMEM) (Corning, Manassas, VA) supplemented 
with NaHCO3 (Sigma-Aldrich, St. Louis, MO), 1% non-essential amino acids (Gibco), 100 
U/ml penicillin-streptomycin (Gibco), 10% (v/v) fetal bovine serum (Seradigm) and 7mM 
HEPES (Gibco). Caco-2 cells were routinely grown in 20-cm Petri plates and subcultured 
at 80% confluence and maintained at 37 °C in a humidified atmosphere of 5% (v/v) CO2 
in air.  
The cells were differentiated at passages 30–32 and collected by dissociation of a 
90% confluent stock culture with 0.25% trypsin/EDTA. For the inflammation assay, Caco-
2 cells were seeded in 24-well plate at a concentration of 1-2 x 105 cells/cm2 and were 
differentiated for 17 days with the medium changed every 2-3 days. Replicate supernatants 
collected from B. infantis ATCC 15697 growing on lactose, LNT, and LNnT were mixed 
in equal volume and added into the DMEM at the final concentration of 15% (v/v). 100 
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µM of acetic acid, lactic acid, and formic acid controls were mixed with DMEM. 
Subsequently, media was added to each well in triplicates and incubated at 37° C in a 5% 
CO2 atmosphere for 2 hours. For negative and positive controls, triplicates were seeded 
with only DMEM. After incubation, 10 µl of 5 mg/ml lipopolysaccharide (LPS) in PBS 
was added into the wells and incubated for 24 h for treatments. LPS alone was used for 
negative control. PBS alone served as the carrier solution and a reference control. After 
incubation, the cells were detached from the plate surface by incubation with 
trypsin/EDTA, suspended in 500 µl of RNAlater solution and stored at -80°C until RNA 
extraction.  
The relative gene expression of interleukin-8 (IL-8) linked with LPS-induced 
inflammation expression was quantified using qRT-PCR. Total RNA was extracted using 
the Ambion RNAqeous-Mini kit (LifeTechnologies, Carlsbad, CA) according to the 
manufacturer’s instructions. Cells suspended in lysis buffer were transferred to Lysing 
Matrix D tubes specific for eukaryotic cell and tissues culture (MP Biomedicals LLC, 
Solon, Ohio) and were subject to a speed of 5.5 m/sec for 30 sec twice using the FastPrep 
24 bead beader (MP Biomedicals, Santa Ana, CA). The total RNA was eluted in 50 µl of 
EB solution and immediately subjected to DNase treatment with the Ambion Turbo DNA-
free (Life Technologies, Carlsbad, CA) using 1 µl of DNase I for half-hour. Total RNA 
was converted to cDNA using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Carlsbad, CA) according to manufacturer's instructions. The 
resultant cDNA was quantified in a Nanodrop 2000 Spectrophotometer (Thermo Fisher 
Scientific Inc., Agawam, MA). The qRT-PCR analysis was performed using a 7500 Fast 
Real-Time PCR System (Applied Biosystems, Singapore) with PowerUP SYBR Green 
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Master Mix (Applied Biosystems, Foster City, CA) using 200ng of cDNA with primers 
GAPDH-F (5¢-GTCGCTGTTGAAGTCAGAGG-3¢) and GAPDH-R (5¢-
GAAACTGTGGCGTGATGG-3¢) for endogenous control and primers IL-8-F (5¢-
GACCACACTGCGCCAACAC-3¢) and IL-8-R (5¢-CTTCTCCACAACCCTCTGCAC-
3¢)[209]. The PCR cycling conditions were applied as recommended by the manufacturer 
and tailored specifically to the target genes. Additional markers of inflammation were 
tested using primers IL-10-F (5¢-GGTTGCCAAGCCTTGTCTGA-3¢), IL-10-R (5¢-
AGGGAGTTCACATGCGCCT-3¢)[210] and TNF-a-F (5¢-
TCAACCTCCTCTCTGCCATC-3¢), TNF-a-R (5¢-CCAAAGTACACCTGCCCAGA-
3¢)[211]. 
2.4 Results 
2.4.1 B. longum subsp. infantis exhibits divergent growth phenotypes during 
utilization of the milk oligosaccharides lacto-N-tetraose and lacto-N-neotetraose 
In order to understand B. infantis metabolism of HMOs, the type strain ATCC 
15697 was subjected to growth on purified HMO species and constituent mono- and di-
saccharides. Accordingly, B. infantis ATCC 15697 grew vigorously on lactose (OD600nm, 
asym=1.27±0.12, k=0.56±0.03 h-1) as well as galactose (OD600nm, asym =1.20±0.13, 
k=0.61±0.02 h-1) (Figure 2.1). The HMO species LNT was utilized as a sole carbohydrate 
source to a similar extent (OD600nm, asym =1.19±0.24, k=0.51±0.02 h-1) as these two 
constituent residues (Figure 2.1). Interestingly, the structural isomer LNnT promoted a 
more moderate growth profile (OD600nm, asym =0.85±0.09, k=0.57±0.04 h-1) (p<0.05) (Figure 
2.1). The B. infantis type strain did not grow on the HMO constituents GlcNAc and fucose 
as a sole carbohydrate source. It is noteworthy that growth on glucose was inconsistent in 
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terms of final OD600nm; therefore, a comparison to the other carbohydrates was limited. The 
significant difference between LNT and LNnT utilization (p<0.05) suggests that these 
HMOs are metabolized via differential mechanisms that vary in efficiency (Figure 2.1A). 
Differences in growth rates between the HMO species were not observed which indicates 
an equivalent preference for LNT and LNnT (Figure 2.1B). B. infantis ATCC 15697 
exhibited similar growth rates for lactose, galactose, and LNnT (p>0.05). Although growth 
efficiencies on galactose and LNT are similar (Figure 2.1A), B. infantis ATCC 15697 
prefers galactose to LNT as indicated by growth rate (p<0.05). In aggregate, the single 
structural difference between LNT and LNnT is directly linked to the efficiency by which 
B. infantis utilizes these HMO species. Previous studies indicate that ATCC 15697 grows 
on both LNT and LNnT to achieve a OD600nm > 0.8, however these studies did not report 
the specific asymptotic growth (i.e. efficiency) or growth rate (i.e. preference) when 
growing on these two HMO species [45, 185, 212, 213]. Thus it is significant that ATCC 
15697 exhibits clear differences in utilization between LNT and LNnT when accumulating 
biomass to OD600nm values greater than 0.8. 
2.4.2 Metabolic endproducts are differentially secreted dependent on the milk 
oligosaccharide substrate lacto-N-tetraose or lacto-N-neotetraose  
Fermentative endproducts were profiled to detail the metabolic consequences of 
HMO carbohydrate flux through the F6PPK pathway. During hexose fermentation, acetic 
and lactic acids are typically secreted in a theoretical ratio of 1.5. In contrast, formic acid 
production is not expected under most conditions tested to date [188, 213]. The absolute 
concentrations of lactic acid, acetic acid, formic acid, ethanol, and the ratios between these 
metabolites are depicted in Figure 3.2. B. infantis ATCC 15697 produces similar 
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concentrations of lactic acid while growing on galactose, lactose, and LNT (42.5±5.7, 
47.8±5.7 and 46.5±2.5 mM respectively) (p>0.05, Figure 2.2A). A much lower lactic acid 
concentration, however, was secreted while utilizing LNnT (29.5±5.9 mM) compared to 
the metabolism of other carbohydrates (p<0.05). Interestingly, formic acid and ethanol 
concentrations were significantly higher while growing on LNnT (16.3±4.1 mM and 
2.5±1.1 mM respectively). This is contrasted with the relatively smaller concentrations 
while growing on LNT, lactose, and galactose (p<0.05, Figure 2.2C and 2.2D).  
LNT metabolism resulted in the highest concentration of secreted acetic acid 
(84.8±4.4 mM, Figure 2.2B) and significantly differed from LNnT metabolism (p<0.05). 
In general, fermentative endproduct concentrations are expected to be positively correlated 
with the final biomass [214], as more carbohydrates processed by the F6PPK pathway 
results in more organic acids secreted. Therefore, it is expected that lactic acid and acetic 
acid concentrations will be higher when greater biomass is achieved [213]. However, acetic 
acid concentrations while utilizing galactose, lactose, and LNnT did not significantly differ 
from each other (p>0.05). Although the final biomass achieved during LNnT utilization is 
slightly lower, absolute acetic acid concentrations remain relatively static. Overall, these 
data support the hypothesis that B. infantis deploys a different mechanism while utilizing 
LNnT.  
2.4.3 The ratio of secreted endproducts indicate an alternative pathway for lacto-N-
neotetraose metabolism 
Bifidobacteria, including B. infantis, catabolize 2 moles hexose to secrete 2 moles 
of lactic acid and 3 moles of acetic acid via the F6PPK pathway (Figure 2.3). This 
theoretical yield (i.e. acetate:lactate ratio of 1.5) was achieved during growth on galactose 
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and lactose (1.56±0.01 and 1.58±0.01, respectively, Figure 2.2E). During HMO 
metabolism, LNT and LNnT utilization shifted the ratio towards greater acetic acid 
production (1.84±0.01 and 2.08±0.14, respectively, p<0.05, Figure 2.2E). Again, this is 
likely due to the deacetylation of the GlcNAc residue, at least in part. Notably this ratio 
significantly diverges between LNT and LNnT utilization with the latter experiencing a 
stronger shift (p<0.05). If both HMO isomers increased the relative proportion of acetic 
acid via GlcNAc deacetylation, the higher ratio during LNnT metabolism is due to either 
decreased lactic acid production and/or increased acetic acid production from acetyl-CoA 
conversion.  
LNnT metabolism was characterized by a significant increase in formic acid and 
ethanol production despite lower biomass. Accordingly, the ratio of formic acid to lactic 
acid was significantly higher during LNnT metabolism (p<0.05, Figure 2.2F). Similarly, 
LNnT metabolism increased the formic acid to acetic acid ratio significantly (p<0.05, 
Figure 2.2G). The theoretical formic acid to acetic acid ratio is 2:5 during more than 50% 
conversion of acetyl-CoA to acetic acid [193]. This ratio was approached during LNnT 
metabolism (Figure 2.2G). This means, in part, that pyruvate is shunted towards acetyl-
CoA resulting more formic acid and acetic acid production rather than lactic acid. 
Accordingly, ethanol to lactic acid ratio during LNnT fermentation differed significantly 
from LNT, as well as the other carbohydrates (p<0.05, Figure 3.2H). The theoretical ratio 
is 1:1 when 50% of acetyl-coA converted to ethanol. The higher ethanol to lactic acid ratio 
in LNnT indicates that ethanol production occurs for regenerating NAD+. The theoretical 
ratio has not been reached (~0.08), thus this explains that acetyl-CoA was mostly converted 
to acetic acid than ethanol to increase ATP production rather than NAD+ recycling. This 
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indicates a clear metabolic shift towards these endproducts occur while subsisting on 
LNnT.  
2.4.4 Oligosaccharide transport gene expression remains similar regardless of lacto-
N-tetraose and lacto-N-neotetraose substrates 
As with other bifidobacteria examined to date, the B. infantis ATCC 15697 encodes 
several family 1 solute binding proteins (F1SBPs), ATP-binding domains, and permeases 
that assemble into ABC transporters with predicted affinity for oligosaccharides [11, 184, 
215]. The expression of four F1SBPs and their cognate ABC permeases during LNT and 
LNnT utilization was evaluated to test the hypothesis that transport contributes to the 
differential metabolic phenotypes (Figure 2.4A and 2.4B). These F1SBPs were previously 
identified to bind glycans that incorporate HMO moieties [184]. Three F1SBP (Blon_0883, 
Blon_2344 and Blon_2347) and four ABC permeases (Blon_2175, Blon_2176, Blon_2345 
and Blon_2346) were induced more than 2-fold during the growth of LNT or LNnT as the 
sole carbon source relative to lactose (p<0.05). Only Blon_2347 expression differed 
significantly between the metabolism of the two HMO species (p<0.05, Figure 2.4A). 
Interestingly, both LNT and LNnT induced the F1SBP Blon_0883, although its adjacent 
permease proteins Blon_0884 and Blon_0885 were not induced (p>0.05). Main effect 
analysis via two-way ANOVA indicates that Blon_2347 exhibits the strongest induction 
among the four F1SBP genes regardless of substrate (p<0.05, Figure 2.4A). Among the 
permeases, it is notable that the highest relative expression occurred in transcription of 
Blon_2346, followed by Blon_2345 (p<0.05, Figure 2.4B). These genes are located in a 
40-kb catabolic cluster dedicated specifically to HMO metabolism [11]. This indicates that 
B. infantis deploys HMO cluster transporters while utilizing both LNT and LNnT which 
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differs significantly from its corresponding component, lactose. Although the differential 
metabolic phenotype between LNT and LNnT is not linked to the expression of these 
transport genes indicating that it is likely a function of intracellular catabolic operations.  
2.4.5 B. infantis upregulates N-acetylglucosamine metabolic genes while utilizing 
lacto-N-tetraose and lacto-N-neotetraose  
During HMO hydrolysis, GlcNAc is liberated from the oligosaccharide and likely 
subjected to deamination and deacetylation before entering the F6PPK pathway (Figure 
2.3). This is catalyzed by GlcNAc-6-phosphate deacetylase (nagA; Blon_0882, EC 
3.5.1.25) and glucosamine-6-phosphate isomerase/deaminase (nagB; Blon_0881, EC 
3.5.99.6). Both Blon_0881 and Blon_0882 exhibited significant upregulation while 
growing on LNT and LNnT relative to lactose (p<0.05). Specifically, LNT induced fold 
changes of 19.34±3.21 and 21.84±3.90 of Blon_0881 and Blon_0882 respectively, whereas 
LNnT prompted a similar induction measured at 18.71±5.43 and 20.61±6.19 (Figure 2.4C). 
This upregulation is interpreted as consistent with GlcNAc catabolism providing evidence 
that deacetylation occurs during LNT and LNnT utilization. Significant differences in the 
expression of these GlcNAc genes were not detected between LNT and LNnT metabolism. 
This expression profile could reflect the growth rate similarity between LNT and LNnT as 
depicted in Figure 2.1B.  
2.4.6 The B. infantis transcriptome diverges during lacto-N-tetraose and lacto-N-
neotetraose metabolism 
The B. infantis ATCC 15697 transcriptome while utilizing HMOs was previously 
characterized by RNA-seq [45]. Given the differential metabolism observed in the current 
study, specific pathways predicted to be relevant to LNT and LNnT utilization were 
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examined in greater depth according to differential gene expression beyond normalized 
counts. Accordingly, raw reads were retrieved and subjected to differential expression 
analysis (i.e. 2-fold change) for HMO utilization cluster genes, galactose catabolic genes 
(i.e. Leloir pathway), GlcNAc-related genes, glycosyl hydrolases and the F6PPK pathway 
as listed in Table A2.2.  
Genes involved in galactose metabolism (Blon_2171, Blon_2172, and Blon_2174) 
and adjacent ABC transporters (Blon_2175, Blon_2176, and Blon_2177) are strongly 
upregulated in both LNT and LNnT compared to lactose (p<0.05) (Figure 2.5). Moreover, 
LNnT prompted stronger induction of these genes relative to LNT (p<0.05). Similarly, 
F1SBPs and permeases localized to the HMO utilization cluster (i.e. Blon_2344-2352) 
were upregulated by both LNT and LNnT relative to the lactose control (p<0.05). In 
addition, Blon_2344, Blon_2347 and Blon_2352 were significantly upregulated during 
LNT fermentation when compared to LNnT significantly (p<0.05).  
The GlcNAc utilization genes Blon_0881 (nagB) and Blon_0882 (nagA) were 
significantly upregulated while B. infantis utilizes both LNT and LNnT relative to lactose 
(p<0.05, Figure 2.5). However, there is no significant difference between LNT and LNnT 
metabolism (p>0.05). This is consistent with the qRT-PCR gene expression analysis.  
The key enzyme fructose-6-phosphate phosphoketolase (xfp, Blon_1722, EC 
4.1.2.22) has been postulated to be among highly expressed B. infantis genes regardless of 
carbohydrate substrate [45]. Interestingly, F6PPK pathway genes are downregulated by 
LNT relative to lactose and LNnT (p<0.05, Figure 2.5). In addition, LNnT showed strong 
upregulation of those genes compared to lactose (p<0.05), except for Blon_1722, 
Blon_1096 and Blon_1368 that did not significantly differ (p>0.05). This is interesting as 
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the biomass and growth rate achieved with LNT or lactose did not significantly differ 
(p>0.05, Figure 2.1). Despite the potential for greater flux through the central fermentative 
pathway as per the transcriptome, LNnT prompted less biomass production (p<0.05). 
Furthermore, lactate dehydrogenase (ldh; Blon_0840, EC 1.1.1.37), converts pyruvate to 
lactate to recycle cofactors and was significantly induced by LNnT relative to lactose and 
LNT (p<0.05). The relationship between ldh expression and LNnT prompting lower lactic 
acid concentrations is unclear. This is potentially indicative of variation between the 
physiological states of the cells during sample collection (i.e. mid-exponential or stationary 
phase). Accordingly, high levels of lactic acid was observed at the beginning of 
fermentation of oligofructose by B. animalis and replaced by formic acid at later stages 
[216].  
Interestingly, and potentially underlying differential metabolism, acetate kinase 
(ack; Blon_1731, EC 2.7.2.1) was more strongly upregulated while consuming LNnT 
relative to lactose and LNT (p<0.05). Acetate kinase catalyzes substrate-level 
phosphorylation in the F6PPK pathway that is both involved in conversion of 
phosphoketolase to acetyl-P and conversion of acetyl-coA to acetate, and thus reflects 
relatively higher acetic acid secretion during LNnT fermentation. 
As LNnT utilization is characterized by increased formic acid production, putative 
genes involved in this pathway were interrogated. It is noteworthy that this metabolic 
process is incompletely characterized in the bifidobacteria. Formate acetyl transferase 
(Blon_1715, EC 2.3.1.54) and pyruvate formate lyase (Blon_1714, EC 1.97.1.4) 
potentially converts pyruvate to acetyl-coA and produces of formic acid. Accordingly, 
Blon_1715 is highly expressed during LNnT utilization relative to lactose and LNT 
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(p<0.05). Conversely, LNT metabolism is not characterized by increased formic acid 
production and prompted a downregulation of both Blon_1714 and Blon_1715 relative to 
lactose and LNnT (p<0.05). Although F6PPK genes were upregulated by LNnT relative to 
lactose, the strongest change was observed in formate acetyl transferase (2-fold change = 
1.20). Again, this is consistent with increased formic acid production during LNnT 
metabolism to provide evidence that differential phenotypes exhibited between LNnT and 
LNT is regulated at the gene expression level, at least in part. 
25 key glycosyl hydrolases (GHs) were selected for further analysis (Figure 2.5) 
[11, 185, 217]. A total of 13 loci significantly differ between LNT and LNnT metabolism 
(p<0.05). Among β-galactosidases, Blon_2016 (GH family 42) and Blon_2334 (GH family 
2) were downregulated during LNT utilization relative to lactose and LNnT (p<0.05). This 
is interesting because Blon_2016 was shown to have specificity to type I HMO such as 
LNT [218] and Blon_2334 was shown to be constitutively expressed in the utilization of 
pooled HMO and other complex oligosaccharides [45, 217]. β-glucosidase Blon_1905 was 
significantly upregulated by both LNT and LNnT compared to lactose (p<0.05) with 
expression during LNnT growth significantly higher than LNT (p<0.05).  
Salient to general HMO metabolism, an a-L-fucosidase Blon_0248 (GH family 29) 
was significantly upregulated by LNnT compared to lactose and LNT (p<0.05). 
Interestingly, another GH 29 a-L-fucosidase (Blon_0426) is strongly upregulated by LNT 
whereas it is downregulated by LNnT (p<0.05). Other fucosidases Blon_2335 and 
Blon_2336 were strongly upregulated by LNT rather than LNnT (p<0.05). Blon_0625 and 
Blon_2460 were downregulated in both HMO species compared to lactose, with a 
significantly stronger downregulation observed in LNnT than LNT (p<0.05). Blon_2468, 
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an endo-beta-N-acetylglucosaminidase, which generally releases N-glycans from human 
milk glycoproteins was upregulated by LNT while it was downregulated by LNnT 
(p<0.05). 
2.4.7 B. longum subsp. infantis exhibits growth phenotype variance while utilizing 
lacto-N-tetraose and lacto-N-neotetraose in a strain-dependent manner 
In order to evaluate potential phenotypic variation within B. infantis, three strains 
in addition to ATCC 15697 were subjected to growth on glucose, galactose, lactose, LNT, 
and LNnT as a sole carbon source (Table A2.3). Both B. infantis UMA299 and UMA300 
utilized GlcNAc as a sole carbohydrate substrate in contrast to ATCC 15697. None of the 
B. infantis strains tested utilized fucose as a sole fermentative substrate. UMA299 exhibited 
lower growth on LNT (OD600nm, asym=0.69±0.09, k=0.57±0.05 h-1) and LNnT (OD600nm, 
asym=0.71±0.06, k=0.68±0.06 h-1) compared to constituent carbohydrate residues within 
HMOs (p<0.05, Table A2.3). This is significant, as UMA299 does not utilize pooled HMO 
efficiently in contrast to other B. infantis strains [198]. This is likely due to the absence of 
two F1SBP transporter genes (Blon_2344 and Blon_2351) in its HMO catabolic cluster 
[197]. Interestingly, and despite limited growth, UMA299 exhibited a higher preference 
for LNnT with significantly lower growth rate on LNT (p<0.05). In addition, UMA299 
exhibited a OD600nm, asym of 0.42± 0.09 on soluble GlcNAc with a growth rate of 0.16±0.01 
h-1 which is significantly lower compared to other carbohydrates tested (p<0.05). 
B. infantis UMA300 utilized LNnT efficiently (OD600nm, asym=1.30±0.12, 
k=0.51±0.05 h-1) which is to the same extent as LNT (OD600nm, asym= 0.99±0.20, k=0.71±0.05 
h-1). The strain utilized galactose to similar cellular concentrations as LNT and LNnT and 
inefficiently utilizes lactose and GlcNAc (Table A2.3). In terms of growth rate (k), 
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UMA300 experienced the highest rate on LNT and galactose with a significantly lower 
growth rate on LNnT (p<0.05). This provides additional evidence that the two HMO 
species are utilized by divergent mechanisms by B. infantis strains. Despite achieving 
highest biomass concentrations on LNnT, UMA300 preference as determined by growth 
rate did not vary appreciably between LNnT and lactose (p>0.05). UMA300 low growth 
rate on GlcNAc suggests that this aminosugar is not preferred relative to the other 
carbohydrates tested (p<0.05). 
In contrast to UMA300, B. infantis UMA301 exhibited vigorous growth on lactose 
(OD600nm, asym=1.29±0.05, k=0.56±0.05 h-1), followed by galactose (OD600nm, asym=1.22±0.05, 
k=0.63±0.06 h-1) and LNT (OD600nm, asym=1.01±0.17, k=0.44±0.06 h-1) all of which does not 
differ significantly (p>0.05, Table A2.3). UMA301, however, achieved significantly lower 
biomass concentrations on LNnT (OD600nm, asym=0.86±0.04, k=0.40±0.01 h-1) concomitant 
with a lower growth rate. This suggests a clear preference for LNT rather than LNnT 
between these two HMO tetrasaccharides. As with ATCC 15697, UMA301 does not utilize 
GlcNAc as a sole carbohydrate source.  
Consistent with the growth, ATCC 15697, UMA299, and UMA301 consumed 
galactose and lactose greater than 40%, whereas UMA300 consumed lactose at 25% 
(p<0.05, Figure A2.1A). Similarly, UMA299 were consumed GlcNAc to a greater extent 
than UMA300. 
In order to determine phenotypic variation as a function of carbohydrate source and 
B. infantis strain, principal component analysis (PCA) and hierarchal clustering was 
performed. This analysis incorporated both final asymptotic OD600nm and growth rate data 
for strains growing on individual substrates (Figure 2.6). The first principal component 
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(PC1) explains 40.8% variation in OD600nm, asym values, whereas PC2 captures 37.7% 
variation (Figure 6A). The scores of each component grouped as strains clustered closely 
(within the normal probability). This indicates that the growths are consistent among 
biological replicates regardless of fermentative substrate.  Arrows oriented towards the 
same direction denote that growth on a particular carbohydrate is correlated with that PC 
component with the angle between arrows indicating a similar response profile (Figure 
2.6A). LNT and galactose utilization vectors emanated towards similar directions that is 
negatively correlated with both PCs. These two vectors aligned along PC1 where ATCC 
15697 and UMA301 growths clustered. UMA300 growth, however, aligned positively 
with PC1 in the same direction as the LNnT utilization vector. This indicates that UMA300 
utilized LNnT well relative to other carbohydrates and strains. This is consistent with 
strain-dependent utilization, as UMA300 had a higher final OD600nm, asym during LNnT 
utilization compared to other strains (Figure 2.7D). Interestingly, the LNnT and lactose 
utilization vectors were oriented in opposing directions suggesting utilization differences 
between them. GlcNAc and glucose utilization had a similar alignment and positively 
correlated with both components where UMA299 clustered. This indicates that UMA299 
growths are mostly correlated with GlcNAc and glucose utilization, which is consistent 
with its limited ability to utilize HMO efficiently.  
Hierarchal clustering was employed to determine quantitative similarities between 
strains. The height between the lines indicates the distances between the strains and their 
biological replicates (Figure 2.6B). The PCA and hierarchal clustering were concordant 
and indicated that ATCC 15697 and UMA301 clustered together with the height of less 
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than 4 (Figure 2.6B). Interestingly, this reflects the phylogenic relationship of ATCC 15697 
with UMA301 [197]. 
In addition to final biomass achieved, PCA of growth rates observed on multiple 
substrates resolve onto PC1 to encompass 51.6% variability for each strain and positively 
correlated with all carbohydrates except lactose (Figure 2.6C). This is interesting as 
Bifidobacterium strains were previously determined to possess a preference for lactose over 
glucose [207], with lactose often used as a positive control and propagation of 
bifidobacterial strains. ATCC 15697 and UMA301 co-clustered and negatively correlated 
with PC1. These two strains exhibited similar utilization rates for all substrates tested. 
Interestingly, UMA300 growth rates on galactose, LNT, glucose, and GlcNAc were similar 
and distinctly clustered from other strains (Figure 2.6C) with significantly higher values 
on these carbohydrate sources compared to other strains (p<0.05, Figure 2.7). Hierarchal 
clustering using the Ward method validated the PCA (Figure 2.6D). Hierarchal clustering 
of the growth rate is also consistent with the same analysis of the final biomass (OD600nm, 
asym), which yields a similar distance topology. Accounting for the empirical evidence in 
aggregate, B. infantis utilization of LNT and LNnT diverges in a strain-dependent manner.  
2.4.8 B. longum subsp. infantis strains differentially metabolize lacto-N-tetraose and 
lacto-N-neotetraose 
A comparative analysis of the fermentative endproducts lactic acid, acetic acid, 
formic acid, and ethanol was conducted on the panel of B. infantis strains. These 
endproducts are secreted as a result of carbon flux through the F6PPK pathway with data 
reported as a heatmap with hierarchal clustering analysis (Figure 2.8A). As expected, acetic 
acid and lactic acid production clustered more closely with each other than the ethanol and 
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formic acid production as these two endproducts are secreted regardless of substrate 
(Figure 2.8A).  
The metabolic profiling of ATCC 15697 and UMA301 while fermenting galactose, 
lactose and LNT closely clustered together with high acetic and lactic acid and less formic 
acid and ethanol produced (Figure 2.8A). Interestingly, UMA299 produced higher 
concentrations of formic acid and ethanol when utilizing GlcNAc, glucose, LNT, and 
LNnT relative to other carbohydrates (Figure 2.8A). This indicates that UMA299 utilizes 
LNT via a different metabolic trajectory relative than other strains. This is consistent with 
its final biomass and general phenotype as an atypical HMO consumer (Figure 2.7C).  
ATCC 15697, UMA301, and UMA299 LNnT metabolism was linked to higher 
formic acid and ethanol concentration. UMA300, in contrast, exhibited a significantly 
different metabolic profile that is closely linked to LNT with less formic acid and ethanol 
production than the other strains (Figure 2.8A). This did not differ appreciably from 
galactose, lactose, and glucose metabolism. This suggests that UMA300, unlike other 
strains, preferentially converts pyruvate to lactic acid rather than acetyl-CoA regardless of 
the substrate with the exception of GlcNAc. UMA299 produced higher concentrations of 
acetic acid relative to other carbohydrates reflecting deacetylation of GlcNAc before 
entering central metabolism (Figure 2.3).  
The carbon recovery in metabolites after utilization of mono- and disaccharides are 
depicted in Figure S2.1B. UMA299 recovered almost 100% carbon for all sugars except 
galactose. All strains recovered less than 100% carbon while fermenting galactose. ATCC 
15697, UMA299, and UMA301 achieved almost 100% carbon recovery while utilizing 
lactose. Interestingly, UMA300 exhibited 138% of carbon recovery as determined by 
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metabolite following growth on lactose. This was significantly higher than ATCC 15697 
and UMA301 (p<0.05). This might be due to hydrolysis of the remaining lactose into 
glucose and galactose in the after fermentation medium with UMA300 potentially 
exhibiting a preference for utilizing monosaccharides over lactose. 
The acetic acid:lactic acid ratios secreted after B. infantis strains fermented 
substrates were compared (Figure 2.8B-D). Accordingly, PC1 and PC2 encompass 50.7% 
and 31.2% of the variation for these ratios (Figure 2.8B). UMA300 and UMA301 displayed 
a positive correlation with PC1 whereas ATCC 15697 and UMA299 were negatively 
correlated. This is due to higher ratio values of strains on a particular carbohydrate with 
each strain clustering distinctly due to PC2. The hierarchical clustering of strains was 
consistent with the PCA (Figure 2.8C). This is because UMA299 showed a significantly 
higher ratio in both LNT and LNnT metabolism relative to other strains (p<0.05, Figure 
2.9A). In addition, the direction of the LNT and LNnT vectors are negatively oriented with 
both components with a highly similar magnitude and direction in PCA (Figure 2.8B). This 
explains the close clustering of LNT and LNnT based on Euclidean distance (< 0.95) 
whereas the HMO carbohydrate constituents segregated away from both HMO species 
(Figure 2.8D). The agglomerative clustering of strains revealed no differences for LNT and 
LNnT. This is potentially due to GlcNAc deacetylation increasing acetic acid production 
during HMO utilization.  
Formic acid production underlies divergent mechanisms for LNT and LNnT 
metabolism. Accordingly, the PCA performed on the acetic acid:lactic acid:formic acid 
ratios clearly indicates that LNT and LNnT fermentation proceeds via distinctive metabolic 
routes as these vectors are oriented in opposing directions along PC1 (captures 52.0% 
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variation) (Figure 2.8E). This suggests that B. infantis strains shunt LNnT catabolism 
towards conversion of pyruvate to acetyl-CoA rather than lactic acid to subsequently 
secrete formic acid.  
UMA300 was positively positioned along PC1 whereas ATCC 15697 and 
UMA301 were primarily explained by PC2. Interestingly, ATCC 15697 and UMA301 do 
not cluster together as depicted in Figure 2.8F despite exhibiting phenotypic and 
phylogenetic similarities. However, if the significance of height in the hierarchical 
clustering is increased, they cluster together and only UMA300 stands alone. This is due 
to UMA300 not significantly secreting formic acid except during GlcNAc fermentation. B. 
infantis ATCC 15697 and UMA301 produced significantly more formic acid during LNnT 
fermentation than LNT that resulted in a decrease of the ratio (p<0.05, Figure 2.9B).  
The ethanol to lactic acid ratio was dependent on the carbohydrate source and strain 
(Figure 2.9C). UMA300 did not produce ethanol regardless of the substrate whereas 
UMA299 exhibited a higher ratio for both LNT and LNnT relative to other strains (p<0.05). 
Interestingly, UMA301 had limited ethanol production during LNT fermentation while the 
ratio increased in LNnT utilization. This means that all strains except UMA300 utilize 
LNnT along a similar metabolic route. Thus LNnT utilization in ATCC 15697 and 
UMA301 might involve NAD+ regeneration through ethanol production whereas recycling 
NAD+ in LNT utilization most likely occur during pyruvate to lactic acid conversion.   
2.4.9 Human milk carbohydrate utilization mitigates lipopolysaccharide-induced 
IL-8 expression in Caco-2 epithelial cells  
It is known that metabolism of specific carbohydrates may influence bifidobacterial 
interactions with intestinal epithelia under certain conditions. Pooled HMO-grown 
 66 
bifidobacteria reduce inflammatory markers compared to glucose or lactose-grown 
bifidobacteria [219, 220]. These previous studies examined adhesive properties of 
bifidobacteria and bacterial translocation in exponential growth instead of cell-free 
supernatants collected at stationary phase. Differential metabolism of LNT and LNnT 
inspired the hypothesis that host-microbial interactions may be influenced in a milk 
oligosaccharide-dependent manner. In order to address this, metabolites present in spent 
media subsequent to B. infantis growth on lactose, LNT, and LNnT were evaluated for 
their ability to mitigate inflammation. Specifically, it was hypothesized that higher acetic 
acid and formic acid concentrations secreted from LNnT metabolism will differentially 
influence inflammation. Gene expression of the cytokine marker of inflammation IL-8 was 
measured in Caco-2 cells following lipopolysaccharide-induced inflammation (Figure 
2.10). Accordingly, spent media from all three fermentations significantly reduced IL-8 
expression compared with the negative control (p<0.05). However, there was no significant 
difference between the three milk carbohydrates. In addition, the markers of inflammation 
IL-10 and TNF-a were assayed to yield inconsistent and thus inconclusive results. 
Although B. infantis metabolism of these human milk carbohydrates protects against 
inflammation, it is unclear to what extent that B. infantis alone is responsible for the anti-
inflammatory effect. In addition, purified acetic acid, lactic acid, and formic acid were 
tested, however, the results were inconclusive due to variation between biological 
replicates. 
2.5 Discussion 
Bifidobacterium longum subsp. infantis evolved to utilize glycans secreted in 
human milk to generate ATP as well as provide substrates for anabolic processes. 
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Accordingly, its genome incorporates a 40-kb locus dedicated to human milk 
oligosaccharide utilization that is conserved in all B. infantis strains isolated to date [11, 
197]. The activities encoded by the HMO gene cluster allocate degradation products to be 
further metabolized prior to entering the F6PPK pathway, the characteristic fermentative 
pathway unique to the Bifidobacterium genus [188]. HMOs evade digestion during 
gastrointestinal tract transit and thus are available to B. infantis to translocate to 
intracellularly [184, 196]. The F6PPK pathway terminates invariably in the extracellular 
secretion of acetic acid and lactic acid, with formic acid and ethanol generated to a lesser 
extent under specific conditions [188–191]. The potential for B. infantis to differentially 
metabolize purified HMO species has not been fully tested. The HMO tetrasaccharides 
LNT and LNnT differ by a β1-3 and β1-4 linkage between galactose and N-
acetylglucosamine at the non-reducing terminus respectively. Accounting for this 
structural variance, we hypothesized that LNT and LNnT are differentially metabolized 
after initiating distinct transcriptomic cascades to process these HMOs.  
Previous research conducted on B. infantis provided the preliminary observations 
to generate this hypothesis [45, 185]. In this current study, the model HMO-consuming 
strain B. infantis ATCC 15697 exhibits higher growth efficiency (i.e. asymptotic final OD) 
while metabolizing LNT rather than LNnT. This occurred in the absence of a preference 
for LNT over LNnT extrapolated from their similar growth rates. Thus ATCC 15697 may 
experience enhanced fitness when encountering LNT in the infant gut, although this 
remains to be tested in an in vivo system. Moreover, ATCC 15697 diverges in the metabolic 
fate of carbons during LNT or LNnT utilization. The ratio of secreted acetic acid to lactic 
acid (AA:LA) is considerably higher for LNT and LNnT than other carbohydrates. 
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Importantly, LNnT promotes a significantly higher AA:LA ratio relative to LNT. The 
deacetylation of GlcNAc via deacetylase activity (EC 3.5.1.25, Figure 2.3) likely 
contributes to the increase in relative concentrations of acetic acid during LNT metabolism.  
Of particular importance is that LNnT metabolism significantly increases formic 
acid production. This is not observed during LNT metabolism and constitutes a major 
metabolic shift solely attributable to the isomeric composition of LNnT. Thus the AA:LA 
ratio increases during LNnT fermentation likely due to GlcNAc deacetylation and a 
simultaneous decrease in lactic acid in shunting pyruvate towards formic acid production. 
The conversion of pyruvate to acetyl-CoA and subsequently to acetic acid during LNnT 
utilization results in formic acid and ethanol production. Modulation of acetic acid 
production harnesses higher levels of ATP during LNnT fermentation. This is consistent 
with the relative inefficiency LNnT is utilized for biomass as limited ATP restricts cellular 
growth. Bifidobacteria are known to increase formic acid secretion during inefficient 
metabolism of unfavorable substrates [193, 216, 221–223]. It is noteworthy that previous 
studies observed cellular growth considerably lower than the accumulated biomass 
generated on LNnT in the present study.  
In addition, increased ethanol production during LNnT metabolism recycles NAD+ 
following reduction of acetyl-coA. Since formic acid is generated at the expense of lactic 
acid, recovering NAD+ is critical as lactic acid production recycles cofactors and does not 
yield ATP [191]. On a molar basis the 2-carbon pathway terminating in ethanol recoups 
double the amount of NAD+ than the 3-carbon arm (i.e. pyruvate to lactic acid). Whereas 
it is clear that LNnT shifts metabolism towards formic acid and ethanol production, the 
molecular mechanisms underlying these alternative pathways remains incompletely 
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understood. It is clear, however, that the terminal β1-4 linkage in LNnT prompts this 
divergent physiological response. 
In an effort to determine the contribution of global gene expression to LNT and 
LNnT metabolism, previously generated RNA-seq data was analyzed in addition to 
targeting key loci with qRT-PCR. A previous study of Bifidobacterium breve UCC2003 
concluded that there are overlapping metabolic transcriptional networks with some critical 
features that are unique between LNT and LNnT metabolism [224]. It is noteworthy that 
B. breve evolved the capacity to hydrolyze HMO extracellularly and imports degradation 
products. There is limited evidence that B. infantis is able to do so, which indicates a 
fundamental physiological difference between the two species. As B. infantis captures 
HMO from its extracellular environment, the complement and expression transport 
proteins may catalyze or restrict metabolism of a given HMO species. Among F1SBPs, 
Blon_2347 expression differed between the two HMO species, whereas Blon_2177 and 
Blon_2344 was expressed regardless of the specific HMO. Interestingly, the global 
transcriptome exhibited a different expression profile for these particular genes. Additional 
studies are required to resolve the conflict between expression of transporters predicted to 
be active on type I glycans (i.e. LNT)[184] that were observed to be induced by the type II 
LNnT. Further characterization of the functional interactions between transport systems 
and HMO substrates may be essential to address these discrepancies.  
The aminosugar residue GlcNAc is a constituent of LNT, LNnT, and all HMOs 
with a degree of polymerization ≥ 4. Prior to entering the F6PPK pathway, GlcNAc is 
processed by two enzymes putatively encoded within the ATCC 15697 genome. This 
includes GlcNAc-6-P deacetylase (nagA; Blon_0882) that deacetylates GlcNAc prior to 
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deamination by glucosamine-6-P isomerase (nagB; Blon_0881). B. infantis expresses both 
of these proteins when grown on pooled HMO as reported in a previous study [217]. Both 
LNT and LNnT upregulated these loci supporting the postulate that HMO-bound GlcNAc 
metabolism contributes to skewing the AA:LA ratio. The elevated AA:LA ratio was 
observed for pooled HMO and LNT in a previous study that focused primarily on 
galactooligosaccharides [213]. It is important to note that GlcNAc-bound in HMO may not 
be fully catabolized through the F6PPK pathway as GlcNAc could serve as a substrate in 
anabolism including peptidoglycan and other biosynthetic processes [185]. Interestingly, 
ATCC 15697 does not utilize GlcNAc when supplied as sole carbon source in the media 
in contrast to other B. infantis strains. This may be due to a genetic or regulatory variation 
inherent to the strain. Moreover, hexosaminadase genes were expressed similarly 
regardless of the particular HMO isomer. These enzymes liberate GlcNAc from galactose 
through hydrolyzing the β1-3 linkage that is present in both LNT and LNnT.  
The terminal galactose, contrastingly, is connected to GlcNAc via a β1-3 linkage 
in LNT and a β1-4 linkage in LNnT. Thus it was unexpected that a type I glycan-active 
(e.g. LNT) b-galactosidase (Blon_2016) is downregulated by LNT and not LNnT (p<0.05) 
[218]. This may be due to constitutive expression of other b-galactosidase that cleaves the 
terminal galactose in vivo. It is significant that both HMO isomers upregulate two genes 
that are predicted to feed galactose into the F6PPK pathway. This includes gal-1-P 
uridylyltransferase (galT; Blon_2172) and UDP-glc epimerase (gale; Blon_2171) that are 
localized adjacent to HMO transporters on the ATCC 15697 chromosome. Furthermore, 
LNnT induces these genes to a greater extent than LNT. This provides mechanistic detail 
for the physiological differences between LNnT and LNT fermentation. 
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Interestingly, LNT and LNnT upregulates a-L-fucosidase gene expression despite 
lacking fucosyl moieties within their respective oligosaccharide structure. Accordingly, 
LNT strongly upregulates two fucosidases localized to the HMO catabolic cluster. This 
suggests that there is overlapping regulatory systems or B. infantis recognizes LNT and 
LNnT as signaling molecules to prepare for metabolizing fucosylated HMO. HMO 
tetrasaccharides is utilized early in fermenting pooled HMOs prior to fucosylated 
glycans[187].  
Constituent monosaccharides bound in HMO are transformed into substrates 
catabolized through the F6PPK pathway. Accordingly, LNnT upregulates several genes in 
this central metabolic pathway likely to satisfy energy demands from a more inefficiently 
metabolized oligosaccharide. It is interesting that both acetate kinase and lactate 
dehydrogenase are upregulated by LNnT relative to LNT or lactose. The former is expected 
given the physiological evidence for increased acetic acid secretion. Lactate dehydrogenase 
upregulation may be a consequence of fully activating a central metabolic regulon to 
maintain the NAD+/NADH homeostasis. There is a significant link between formic acid 
production and transcriptional processes. LNnT strongly induces formate acetyl transferase 
(pfl; EC 2.3.1.54), which catalyzes formic acid and acetyl-CoA production from pyruvate. 
In contrast, LNT downregulates this gene as well as pyruvate formate lyase, the latter of 
which appears to be constitutively expressed during LNnT fermentation. This represents a 
strong mechanistic association between the LNnT structure and B. infantis genomic 
features to drive the metabolic phenotype.  
As bacterial strains of a given taxon may exhibit profoundly dissimilar phenotypes, 
three additional B. infantis strains were examined. B. infantis UMA301 exhibits a very 
 72 
similar metabolic response to the LNT and LNnT relative to ATCC 15697. Interestingly, 
these two strains are closely related phylogenetically [197] which suggests that metabolic 
signature may be a function of phylogenetic divergence for B. infantis HMO utilization. 
Similarly to ATCC15697, LNnT shifts UMA301 metabolism towards formic acid and 
increases the ratio of acetic acid to lactic acid secretion.  
In contrast, UMA300 efficiently utilizes both LNnT and LNT and does not produce 
formic acid and ethanol on either substrate to the same extent as ATCC 15697 and 
UMA301. This is likely a function of UMA300 processing LNnT in a similar manner as 
LNT, which obviates the need for a metabolic shift. The inefficient HMO-consumer 
UMA299 exhibits a metabolic response congruent with this unique phenotype among B. 
infantis examined to date [197]. The limited capacity to utilize HMO has been attributed 
to genetic defects within its HMO genomic cluster and provides a control strain linking 
genotype with metabolic phenotypes. As a result of inefficient growth on LNT and LNnT, 
UMA299 increases the AA:LA ratio and formic acid/ethanol production. This is consistent 
with the hypothesis that diminished capacity for utilizing HMO promotes higher acetic acid 
concentrations compared to other carbohydrates despite achieving low optical density.  
A cell culture approach was used to further develop a model of host-microbial 
interactions that incorporates inefficient metabolism of specific HMOs. Cell-free 
supernatants from B. infantis HMO fermentations were evaluated for their anti-
inflammatory properties on Caco-2 cells. Given the parameters tested, it appears that B. 
infantis reduces inflammation regardless of milk carbohydrate source. Specific anti-
inflammatory molecules presented or secreted by B. infantis remains hypothetical. 
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Moreover, the extent to which other HMO structures diminish inflammatory outcomes is 
not understood. 
In conclusion, LNT and LNnT utilization increased the AA:LA ratio in all strains. 
In instances where LNT or LNnT was inefficiently utilized, carbon was shunted towards 
formic acid and ethanol secretion. A fully integrated mechanistic model underlying this 
phenotype remains incompletely developed. Thus, there is a scientific need to investigate 
all purified HMO species, additional B. infantis strains, as well as other bifidobacterial 
species to ascertain linkages between HMO structure and physiological responses. This 
will further refine the metabolic model by which bifidobacteria utilize HMO to colonize 
the nursing infant colon. In addition to fundamental biological research, there are broad 
implications to infant nutrition and health. There is accumulating evidence that rationally 
designing interventions to enhance infant nutrition will require judicious selection of 
HMOs. This could involve incorporating a single HMO species or a mixture. Clearly a 
specific HMO tetrasaccharide has different metabolic consequences depending on the B. 
infantis population. There is the potential for strain-level effects to influence the emergent 
properties of the infant gut microbiome community. Accounting for variation between 
bifidobacteria, HMO structures, the biology of the infant, and their hosted microbiome 
communities may enable delivery of precision nutrition and increase impact of the 
intervention. 
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Table 2.1 List of strains used in this study a 
Strain Species Origin 
ATCC 15697 B. longum subsp. infantis Human infant feces 
UMA299 B. longum subsp. infantis Human infant feces 
UMA300 B. longum subsp. infantis Human infant feces 
UMA301 B. longum subsp. infantis Human infant feces 
a UMA: University of Massachusetts Amherst Culture Collection, ATCC: American Type 
Culture Collection.  
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Figure 2.1 B. longum subsp. infantis ATCC 15697 growth kinetics while utilizing 
milk carbohydrates. The final asymptotic OD600nm (A) and growth rate (k, h-1) (B) of 
B. infantis ATCC15697 subsisting on mMRS medium containing 2% (wt/v) galactose 
(Gal), lactose (Lac), lacto-N-tetraose (LNT) or lacto-N-neotetraose (LNnT). The growth 
kinetics was calculated with Wolfram Mathematica 10.3. The data depicts mean ±SD of 
three independent experiments. The single asterisk (*) indicates the significant 
differences between carbohydrate utilizations evaluated by one-way ANOVA and 
Tukey’s multiple comparison (p<0.05). 
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Figure 2.2 B. longum subsp. infantis ATCC 15697 fermentative endproducts while 
utilizing milk carbohydrates through the F6PPK pathway. Absolute concentrations of 
lactic acid (A), acetic acid (B), formic acid (C), and ethanol (D). In addition, acetic acid 
to lactic acid ratio (E), formic acid to lactic acid ratio (F), formic acid to acetic acid ratio 
(G), and ethanol to lactic acid ratio (H). All panels represent B. infantis ATCC15697 
growing on mMRS medium containing 2% (wt/v) galactose (Gal), lactose (Lac), lacto-N-
tetraose (LNT), or lacto-N-neotetraose (LNnT). Averages from independent biological 
replicates (triplicate or more) are shown with bars representing standard deviations of the 
means. The values for organic acid production are expressed in millimolar (mM) absolute 
concentration. A single asterisk (*) denotes significant differences between metabolite 
production evaluated by one-way ANOVA and Tukey’s multiple comparison test 
(p<0.05). 
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Figure 2.3 Bifidobacterium longum subsp. infantis metabolic pathways for utilization 
of lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT) and their constituent 
monosaccharides. LNT and LNnT translocate through the cell membrane facilitated by 
ABC transporters. Intracellular glycosyl hydrolases process HMO into constituent 
monosaccharides to enter the central fermentative pathway. This pathway involves the 
characteristic fructose-6-phosphate phosphoketolase (F6PPK) activity denoted in blue. 
Genes encoding intracellular metabolic enzymes are depicted next to arrows according to 
their locus tag in the ATCC 15697 genome. Solid arrows are direct conversions with 
dashed arrows depicting the sequential actions of multiple enzymes. Predicted catabolic 
operations that feed into the F6PPK pathway and their corresponding products are 
denoted as purple. Stoichiometric coefficients of secreted metabolites, ATP, and NAD+ 
produced during metabolism are labeled in red. Experimental observations depicted in 
Figure 2.1 and 2.2 including stoichiometry are incorporated.   
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Figure 2.4 ATCC 15697 gene expression while subsisting on milk oligosaccharides 
as a sole carbon source. The x-axis represents gene locus tags of Family 1 solute 
binding proteins (A), ABC permeases (B), and GlcNAc-active genes (C). The y-axis 
depicts the fold changes in gene expression relative to the control lactose as measured by 
qRT-PCR. LNT and LNnT are denoted in purple and gray. The error bars show standard 
deviations of three biological replicates except for LNnT. Single asterisk (*) indicate 
p<0.05 evaluated by one-way ANOVA and Tukey’s multiple comparison.   
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Figure 2.5 Relative gene expression within the global transcriptome depicted as 
log2-fold change. The log2-fold change gene expression from independent biological 
duplicates was performed from raw reads using the R package DESeq2. The 2-fold 
change expressions were subjected to hierarchal clustering using Euclidean distance and 
depicted as z-scores. Gene annotations and predicted functions are reported in Table 
A2.2.  
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Figure 2.6 Strain dependent variation of human milk oligosaccharide utilization. (A) 
and (C) depict the 2D-principal component analysis (PCA) performed on the final 
asymptotic OD600 and the growth rate (k, h-1) respectively. The arrows in PCA plot 
represent the correlation of variables with the principal components (PC1 and PC2). 
Points represent the scores of each component grouped as biological replicates. The 
ellipses encompassing each strain capture 68% of the normal probability of the scores 
within corresponding strains. Panels (B) and (D) show the hierarchal clustering 
dendrogram of strains on the final asymptotic OD600nm and the growth rate (k, h-1) using 
ward method and Euclidean distance. The y-axis measures closeness of either individual 
strains or clusters. The boxes show the 95 % of clustering and closeness of the strains.  
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Figure 2.7 Growth kinetics of B. longum subsp. infantis strains subsisting on milk 
carbohydrates. The final asymptotic OD600nm and growth rate (k, h-1) of B. infantis strains 
while growing on mMRS medium containing 2% (wt/v) galactose (A), lactose (B), lacto-
N-tetraose (LNT) (C), and lacto-N-neotetraose (LNnT) (D). The growth kinetics was 
calculated with Wolfram Mathematica 10.3 and represents the mean ±SD of three 
independent experiments. Purple and red bars indicate bacterial growth and growth rate 
respectively. The asterisks indicate the significant differences between strains evaluated 
by one-way ANOVA and Tukey’s multiple comparison. Single asterisk (*) indicates 
p<0.05, double asterisks (**) p<0.005, triple asterisks (***) p<0.0005, and quadruple 
asterisks (****) p<0.0001. The growth kinetics for glucose and GlcNAc were not 
included as not all strains consume these monosaccharides.  
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Figure 2.8 Analysis of B. longum subsp infantis strains secreted fermentative 
endproducts while utilizing milk carbohydrates.(A) metabolites secreted by B. infantis 
strains for each carbohydrate clustered by Euclidean distance calculated with 
MetaboAnalyst 3.0. The scaling was performed by mean-centering and dividing by the 
standard deviation of each metabolite. The red denotes lower concentrations of the 
metabolite with yellow approaching higher concentrations. Panels (B) and (E) display the 
2D-principal component analysis (PCA) plot depicting acetic acid to lactic acid ratios and 
acetic acid to lactic acid to formic acid ratios respectively. The arrows in PCA plot 
represent the correlation of the variables with the principal components (PC1 and PC2). 
Points represent the scores of each component grouped as biological replicates. The 
ellipses for each strain incorporate 68% of the normal probability of the scores for 
corresponding strains. Panels (C) and (F) are hierarchal clustering dendrogram of strains 
according to acetic acid to lactic acid ratios and acetic acid to lactic acid to formic acid 
ratios using the Ward method and Euclidean distance. The y-axis measures the closeness 
of either individual strains or their calculated clusters. Panels D) and (G) represent 
hierarchal clustering based on p-values calculated with multiscale bootstrapping between 
acetic acid to lactic acid ratio and acetic acid to lactic acid to formic acid ratio. The y-axis 
measures the closeness of either individual substrates or clusters according to two 
metrics: Approximately Unbiased p-value (AU in red) and Bootstrap Probability value 
(BP in blue). Clusters exhibiting AU values greater than 95% are highlighted by 
rectangles.  
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Figure 2.9 Endproduct ratios of B. longum subsp. infantis strain fermentative 
endproducts while utilizing the milk carbohydrates. Acetic acid to lactic acid ratio 
(A), acetic acid to lactic acid to formic acid ratio (B), and ethanol to lactic acid ratio (C). 
Colors indicate the following carbohydrate substrates: Purple, galactose; red, lactose; 
dark blue, lacto-N-tetraose; green, lacto-N-neotetraose. Averages from independent 
biological replicates (at least triplicate) are shown with bars representing standard 
deviation from the mean. The asterisks indicate the significant differences evaluated by 
two-way ANOVA and Tukey’s multiple comparison. Single asterisk (*) indicates p<0.05, 
double asterisks (**) p<0.005, triple asterisks (***) p<0.0005 and quadruple asterisks 
(****) p<0.0001. 
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Figure 2.10 Gene expression of inflammatory marker Interleukin-8 in Caco-2 
epithelial cells exposed to spent media following milk oligosaccharide fermentation. 
The y-axis represents the fold change in IL-8 expression relative to phosphate buffer 
solution (PBS). The x-axis depicts the sources of B. infantis metabolites which are used 
to treat Caco-2 cells after lipopolysaccharides (LPS) induction. The error bars show 
standard deviations of biological duplicates, each measured with three technical 
replicates. The single asterisks (*) indicate the significant differences evaluated by one-
way ANOVA and Tukey’s multiple comparison (p<0.05).  
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3.1 Introduction 
Human milk contains host-indigestible oligosaccharides at high concentrations (5–
20 g/l) [175] which are often utilized for energy and metabolite production by the infant 
gut microbiome, specifically bifidobacteria [9, 225, 226]. These oligosaccharides enhance 
bifidobacterial fitness to establish representation relative to competing genera [183]. 
Bifidobacterium longum subsp. infantis (B. infantis) is a special member of infant gut 
microbiome with a 43-kb gene cluster that lead the utilization of human milk 
oligosaccharides (HMOs)[11]. The B. longum subsp. infantis ATCC 15697 genome 
features five distinct gene clusters with the predicted capacity to bind, cleave, and import 
milk oligosaccharides. These contain solute binding proteins, ABC permeases, and 
glycosyl hydrolases such as fucosidases and sialysidases which are active for respective 
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HMOs utilization [45, 186, 187, 197, 199, 227, 228]. Importantly, solute binding proteins 
and ABC permeases, a transport mechanism for B. infantis to recognize oligosaccharides 
and transport them inside the cells in their intact form [45, 229]. Previous comparative 
genomic hybridizations (CGHs) were used to associate genotypic biomarkers among B. 
longum strains exhibiting various HMO utilization phenotypes and host associations [197]. 
Interestingly, B. infantis UMA299 (JCM 1260) misses two F1SBP transporter genes 
(Blon_2344 and Blon_2351) in its HMO catabolic cluster [197]. The missing transporters 
might contribute to the inefficient metabolism of  HMOs, especially LNT and LNnT [229, 
230]. Additionally, not all the types of HMOs are utilized at the same rate by B. infantis.  
Previously, we interrogated four B. infantis strains for their ability to utilize LNT 
and LNnT [229]. Multilocus sequence typing provided taxonomic subspecies designations 
and grouped the strains between B. infantis [197]. Therefore, we chose the strains 
according to their distance to ATCC 15697. We observed that B. infantis strains deployed 
differential mechanisms on the human milk tetrasaccharides determined by growth and 
metabolite production. In this study, we interrogate same strains for their strain-dependent 
utilization of pooled HMO followed by growth, glycoprofiling, and metabolite production. 
Metabolite production shows us the efficiency of the energy metabolism during utilization 
of HMOs whereas glycoprofiling allows us to display which type of HMOs from pooled 
donors are utilized or preferred by each B. infantis strains.  
3.2 Materials and Methods 
3.2.1 Bacterial strains and propagation 
Bifidobacterium longum subsp. infantis strains ATCC 15697, UMA299, UMA300 
and UMA301 were propagated in De Man Rogosa Sharp (MRS, BD Difco, Sparks, MD) 
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medium supplemented with 0.05 % (wt/v) L-cysteine hydrochloride (Acros Organics, New 
Jersey, USA) [201] at 37° C under anaerobic conditions (Coy Laboratory Products, Grass 
Lake, MI). Bacterial strains were routinely verified as described previously [229].  
3.2.2 Microplate growth assay  
Growth phenotypes were evaluated in a 96-well plate using microplate reader. 
Overnight cultures were inoculated 1% (v/v) to modified MRS media (mMRS; a defined 
carbohydrate substrate and no acetate). Pooled HMO, LNT and LNnT (Glycom, Denmark) 
and 2´FL (donated from Mills Lab at UC Davis) were used at a final concentration of 2 % 
(wt/v) as the sole carbon source. Carbohydrate sources were incorporated into culture 
media in non-limiting concentrations. The growth assay was conducted anaerobically at 37 
°C for 48 h by assessing optical density at 600 nm (OD600nm) in an automated PowerWave 
HT microplate spectrophotometer (BioTek Instruments, Inc. Winooski, VT) placed within 
the anaerobic chamber. Each strain was evaluated in biological triplicates with three 
technical replicates. Inoculated mMRS media in the absence of carbohydrate substrates and 
in the presence of lactose were served as the negative and positive control, respectively. 
Growth kinetics were calculated using growthcurver package in R [231]. 
3.2.3 Analysis of human milk oligosaccharides (HMO) by Nano-LC Chip Q-TOF MS 
The diluted and purified HMO were analyzed by an Agilent 6520 accurate-mass 
Quadrupole-Time-of-Flight (Q-TOF)-LC/MS with a microfluidic nano-electrospray chip 
(Agilent Technologies, Santa Clara, CA, USA). Oligosaccharides were separated by a 
HPLC-chip with a 40-nL enrichment column and a 43-mm x 75μm analytical column, both 
packed with 5μm graphitized carbon. The system composed of a capillary pump with a 
flow rate of 4.0μL/min and a nanopump with a flow rate of 0.3μl/min. Both systems use 
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binary solvent: 3% ACN, 0.1% formic acid in water (A) and 90% ACN, 0.1% formic acid 
in water (B). Two microliters of samples were carried by capillary pump with isocratic 
100% solvent A (0%B). HMO separation and elution was performed by nanopump with 
65 mins binary gradient followed the program:  0–2.5 min (0% B), 2.5–20 min (0–16% B), 
20–30 min,(16–44% B), 30–35 min (44–100% B), 35–45 min ( 100% B), 45–45.01 min 
(100-0% B), 45.01-65 min (0% B). Data were acquired within the mass range of 450-2500 
m/z in positive ionization mode with an acquisition rate of 1 spectra/s. An internal 
calibration ion was performed using 922.009798 and 1221.990637 m/z for continual mass 
calibration (ESI-TOF Tuning Mix G1969-85000, Agilent Technologies, Santa Clara, CA, 
USA).  For Tandem MS (MS/MS), the spectra were acquired with MS/MS scan 100-2500 
m/z with acquisition rate of 1 spectra/s.  The collision energy was set at 1.3V/100Da with 
an offset of -3.5V.  
3.2.4 Human milk oligosaccharides (HMO) identification 
HMO were identified using the Find Compounds by Formula function of Mass 
Hunter Qualitative Analysis Version B.07.00 (Agilent Technologies, Santa Clara, CA). 
The function matched oligosaccharide masses in the positive control sample with the 
human milk library [177, 232] using a mass error tolerance of 20 ppm. The 
oligosaccharides were extracted with minimum peak height of 1000 counts and allowing 
charge state of +1-2. The compositions of each identified oligosaccharides were confirmed 
by Tandem MS and only confirmed HMO structures were selected to created HMO sample 
library with specific mass and retention time. Any HMO in the positive control sample that 
were not previously identified by Find Compounds by Formula function but were 
structurally confirmed by Tandem MS were also included in the HMO sample library. This 
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library was used in MassHunter Profinder Version B.08.00 (Agilent Technologies, Santa 
Clara, CA, USA) as an input library for peak integration.   
The individual peaks of HMO in each sample were automatically integrated using 
the Batch Targeted Feature Extractor from MassHunter Profinder Version B.08.00 (Agilent 
Technologies, Santa Clara, CA, USA). The software matched the confirmed HMO mass 
and their retention time from the HMO sample library with the MS data automated 
integration the peak with mass tolerance of 20ppm and allowed charge stage of +1-2. All 
integrated peaks were manually checked and reintegrated for any incorrect integration. 
3.2.5 Characterization of microbial fermentative end products 
End products from bacterial fermentation were quantitated by HPLC. Bacterial 
strains were initially propagated as described above. Cell-free supernatants from 
microplate growths were obtained at stationary phase and filtered through a 0.22 µm filter 
(Sartorius Corp, Bohemia, NY) following centrifugation and stored at -20° C until further 
analysis. Organic acids were quantified using an Agilent 1260 Infinity HPLC system 
(Agilent Technologies, Santa Clara, CA) equipped with a Wyatt Optilab T-rEX refractive-
index detector (Wyatt Technology Corp., Santa Barbara, CA). Separation was carried out 
using an Aminex HPX-87H column (7.8 mm ID x 300 mm, Bio Rad Laboratories, 
Hercules, CA) at 30° C in a mobile phase of 5 mM H2SO4 at flow rate of 0.6 ml/min with 
20 µl of injection volume. Standards including organic acids (i.e. acetic acid, lactic acid, 
formic acid), ethanol, 1,2-propanediol and carbohydrates (i.e. glucose, galactose, lactose, 
GlcNAc, fucose) were acquired from Sigma-Aldrich Co. (St. Louis, MO). Metabolite 
concentrations were calculated from standard curves derived from external standards for 
seven concentrations (0.1, 0.5, 1, 5, 10, 20 and 50 mM). Metabolite profiling was carried 
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out in triplicate and each measurement was performed in duplicate. The metabolite 
profiling for each strain were analyzed using MetaboAnalyst 3.0 
(http://www.metaboanalyst.ca)[206].  
3.2.6 Enzyme Assay 
The enzymatic assay was performed to determine the localization of the enzymes 
β-galactosidase, β-N-acetylhexosaminidase, and α-L-fucosidase. Bifidobacterial cells 
were grown in MRS overnight and harvested by centrifugation at 16, 000 x g for 2 min. 
The pelleted cells were resuspended in 50mM sodium phosphate buffer (pH 7.0). Extracts 
were separated in two and cell free extracts were obtained through beadbeating at 5.5 m/sec 
for 30 seconds twice using FastPrep 24 (MP Biomedicals, Santa Ana, CA). This was done 
to separate cytoplasmic fraction from the cell walls. Each fraction (50 μl) was incubated 
with 1mM substrate (250 μl) in 50 mM sodium phosphate buffer at 37° C for 30 min in 1.5 
ml centrifuge tubes. The substrates used were 4-nitrophenyl-N-acetyl- β-D-glucosaminide, 
2-nitrophenyl-N-β-D-galactopyranoside, 2-chloro-4-nitrophenyl-α-L-fucopyranoside. 
The reaction was stopped by adding 300 μl of 1 M Na2CO3. The amount of released 4-
nitrophenol were determined by measuring the absorbance at 405 nm in a microplate reader 
(BioTek Instruments, Inc. Winooski, VT). When lactose, LNT, LNnT, HMO and 2´-
fucosyllactose were used as the substrates, the reaction terminated by heating 95° C for 5 
min. The released monosaccharides were visualized by HPLC as described above. 
3.3 Results 
3.3.1 B. infantis strains differentially grow on pooled HMO 
The most vigorous growth was observed in UMA301 with 0.62±0.08 of OD600nm, 
asym followed by ATCC 15697 with 0.55±0.06 and UMA299 with 0.49±0.04 (Figure 3.1A, 
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p>0.05). A significantly lesser growth observed in UMA300 with 0.34±0.05 of OD600nm, 
asym. Similarly, concordance with the final biomass, growth rate was significantly lower in 
UMA300 (k=0.23±0.02 h-1, Table A3.1, p<0.05). As expected significantly higher growth 
rate occur in type strain ATCC 15697 (k=0.78±0.05 h-1) followed by UMA301(0.63±0.01 
h-1) (Table A3.1, p<0.05). This indicates a clear adaptation to HMO utilization in ATCC 
15697 than other strains.  
3.3.2 B. infantis strains differentially consume human milk oligosaccharides  
In total, 36 HMOs including isomers/anomers were monitored and structures were 
confirmed by Tandem MS. Total and individual HMO consumptions by four B. infantis 
strain were visualized in Figure 3.2 and 3.3. The total consumptions of HMO by 
ATCC15697 with 84.0±1.3 % and UMA301 with 79.8±2.0 % were significantly higher 
compared to UMA299 and UMA300 (p<0.05, Figure 3.2). ATCC 15697 and UMA301 
consumed all lacto-N-(neo)tetraose isomers effectively (Figure 3.3A), while smaller 
carbohydrates contained 2_1_0_0 structures consumed partially. ATCC15697 and 
UMA301 consumed all LNFP, LNDFH, FLNH, DFLNH isomers completely (Figure 
3.3B). On the other hand, they partially consumed FL (2_0_1_0) and LDFT (3_1_2_0). 
The compounds contain only hexose and fucose did not seem to be consumed effectively 
by ATCC 15697 and UMA301 strains. It was observed that larger fucosylated HMOs were 
preferred over smaller ones. Sialylated HMOs were partially consumed by ATCC15697 
and UMA301 (Figure 4.2B).  
UMA299 and UMA300 showed very low consumption overall (Figure 3.2). This 
is expected due to their lower biomass and growth rate experienced in microplate. 
However, the identification of individual HMOs reveals that there seems to be an 
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accumulation of some compounds that lead to the low consumptionn. The accumulation 
was observed in some of neutral HMOs, some of fucosylated compounds, and all sialylated 
HMOs (Negative consumption means that the area of that respective compound in bacterial 
fermentation samples is higher than that in pre-fermentation samples, data not shown). 
UMA299 and UMA300 did not consume all lacto-N-(neo)tetraose isomers as effective as 
other two strains (Figure 3.3A, p<0.05). This is consistent with previous results for 
UMA299 as it utilizes LNT and LNnT inefficiently. Interestingly, UMA300 was 
previously shown to utilize both LNT and LNnT effectively whereas it did not consume 
them effectively in pooled HMOs. This might be due to its higher preference towards other 
compounds. Nevertheless, main effect analysis showed that UMA299 and UMA300 
consumes neutral HMO different than each other (p<0.05). UMA300 showed an 
accumulation in 3 of trisaccharide neutral HMOs and a Hexose2HexNAc2, whereas 
UMA299 was effectively utilizing Hexose2HexNAc2. 
UMA299 consumed all fucosyllactose isomers (2_0_1_0) and LDFT (3_1_2_0) 
and only 2 of 5 lacto-N-fucopentaose (LNFP) isomers (3_1_1_0). UMA299 did not 
consume lacto-N-difucohexaose (LNDFH) isomers which were accumulated in the 
supernatants. On the other hand, UMA300 only consumed one isomer of fucosyllactose, 3 
of 5 lacto-N-fucopentaose (LNFP) isomers (3_1_1_0), all isomers of FLNH and DFLNH. 
The linkage difference between the isomers might prevent them from consuming one or 
the others. The consumption of sialylated HMOs showed that UMA299 and UMA300 
displayed an accumulation of all identified compounds (Figure 3.3C).  
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3.3.3 Secretion of carbon metabolites alter among four B. infantis strains during 
pooled HMO consumption 
The secreted metabolites through fructose-6-phosphate phosphoketolase (F6PPK) 
pathway were shown in Figure 3.4. Lactic acid, acetic acid and formic acid were secreted 
constitutively but variably among strains. Ethanol concentration were incomparable due to 
ethanol existences in pre-fermentation HMO samples. ATCC15697 and UMA301 highly 
secreted lactic acid (23.19±0.15 mM and 26.49±1.26) and acetic acid (40.10±0.78mM and 
43.99±1.59 mM) (Figure A3.1 and Figure 3.4A). Lactic acid concentrations for both strains 
were significantly higher than UMA299 (p<0.05). UMA301 also showed significantly 
higher acetic acid concentrations than UMA299 and UMA300 (p<0.05). On the other hand, 
UMA299 showed significantly higher concentrations of formic acid (6.80±0.91 mM) than 
ATCC15697 (4.16±1.17 mM) and UMA300 (3.42±0.94 mM) (Figure A3.1, p<0.05). In 
addition, the metabolite secretion in UMA299 while utilizing pooled HMOs was clustered 
differently than other strains while the others showed similar phenotypes (Figure 3.4A).  
The theoretical ratio of acetic acid to lactic acid in hexose fermentation through 
F6PPK pathway is 1.5. The Figure 3.4B shows the acetic acid to lactic acid ratio after 
pooled HMO consumption. The theoretical ratio was reached in UMA300 with the ratio of 
1.56±0.02 and it was significantly lower than other strains (p<0.05). This is interesting that 
UMA300 also produced lower concentrations of formic acid. The highest ratio was 
observed in UMA299 with 1.95±0.03. UMA301 and ATCC15697 showed similarity to 
each other but higher ratio than their corresponding lactose control (data not shown). 
Pooled HMO fermentation revealed shift in central metabolism and resulted in increase in 
the ratio of acetic acid to lactic acid. 
94 
 
Additionally, secretion of 1,2-propanediol (1,2PD) was observed in all strains. This 
metabolite is expected in fucose degradation which is not utilized by F6PPK. Interestingly, 
B. infantis does not possess genes required for production of 1,2PD, instead the genes 
possessed leads to the production of lactate and pyruvate. In our study, we observed smaller 
amounts of 1,2-propanediol after fermentation of pooled HMOs, indicating a more 
complex utilization of fucosylated compounds. UMA299 showed significantly higher 
concentrations of 1,2PD than other strains (7.76±0.48 mM, p<0.05, Figure A3.1). In order 
to see the significance of 1,2PD to fucosylated HMOs utilization, we checked lactose 
samples and no 1,2PD was observed.  
3.3.4 Utilization of 2´-fucosyllactose among four B. infantis strains leads 1,2-
propanediol production  
We observed a differential utilization of 2´FL in pooled HMOs and its differential 
utilization within the HMO species; therefore, we analyzed its utilization using pure 
compound by B. infantis strains. UMA299 showed higher growth in 2´-fucosyllactose 
(2´FL) with asymptotic OD600nm of 0.79±0.08 which was significantly higher than ATCC 
15697 with asymptotic OD600nm of 0.41±0.11 (Figure 3.5A). UMA300 and UMA301 
showed moderate growths. The growth rate of all strains did not significantly differ 
(p>0.05, Table A3.1).  
The metabolite production for 2´FL was shown in Figure A3.2 and Figure 3.5B. 
All strains produced 1,2PD, acetic acid, lactic acid, formic acid and ethanol during 
consumption of 2´FL. UMA299 showed significantly higher concentrations of acetic acid 
(59.64±3,62 mM), lactic acid (29.14±1.86 mM), and 1,2PD (14.37±1.20 mM) compared 
to other strains (p<0.05) accompanied by low formic acid (11.67±0.91 mM) and ethanol 
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(4.24±0.24 mM) concentrations during the growth of 2´FL. This was consistent with its 
higher growth. This also led UMA299 cluster differently than other strains (Figure 3.5B). 
Consistent with the growth, inefficient utilization of 2´FL by ATCC 15697 revealed higher 
formic acid (19.94±0.82 mM) than both UMA299 and UMA301 (p<0.05), but lower lactic 
acid (8.89±2.43 mM), acetic acid (39.32±1.49 mM) concentrations (p<0.05). 1,2PD 
concentrations was similar with other strains except UM299. Similarly, UMA300 
utilization of 2´FL yielded higher formic acid (19.99±0.91 mM) and ethanol (5.46±0.26 
mM) production compared to UMA299 and UMA301 (p <0.05), but moderate acetic 
(47.11 ±1.29 mM) and lactic acid (13.27±1.32 mM) concentrations (Figure A3.2). This 
also led this strain to be clustered far from UMA301 and ATCC 15697 (Figure 3.5B). 
UMA301 showed significantly lower ethanol concentration (1.91±0.26 mM) than other 
strains (p<0.05).  
Acetic acid to lactic acid ratio was shown in Figure A3.2F. 2´FL utilization showed 
higher ratio than their lactose control (p<0.05). UMA299 showed lower ratio of acetic acid 
and lactic acid with 2.05±0.02 consistent with high consumption. This was significantly 
lower than ATCC 15697 and UMA300. Highest ratio was observed in ATCC 15697 with 
4.60±0.94 followed by UMA300 with 3.60±0.28. UMA 301 showed a ratio of 2.92±0.05.  
3.3.5 Not the locations and but the activities of	 β-galactosidase, β-N-
acetylhexosaminidase and α-fucosidase differ among B. infantis strains 
Through glycoprofiling, we observed that there could be an accumulation on some 
individual HMOs. This led us to consider if this accumulation occurs extracellular activities 
of larger HMO compounds. We determined the localization of enzymes (intracellular vs 
extracellular) by incubating several substrates with whole cells and cell lysates. All B. 
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infantis strains possess both extracellular and intracellular β-galactosidase as we observed 
release of p-nitrophenol (pNp) (Figure 3.6). UMA300 showed the lowest enzymatic 
activity on all comparisons, although the cell densities were adjusted before the enzymatic 
assay. Although there were some nitrophenol amount released in the whole cell incubation 
with pNp-N-acetylglucosaminide, we count that as a background where all strains possess 
only intracellular β-N-acetylhexosaminidase. This indicated that the localization of 
enzymes did not differ among strains but the enzyme activity (the amount of nitrophenol 
released) differed. UMA299 released significantly higher amounts of nitrophenol (p<0.05) 
compared to other strains. We also confirmed these activities of the sugar release after 
fermentations of B. infantis strains cell-free lysates or whole cell with LNT, LNnT, 2´FL. 
ATCC 15697 lysates showed release of glucose, galactose and GlcNAc after incubation 
with 1mM LNT and LNnT (Figure A3.3). The chromatograms of whole cell ATCC 15697 
incubation with LNT and LNnT showed very little amounts of glucose and galactose 
(Figure A3.3) but not GlcNAc. ATCC 15697 is known to utilize HMOs in their intact form 
due to intracellular β-galactosidase, β-N-acetylhexosaminidases. This might be due to the 
release of sugars after chopped intracellular but not extracellular degradation due to the 
osmosis balance in the cells. The lysates of UMA300 incubation with LNT and LNnT 
showed a release of galactose and GlcNAc but not glucose. The whole cell incubation of 
UMA300 with LNT and LNnT did not show any released sugar. 
3.4 Discussion 
 Following birth, microbes resides in the human gut where they create a commensal 
ecosystem. Combination of the dietary pattern and the genetic evolution of a microbe allow 
them to adapt the environment which they are living in. Microbial metabolic networks such 
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as carbon acquisition and assimilation establish the activities in the gut and determine the 
infant’s wellness being as well. Bifidobacteria were known to be a representative member 
of the infant gut [233] and B. infantis was found to have an adaptive mechanism for human 
milk oligosaccharides which provides them advantage over residence in the gut [11, 234]. 
Human milk contains various prebiotics components that promote the growth of 
bifidobacteria [183]. The composition of oligosaccharides in human milk varies among 
individuals [235, 236] and this variety determines the composition of the microbes in the 
infant gut [237]. In addition, the genetic traits of species also determines the type of the 
strains to reside [197, 238].  
 B. infantis strains represent two different group in their ability to utilize human milk 
oligosaccharides (Albert et al, In preparation). For example, B. infantis UMA299 (JCM 
1260) misses two F1SBP transporter genes (Blon_2344 and Blon_2351) in its HMO 
catabolic cluster [197]. In this study, we determine whether these genetic characteristics 
affect the utilization phenotype.    
 UMA299 grew moderately on the pooled HMOs. Although its total consumption 
of HMOs lower than 20 %, most of these were fucosylated compounds with DP=3 and 4. 
Its capacity with missing two transporters explains its inefficient utilization of pooled 
HMOs and LNT and LNnT [229]. The two solute binding proteins Blon_2344 and 
Blon_2351 resides next to sialidases and hexosaminidases. This coincides that this strain 
showed no utilization of sialylated HMOs and limited utilization of neutral HMOs. 
However, fucosylated HMOs might require different set of transport mechanism that 
UMA299 likely to deploy and able to grow on these compounds. The ability of UMA299 
grown on fucosylated compounds was also confirmed by its efficient growth on pure 2´FL. 
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In both pooled HMO metabolism and 2´FL metabolism, this strain produced significantly 
higher amounts of 1,2PD, which was suggested to be a metabolite for fucose metabolism 
[239]. Although B. infantis did not have the genes necessary for this metabolite to be 
produced [239], we observed the presence of 1,2PD, which might need for further 
investigation for the mechanisms deployed and the preference of this strain on the 
fucosylated compounds in pooled HMOs.  
Interestingly, UMA300 does not utilize pooled HMO efficiently, however, our 
previous results showed that this strain used both LNT and LNnT to high concentrations 
[229]. This might be due to the preference of other HMO types for carbohydrate and energy 
assimilation for this strain. UMA300 showed up to 100 % utilization of fucosylated HMOs 
with DPs over 5. It consumes moderately fucosylated lactose in both pooled HMOs and 
pure 2´FL.  
Generally, we observed that inefficient utilization of carbohydrates leads formic 
acid formation and lower acetic acid to lactic acid ratio in B. infantis metabolism. However, 
although UMA300 did not utilize pooled HMOs efficiently, its metabolism contradicts 
with our previous observations. In contrast to its other phylogenetically relative neighbors, 
this strain does not follow that hypothesis. This is of importance to further investigate 
whether this strain possesses genes to produce formic acid. Interestingly, 2´FL metabolism 
leads to higher formic acid production and acetic acid to lactic acid ratio in UMA300. This 
means that phenotype related to formic acid production is not related to the genetic 
predisposition, it might be related to the phenotypic response. It is still unclear what 
regulates for strains to deploy higher formic acid production.  
99 
 
 ATCC 15697 and UMA301 (JCM7007) are phylogenetically close to each other 
[197]. Our previous results on pure LNT and LNnT growths and corresponding metabolic 
activity showed that these strains deploys similar growth and metabolic phenotype [229]. 
This was consistent with our observations in growth on pooled HMOs and metabolic end 
production in this study. They also deployed similar utilization profiles with neutral and 
fucosylated HMOs glycoprofiling in this study. However, they were different on utilizing 
sialylated HMOs with DP=3. Although they showed similar growth pattern in pure 2´FL, 
the metabolite production differed between these strains. Ethanol, lactic acid, formic acid 
production showed significantly different concentrations between these two strains as well 
as the acetic acid to lactic acid ratio. In addition, the amount of nitrophenyl produced during 
enzymatic assay was also different on both N-acetyl-glucosaminide and galactopyronoside.   
In conclusion, the strain-dependent utilization of pooled HMO is deployed to be 
determined by growth, glycoprofiling, and metabolite production. However, the specific 
genes and mechanism involved in the metabolism of HMOs needs to be investigated; on 
the other hand, we can identify the strain-dependent variances in HMO utilization in 
genomic and functional level.  
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Figure 3.1 Bifidobacterium infantis growth while utilizing pooled human milk 
oligosaccharides. Growth curves of Bifidobacterium infantis ATCC 15697, UMA299, 
UMA300 and UMA301 on modified MRS containing 2 % (w/v) pooled human milk 
oligosaccharides. The curves are drawn from average of three independent experiments.   
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Figure 3.2 Total HMO consumption glycoprofiling for B. longum subsp. infantis 
strains. Total HMO abundance was represented as the normalized percent consumption 
of total HMO. The total HMO area are normalized by area of internal standard. The 
percent consumption was calculated by the difference between the normalized area of 
post-fermentation samples and pre-fermentation samples divided by area of the pre-
fermentation samples. Averages from independent biological triplicates are shown with 
bars representing standard deviations of the means. A single asterisk (*) denotes 
significant differences between strains evaluated by one-way ANOVA and Tukey’s 
multiple comparison test (p<0.05). 
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Figure 3.3 Total HMO consumption glycoprofiling for B. longum subsp. infantis 
strains. Individual HMO (A) neutral HMOs (B) fucosylated HMOs and (C) sialylated 
HMOs abundance was represented as the normalized percent consumption. The 
individual HMO area are normalized by area of internal standard. The percent 
consumption was calculated by the difference between the normalized area of post-
fermentation samples and pre-fermentation samples divided by area of the pre-
fermentation samples. Negative consumption values are cut from the y-axis. Averages 
from independent biological triplicates are shown with bars representing standard 
deviations of the means.   
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Figure 3.4 Analysis of B. longum subsp infantis strains secreted fermentative 
endproducts while utilizing pooled human milk oligosaccharides. Panel (A) denote 
metabolites secreted by B. infantis strains clustered by Euclidean distance calculated with 
MetaboAnalyst 3.0. The scaling was performed by mean-centering and dividing by the 
standard deviation of each metabolite. The red denotes higher concentrations of the 
metabolite with blue approaching lower concentrations. Panel (B) represents acetic acid 
to lactic acid ratio of B. infantis ATCC15697 growing on mMRS medium containing 2% 
(wt/v) human milk oligosaccharides. Averages from independent biological triplicates are 
shown with bars representing standard deviations of the means. A single asterisk (*) 
denotes significant differences between strains evaluated by one-way ANOVA and 
Tukey’s multiple comparison test (p<0.05). 
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Figure 3.5 Analysis of B. longum subsp infantis strains while utilizing pooled 2´-
fucosyllactose. (A) Growth curves of Bifidobacterium infantis ATCC 15697, UMA299, 
UMA300 and UMA301 on modified MRS containing 2 % (w/v) 2´-fucosyllactose. The 
curves are drawn from average of three independent experiments. (B) metabolites 
secreted by B. infantis strains clustered by Euclidean distance calculated with 
MetaboAnalyst 3.0. The scaling was performed by mean-centering and dividing by the 
standard deviation of each metabolite. The red denotes higher concentrations of the 
metabolite with blue approaching lower concentrations.  
 
A 
B 
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Figure 3.6 Enzyme assay of B. longum subsp. infantis strains. The nitrophenol 
amounts represented as millimolar were produced after p-nitrophenol-N-acetyl-
glucosaminide and o-nitrophenol-galactopyronoside fermentation of whole cells and cell-
free lysates of Bifidobacterium infantis ATCC 15697, UMA299, UMA300 and UMA301. 
Averages from independent biological triplicates are shown with bars representing 
standard deviations of the means. Letters denote the significant differences between 
strains evaluated by one-way ANOVA and Tukey’s multiple comparison test (p<0.05). 
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4.1 Introduction 
Human milk contains high concentrations of indigestible oligosaccharides, as well 
as other nutritive molecules that promote growth early in life [171, 175]. These 
oligosaccharides are not digested by the infant; however, they are utilized by commensal 
gut microbiota such as bifidobacteria. Tetrasaccharides lacto-N-tetraose (LNT) and lacto-
N-neotetraose (LNnT) are highly abundant oligosaccharides in human milk. These isomers 
are identical aside from a glycosidic linkage (i.e., β1-3 vs. β1-4), which leads to the 
hypothesis that this dissimilarity might reveal differences in microbial physiology. We 
previously investigated this phenomenon for Bifidobacterium longum subsp. infantis type 
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strain ATCC 15697 supported by growth phenotype, microbial fermentative metabolite 
production and comparative transcriptome analysis [229].  
The utilization of pooled and individual oligosaccharides by pure cultures of gut 
microbiome members was previously investigated [186, 200, 212, 220, 240–242]. 
However, the metabolic activity driven by this utilization was not clearly underlined. Gut 
microbes produce metabolites sequestered by the host, including short chain fatty acids 
(SCFAs) [49, 75, 77, 243]. They compete for food, with metabolites secreted by one 
member often utilized by a secondary microbial population [74]. Adaptation of B. infantis 
to grow on human milk oligosaccharides (HMOs) might reveal interactions with microbes 
in the infant gut which do not possess capacity to utilize HMOs. For instance, some bacteria 
require formate for acetogenesis and butyrate and acetate as the fermentative end products 
[244]. Bacteria that utilize lactic acid may also convert lactate to butyrate [245]. The gut 
microbiome also harbors acetate converting bacteria that produces butyrate [246]. These 
activities simultaneously occur during digestion of dietary oligosaccharides. These cross-
feeding activities between the two members of the gut microbial community have also been 
investigated in their response to dietary oligosaccharides [240, 247–250]. However, these 
are limited to few species. The interactions of the complex communities are still of interest. 
Previously, dietary oligosaccharides were tested for their capacity to manipulate microbial 
interactions in the in vitro batch culture models [52, 251] as well as the human milk 
oligosaccharides [51, 252–254].  
B. infantis utilizes HMOs in their intact form and produce metabolites. Therefore, 
during microbe-microbe interactions, if their adaptation for HMO utilization provides 
domination over other microbes, those microbes will not consume degradant products but 
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rather the metabolites to survive. The difference between the metabolite profile will 
manipulate the community structure. B. infantis mainly produces acetate and lactate; 
however, we showed that inefficient utilization of HMOs results in production of formate 
by B. infantis strains [229]. 
Not much is known about formate production and its role in the intestine. It has 
been previously shown that formate concentrations in the gut were elevated during 
inflammation-associated dysbiosis and this led a fitness of formate utilizing E.coli in the 
gut, which requires oxygen respiration [255]. In vitro models simulating microbe-microbe 
interactions allow us to identify networks of metabolic pathways in the intestine with their 
simultaneous interaction with dietary oligosaccharides. The microbe-microbe interactions 
give signatures for metabolic dysbiosis in the gut during the administration of dietary 
oligosaccharides.  
In this chapter, we investigate the microbe-microbe interaction during simultaneous 
digestion of human milk tetrasaccharides (LNT and LNnT) within a modeled microbial 
community derived from fecal samples from nursing infants. This chapter follows the 
findings and questions regarding differential utilization of tetrasaccharides by B. infantis 
and its effects in the gut microbial interactions. We chose a model that would best 
accommodate our needs for investigation of microbe-microbe interactions in given 
conditions.  
4.2 Materials and Methods 
4.2.1 Preparation of fecal derived communities 
The diapers from two infant donors were collected from week one to five and saved 
in biohazard bags containing oxygen absorber packs (FreshUS, Brea CA) and stored at -
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20°C by mothers until transportation. The fecal samples were transported to the laboratory 
with ice packs. A piece from  the diapers was cut and suspended in 1:1 (v/v) 10X phosphate 
buffered saline (0.1M, containing 0.05 % L-cysteine.HCl (Across Organics, UK) : 20 % 
glycerol solution to make a final glycerol concentration of 10% (a standard glycerol 
concentration used for fecal transplants (Hamilton et al., 2012)). The piece was then 
squeezed into the solution using a tongue depressor, and then discarded after a slurry 
formed. The fecal slurries were then aliquoted into cryo vials and stored at −80ºC until the 
experiments were conducted. The day before inoculation into bioreactors, fecal glycerol 
stocks were thawed, and samples were pooled (30 ul) and inoculated into colon media with 
lactose (1 % w/v). The fecal derived microbial communities were then incubated at 37ºC 
under anaerobic conditions (Coy Laboratory Products, Grass Lake, MI). This step was 
performed to satisfy enough bacterial density before inoculation into bioreactors.  
 In addition to fecal derived microbial communities, Bifidobacterium longum subsp. 
infantis ATCC 15697 (B. infantis) was incubated in De Man Rogosa Sharp (MRS, Oxoid, 
Hampshire, England) medium supplemented with 0.05% (wt/v) L-cysteine (Sigma-
Aldrich, St. Louis, MO) at 37 ºC under anaerobic conditions (Coy Laboratory Products, 
Grass Lake, MI). The day before the inoculation into bioreactors, overnight grown cultures 
in MRS broth were conditioned to the colon media with lactose (1 % w/v) and incubated 
under same conditions overnight.  
 The fecal slurries were formed from the two infant diapers and were used in 
fermentations. In addition, the fecal communities were mixed with equal volumes of B. 
infantis and used for fermentations. In total, 4 different communities were tested in their 
ability to ferment lactose, LNT and LNnT.  
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4.2.2 Colon media composition 
The colon media was prepared as described previously [252] and modified 
accordingly. The media consist of 0.5 g/l bile salts (Oxoid), 2 g/l peptone water (Fluka), 2 
g/l yeast extract (Sigma-Aldrich), 0.1 g/l NaCl (Fisher Chemicals), 0.04 g/l K2HPO4 (Fisher 
Chemicals), 0.01 g/l MgSO4 × 7H2O (Sigma), 0.01 g/l CaCl2 × 6H2O(sigma), 2 g/l NaHCO3 
(Sigma-Aldrich), 0.5 g/l L-Cysteine.HCl (Acros Organics) and Tween-80 2 ml (Sigma-
Aldrich). Hemin (Sigma-Aldrich) was autoclaved separately by dissolving 2 mg/ml in 0.5 
M NaOH and mixed with colon media at the final concentration of 0.002 g/l. Similarly, 
Vitamin K1 (Sigma-Aldrich) was added to colon media after autoclaving at the final 
concentration 10 µl/l.  
For the bioreactors, 400 ml freshly prepared media was supplemented with 4 g of 
lactose, lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT) to make 1 % (w/v) of 
carbohydrate source necessary for fermentations. Then, the prepared media was filtered by 
using sterile bottle top filters (PES membrane, 0.22 μm, CellTreat) and aseptically fed into 
already autoclaved bioreactor vessels.    
4.2.3 In vitro fermentations 
An Eppendorf DASGIP MP-8 4 vessel bioreactor system for in vitro microbial 
community fermentations was used. The three bioreactors containing in-place pH 
(Hamilton Company, Reno, NV), Redox (Hamilton Company, Reno, NV) and Optical 
Density (Exner Process Equipment GmbH, Etllingen, Germany) probes were autoclaved 
at 121 ºC for 15 min. After they were filled with media, the vessels were mounted onto the 
DASGIP reactor base. Then, the vessels were flushed with gas mix (85% N2, 10 % CO2, 5 
%H2) at a constant rate of 25 l/h overnight and the temperature was set to 37 °C and pH 
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was maintained at 6.8 by addition of 4M NaOH. The pumps were designed to feed the 
vessels at a rate according to value of pH. The overnight grown microbiome culture 
obtained from baby fecal samples (4 ml) with or without addition of B. infantis ATCC 
15697 (4 ml) were inoculated into the parallel reactor vessels containing lactose, LNT, or 
LNnT. 3 ml of sample was taken at hour 0, 4, 6 (only lactose), 8, 12, 14 (only LNT and 
LNnT), 16, 18 (only LNT and LNnT), 20, 24, 30, 36, and 48. Samples from each reactor 
were aliquoted equally and centrifuged at 16,000 x g for 2 min. The supernatants were 
separated from the pellet and stored in -20 ºC until HPLC analysis. The pellets were 
dissolved in 1 ml Ambion RNAlater (Life Technologies, Carlsbad, CA) and stored in 4 ºC 
overnight, transferred into -80 ºC until DNA extraction.  
4.2.4 Targeted fermentative end product profiling using HPLC 
Cell-free supernatants stored in -20 ºC were filtered through a 0.22μm filter 
(Sartorius Corp, Bohemia, NY). Short chain fatty acids and lactic acid were quantified 
using an Agilent 1260 Infinity HPLC (Agilent Technologies, Santa Clara, CA) system 
equipped with a Wyatt Optilab T-rEX detector (Refractive Index detector, Wyatt 
Technology Corp, Santa Barbara, CA). Separation was carried out using an Aminex HPX-
87H column (7.8mm ID × 300mm, Bio Rad Laboratories, Hercules, CA) at 30 ºC in a 
mobile phase of 5mM H2SO4 at flow rate of 0.6 ml/min with 20 μl of injection volume. 
Standards including organic acids (i.e., acetic acid, lactic acid, formic acid, propionic acid 
and butyric acid), ethanol, and carbohydrates (i.e., glucose, galactose, lactose, and N-
acetylglucosamine) were acquired from Sigma-Aldrich Co. (St. Louis, MO). Metabolite 
concentrations were calculated from standard curves derived from external standards for 
six concentrations (0.1, 0.5, 1, 5, 10, 20, 50, and 100mM).  
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4.2.5 DNA extraction 
The cell pellets in RNAlater were first washed twice with 1X PBS buffer to remove 
residual RNAlater and centrifuged at 12,000 × g for 2min. Then the samples were subjected 
to DNA extraction using DNeasy Powerlyzer PowerSoil (Qiagen, Germany) kit. Briefly, 
the samples were transferred into PowerBead tubes containing PowerBead solution and 
bead beaded at 4.5 m/sec for 45 sec twice with 5 min ice incubation in between cycles. The 
rest was followed according to the manufacturer’s instructions. The DNA was eluted in 50 
μl Tris buffer provided by the kit. DNA was stored -20 ºC until qPCR and library 
preparation. 
4.2.6 Quantitative real time-PCR 
The qRT-PCR was performed on a 7500 Fast Real-Time PCR System (Applied 
Biosystems, Singapore) with PowerUP SYBR Green Master Mix (Applied Biosystems, 
Foster City, CA) using 5 ng of input DNA. Bifidobacterium infantis/longum (BLIR) [204] 
specific primers were optimized for qPCR conditions by using FWD_BL_BI (5-[HEX]-
AAAACGTCCATCCATCACA) and REV_BI (5-CGCCTCAGTTCTTTAATGT). The 
qPCR reaction run in fast cycling mode with 10 µl reaction volume with conditions as 
follows: 95 ºC for 2 min, 40 cycles of 95 ºC for 1 min, 54 ºC for 1 min, 72 ºC 30sec, 
followed by melting curve 95 ºC for 15 sec, 60 ºC for 1 min and 95 ºC for 15 sec.   
4.2.7 16S profiling library preparation and data analysis 
Purified DNA samples (1 to 50 ng total in up to 36 µl water) were used to PCR 
amplify the V4 region of the 16S rRNA provided by BiooScientific NEXTFlexTM 16S V4 
Amplicon-Seq Kit 2.0 (PerkinElmer Company, BiooScientific Corporation, Austin, TX). 
The primers were developed by BiooScientific as 16S V4 Forward (5’-
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GACGCTCTTCCGATCTTATGGTAATTGTGTGCCAGCMGCCGCGGTAA-3’) and 
16S V4 Reverse (5’-
TGTGCTCTTCCGATCTAGTCAGTCAGCCGGACTACHVGGGTWTCTAAT-3’). 
PCR amplification was performed under following conditions: 95 °C for 4 min, 8 cycles 
of 95 °C for 30 s, 56 °C for 30 s, and 72 °C for 90 s, and 72 °C for 4 min. AMPure XP 
beads (Beckman Coulter, Danvers, MA, USA) were used to purify the PCR products free 
from primers and other contaminants. A second PCR was performed for barcoded indices 
and adaptors using the NEXTflex kit, followed by bead cleanup. Purified PCR products 
were quantified using the Qubit double-stranded DNA (dsDNA) High Sensitivity assay 
(Life Technologies, Carlsbad, CA, USA). The quality of PCR products was measured by 
High Sensitivity DNA ScreenTape assay on the TapeStation 2200 system (Agilent 
Technologies, Santa Clara, CA, USA). PCR products were pooled in equimolar 
concentration (0.5 nM). Sequencing was performed on an Illumina MiSeq platform 
(paired-end, MiSeq reagent kit v2, 30% Phi-X) at the Genomics Resource Laboratory, 
University of Massachusetts Amherst, MA. 
Sequences of 16S rRNA gene amplicons of all 72 bioreactor samples were analyzed 
in QIIME2 (version 2018.8) [256]. Demultiplexed forward and reverse reads were input to 
dada2 method to denoise and dereplicate paired-end sequences as well as filter potential 
chimeras. Forward and reverse reads were truncated at base position 230 and 190 
respectively due to the decrease in quality and reads with number of expected errors higher 
than 1.0 were discarded as a natural choice [257], the method used to remove chimeras was 
set to “pooled” and other parameters followed default [258]. Taxonomic annotations were 
assigned to denoised sequences by using a pre-trained Naïve Bayes classifier [259] based 
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on Greengenes database 13_8 release (99% OTUs, V4)[260] and the q2-feature-classifier 
plugin [261]. Reads were further filtered to remove mitochondria, chloroplast and the 
genus Shigella regarded as contamination. The amplicon sequence variant (ASV) table 
[262] was finally narrowed down to 48 features with total frequency of 537,276. Taxa bar 
plots of phylogenetic level 2 and level 6 were visualized online [263] and further edited 
and colored by GraphPad. In order to proceed to downstream phylogenetic diversity 
metrics, a rooted phylogenetic tree was generated through align-to-tree-mafft-fasttree 
pipeline from the q2-phylogeny plugin [264, 265]. The ASV table was rarefied [266]alpha 
and beta diversity analysis were conducted, with sampling depth 350, through the q2-
diversity and q2-longitudinal (Bokulich N. a., 2017) plugins. Principal Coordinates 
Analysis (PCoA) plots were further downloaded and edited in Inkscape (version 0.92). 
4.3 Results 
4.3.1 Fermentation profile and conditions 
The fermentations of lactose, LNT and LNnT in the bioreactor were monitored 
using optical density, pH and redox probes. The communities followed sigmoid growth 
curve in all fermentations (Figure A4.1). The decreased in pH during growth was 
maintained by addition of 4 M NaOH at most 3ml/min depending on pH. After growth 
reaches a plateau phase, NaOH feeding stopped and pH started to increase for all 
fermentations (Figure A4.1). Redox was stabilized around -300 and -400 before inoculation 
and after inoculation during growth, redox potential decreased over time (Figure A4.1); 
however, the flow rate kept constant for all fermentations. 
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4.3.2 Fecal derived microbiomes exhibit differential metabolite production  
Regardless of B. infantis addition, the SCFA profiling between fecal derived 
microbiomes from 1st and 2nd baby differed from each other (Figure 4.1). In the 1st fecal 
microbiomes, lactate concentrations increased, then decreased after 24th h of fermentation 
and reached undetectable levels after 36th h (Figure 4.1A). B. infantis addition to the 1st 
microbiomes increased lactate production until 24th h of fermentation in LNT whereas it 
decreased in LNnT (Figure 4.1A). This shows that addition of B. infantis facilitated LNT 
fermentation by increasing the lactate production whereas it adversely affected LNnT 
fermentation. This is consistent with the hypothesis that B. infantis does not utilize LNnT 
efficiently and results in lower lactate concentrations as observed in pure cultures. 
In the 2nd fecal microbiomes, lactate concentrations increased in the early hours of 
fermentation, then reached a plateau after the 12 hours of fermentation for lactose, 14 hour 
of fermentation for LNT, 18 hour of fermentation for LNnT (Figure 4.1B). Interestingly, 
LNnT fermentation by microbiomes 2 without B. infantis reached higher lactate 
concentrations compared to other substrates and addition of B. infantis. This coincides with 
microbiomes 1 considering the fact that B. infantis does not utilize LNnT efficiently that 
could have an adverse effect on fermentation profile. In LNT fermentation, addition of B. 
infantis slightly increased the lactate concentrations.  
Acetate concentrations in the 1st microbiomes without B. infantis did not differ 
much between LNT and LNnT concentrations (Figure 4.1C). The concentrations increased 
over time and continued to increase at a slower rate after 24 h. This increase might indicate 
that there are other members of the fecal communities that might use other sources to 
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produce more acetic acid or they use acetate as an energy source therefore we did not 
observe a sharp increase.  
In in the 2nd microbiomes, regardless of carbohydrate source and B. infantis 
addition, acetate concentrations reached to a plateau after 20 hours of fermentation (Figure 
4.1D). This phenomenon might be explained if either there are no other sources leading 
production of acetate or utilization of acetate as a substrate is more prominent in fecal 
communities.  
Formate is a metabolite occurring during B. infantis utilization of LNnT over LNT. 
It was previously indicated that formate was being produced during bifidobacterial 
fermentation with lower optical density [229]. The difference in formate production 
between human milk tetrasaccharides led us to that hypothesis which we argue that 
inefficient LNnT utilization of B. infantis with production of formate might change the 
microbiome structure with divergent metabolite profiling. In this bioreactor set up, we also 
saw that formate production in LNnT fermentation by 1st microbiomes with B. infantis 
addition reached to higher levels compared to that of LNT and LNnT fermentation by 1st 
microbiomes without B. infantis (Figure 4.1E). Then, there was a sudden decrease in their 
concentration after 16th hour. This means that formate was also utilized by other members 
of the microbiome.  
Similarly, the addition of B. infantis into 2nd fecal derived microbiomes increased 
the formate production for LNnT fermentation (Figure 4.1F). B. infantis addition did not 
change the production of formate for LNT fermentation. 
Regardless of fermentation, there was a decrease in formate concentrations for all 
fermentations. This means that formate was being utilized by the other members of the 
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fecal communities leading the production of other metabolites. Formate utilization might 
lead butyrate and acetate production by the acetogens [267]. However, in microbiomes 2, 
we did not observe butyrate production. This means that there are also other members 
involved in formate utilization that does not lead butyrate production.  
The decrease after the 24th h in the lactate concentrations for all fermentation in 1st 
microbiomes indicates that there are other members of the community which are able to 
use lactic acid as an energy and carbon source and produce other metabolites i.e. butyric 
acid. During LNT and LNnT fermentations in fecal communities 1 without B. infantis, 
butyric acid production was observed after the 24 h of fermentation (Figure 4.1G). This 
coincides with the sudden drop at 24th in lactate concentrations. It was previously shown 
that lactate utilizing bacteria produce butyric acid as a major fermentative end product 
[245]. For 1st fecal microbiomes with B. infantis addition, we saw early increase in the 
butyrate concentrations, especially in LNnT fermentation (Figure 4.1G). 
In the fecal microbiomes 2, there was no production of butyrate in any of the 
fermentations. This could be explained by the differences in the composition of the two 
fecal derived microbiomes used at the beginning, regardless of addition of B. infantis.  
Another metabolite produced during fecal fermentations (that bifidobacteria cannot 
produce) is propionate. In the first baby microbiomes supplemented with B. infantis we 
observed propionate production at the 36th hour in LNT fermentation and 48th hour in LNnT 
fermentation (Figure 4.1H), whereas both HMO fermentation showed propionate at the 48th 
h of fermentation in fecal microbiomes 1 without B. infantis. In contrast to butyrate absence 
in fecal microbiomes 2, we observed propionate production in both HMO fermentation 
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regardless of B. infantis addition. However, the concentrations were lower compared to 
that of microbiomes 1 (data not shown).   
Lactose was used as a control fermentation. The microbiome metabolite structure 
differed between the two inoculums (Figure A4.2). For microbiome 1, lactate concentration 
increased over time until 8-12 hour then reached a plateau and after 20th hour it decreased 
and reached non-detectable levels at the 30th hour (Figure A4.2A). This means it has been 
involved in other catabolic activities and this did not change whether B. infantis was added 
or not. In 2nd microbiomes, lactate levels reached at highest around 12 hour and then 
reached a plateau until the end of incubation (Figure A4.2B). The addition of B. infantis 
did not change the behavior of the microbiome community in presence of lactose.  
In lactose fermentation, acetate levels increased until 12 h for all fermentations and 
reached a plateau, while 1st microbiome acetate levels increased, for 2nd microbiome, they 
stayed steady regardless of B. infantis addition (Figure A4.2B). Production of formate 
increased until 8h then decreased for both microbiome communities and regardless of 
carbohydrate source (Figure A4.2C). Butyrate was not observed in the second microbiome 
communities whereas it reached between 10-15mM at the 30th hour regardless of B. infantis 
addition (Figure A4.2D). 1st microbiome propionate levels increased after 30th hour 
whereas it did not change for microbiome 2 fermentations (Figure A4.2E).   
4.3.3. B. infantis counts mostly increase during in vitro fecal fermentation of LNT, 
LNnT and lactose  
To determine how B. infantis abundance changes during HMO metabolism, B. 
infantis concentrations were identified by RT-qPCR. Figure 4.2 shows the B. infantis for 
microbiomes 1 and 2 counts over time. B. infantis inoculated at 104 cfu/ml for both 
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microbiomes as determined by qPCR. In the 1st fecal communities, LNT utilization 
increased B. infantis levels from 12 h to 16 h of fermentation and then stayed steady 
whereas LNnT showed increase from 24 h to 48 h (Figure 4.2A). In 2nd fecal communities, 
only LNnT increased B. infantis concentrations (Figure 4.2B). B. infantis levels in lactose 
fermentations changed over time (Figure A4.3). 
4.3.4 Microbial community structure shifts based on carbon source and B. infantis 
addition 
The fermentative abilities of microbial communities to utilize HMOs displayed a 
donor effect, meaning that the composition of the initial microbiome structure differs. 
Principal Coordinates Analysis (PCoA) on beta diversities revealed a clear separation 
between 1st and 2nd fecal microbiomes (Figure 4.3). The mean phyla composition of initial 
communities was dominated by Firmicutes and Actinobacteria. Actinobacteria relative 
abundance was as follows in initial communities: microbiomes 1 without B. infantis 
addition, 70.2 %; microbiomes 1 with B. infantis (before adding B. infantis), 84 %; 
microbiomes 2 without B. infantis 74 %; microbiomes 2 with B. infantis (before adding B. 
infantis) 74 % (Figure A4.4A) In the 1st fecal microbiomes, without addition of B. infantis, 
the Actinobacteria abundance comprise the 45 % of the total bacteria at the 12th hour for 
both LNT and LNnT, they increased to 61% for LNT and 87 % for LNnT at 20th hour, then 
it decreased to 41 % for LNT and 60 % for LNnT (Figure 4.4A). At the 48th hour, we 
observed a presence of Bacteriodetes (1 % of the total) in LNT, and did not observe the 
same in LNnT. In lactose fermentation, Actinobacteria abundance decreased over time 
from 41 % to 4% with Bacteriodetes presence after 24th hour (1.6 %) until the end of 
fermentation (9.9 %) (Figure A4.5). Supplementation of B. infantis caused clear shifts in 
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the microbial structure. Although the bioreactors did not reach significant biomasses at the 
hour of 12th, presence of B. infantis inversely affected the total Actinobacteria abundance 
in the microbial communities for both LNT (13 %) and LNnT (2 %) (Figure 4.4A). For 
LNnT, Actinobacteria abundance stayed the same until the 30th hour (around 2.5 %) and 
then increased (6.8 %) with increased appearance of Bacteriodetes (12.8 %) and decreased 
Firmicutes abundance (from 97 % to 80 %) till the end of fermentation. This was not 
observed in the communities without B. infantis. For LNT, Actinobacteria abundance 
increased steadily until 30th hour (from 13 % to 40 %). When it started decreasing, 
Bacteriodetes reached to 4 % (Figure 4.4A). In the meantime, lactose as a control also 
started with lower Actinobacteria abundance (4.8 %) than the microbiomes without B. 
infantis (Figure S4.5) 
The 2nd fecal microbial community in LNnT fermentation (without the addition of 
B. infantis) showed a sharp increase in Actinobacteria from 50 % to 71 % of the total 
bacteria at 16th hour and then it stayed relatively steady (Figure 4.4B). On the other hand, 
Actinobacteria only increased from 50 % to 66 % at the 24th hour in the communities with 
addition of B. infantis. As observed in the 1st community samples, Bacteriodetes was also 
not observed in LNnT fermentation without B. infantis whereas it appeared at 48th hour in 
fermentations with B. infantis (Figure 4.4B). This indicates that B. infantis addition 
changes the microbial structure during LNnT fermentation. In LNT fermentation, the 
addition of B. infantis did not affect the fermentation structure in the 2nd microbiomes. The 
Actinobacteria increased from 15 % to 23 % for communities without B. infantis and from 
18 % to 39 % in the microbiomes with B. infantis (Figure 4.4B). It relative stayed relatively 
steady despite the appearance of Bacteriodetes (21.8 % without B. infantis and 18.9 % with 
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B. infantis) while Firmicutes decreased. This might be explained by the replacement of 
Firmicutes with Bacteriodetes over time. In lactose, as opposed to both HMOs, 
Actinobacteria concentrations sharply decreased regardless of B. infantis addition (Figure 
A4.5A). This is because lactose is available to other species whereas Actinobacteria, 
especially Bifidobacterium spp. are more likely to ferment HMOs than other microbial 
species. 
Since the diversity between the communities and different carbon sources is limited 
to 3 different phyla in all fermentations, we determined the microbial structural shifts at 
the genus level. In general, we observed distinctive differences in the communities with or 
without the addition of B. infantis. Actinobacteria levels all belong to Bifidobacterium spp. 
In LNT fermentations, in 1st microbial communities without the addition of B. infantis, the 
second abundant species were Lactobacillales spp. (51 %) at the beginning whereas with 
B. infantis addition we observed clear abundance of Clostridium spp. (75 %) (Figure 4.5A). 
The changes in the abundance of Clostridium spp. over time showed significant correlation 
with acetate (R2=0.8784, p=0.0018), formate (R2=0.7804, p=0.0084) and butyrate 
(R2=0.8779, p=0.0019) productions (Table 4.1) in LNT fermentations with B. infantis. In 
1st community structures regardless of B. infantis presence in LNT fermentations, we 
observed increased abundance of Eubacterium spp. after 24 hours till the end of 
fermentation (14-15 %) (Figure 4.5A). Some Eubacterium spp. were characterized as 
lactate utilizing and butyrate producing [74, 245]. Our linear regression analysis showed 
that the butyrate production in LNT fermentations were strongly correlated with 
Eubacterium spp. (R2=0.9579, p=0.0001 without B. infantis and R2=0.9679, p<0.0001 with 
B. infantis). We also observed decreasing lactate concentrations after 24th hour regardless 
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of B. infantis addition. This coincides with the appearance of Eubacterium spp. which 
could be explained the species belonging to this genus are lactate utilizers and butyrate 
producers. Eubacterium spp. showed significant correlation with decreasing lactate 
concentrations in LNT fermentations without B. infantis (R2=0.5979, p=0.0414) and with 
B. infantis (R2=0.6045, p=0.0396) (Table 4.1). Samples with B. infantis addition showed 
increased abundance of Bacteriodes spp. after 36th hour (4 %). Some strains of Bacteriodes 
spp. can produce propionate, which coincides with propionate production at 30th hour LNT 
fermentations with B. infantis. Propionate production in LNT fermentations showed 
significant correlation with Bacteriodes spp. (R2=0.8596, p=0.0026 without B. infantis, 
R2=0.8383, p=0.0038 with B. infantis, Table 4.1).  In addition, Phascolarctobacterium spp. 
displayed after 36th hour in communities with B. infantis (3 %) and 48th hour communities 
without B. infantis (11 %). This genus can produce propionate and utilizes succinate [268]. 
Our linear regression analysis showed a strong correlation between Phascolarctobacterium 
spp. with propionate production in both 1st fecal communities with and without B. infantis 
(R2=0.9859, p<0.0001 and R2=0.9322, p=0.0004, Table 4.1).  
In LNnT fermentation without the addition of B. infantis in the 1st microbial 
communities, Bifidobacterium spp. dominated the microbial community and increased up 
to 87 % at 20th hour and then decreased to 60 % at the end of fermentation. In contrast, we 
observed high abundance of Clostridium spp. in the fermentation with B. infantis up to 92-
93 %. This coincides with observations in pure cultures [229] because B. infantis does not 
utilize LNnT efficiently, therefore in the presence of B. infantis, other species thrives or B. 
infantis competes with other bifidobacterial species for resources which suppresses them. 
Interestingly, Lactobacillales spp. was in high abundance in the beginning of fermentation 
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(53 %) then it decreased to 14 % over time in the communities without B. infantis. Similar 
to LNT fermentations, abundance of Eubacterium spp. increased starting 30th hour 
regardless of B. infantis addition and reached to 17-19 % of the total population. 
Eubacterium spp. are responsible of butyrate production, and some Eubacterium spp. are 
also propionate producers [269]. Propionate concentrations increased after 30th in LNnT 
fermentations with B. infantis and 36th h in fermentations without B. infantis. Our linear 
regression analysis showed that Eubacterium spp. presence in LNnT fermentations without 
B. infantis strongly correlated with butyrate concentrations (R2=0.9998, p<0.0001) but 
propionate production in samples with B. infantis (R2=0.9769, p<0.0001). Similar to LNT, 
Phascolarctobacterium spp. was observed in both communities regardless of B. infantis 
addition and they found to be correlated with propionate production (R2=0.9859, p<0.0001 
without B. infantis and R2=0.9427, p=0.0003 with B. infantis) (Table 4.1).  
In 2nd fecal microbial communities, the diversity of species was distinctive from the 
1st one. In all fermentations, Lactobacillales and Bifidobacterium spp. were the 
predominant groups (Figure 4.5B). In LNT fermentation, Bifidobacterium spp. levels first 
increased and then decreased in communities without B. infantis, whereas it increased until 
the end of fermentation point in the communities with B. infantis. LNT fermentations 
without B. infantis showed a positive correlation with the production of lactate (R2=0.9181, 
p=0.0102) and acetate (R2=0.8956, p=0.0125) whereas we did not observe significant 
correlation with metabolite production in LNT fermentations with B. infantis. Although we 
observed Clostridium spp. in communities with B. infantis at 48th hour in LNT 
fermentations we did not observe this without addition of B. infantis. There is no butyrate 
production in 2nd fecal communities regardless of HMO type and addition of B. infantis. 
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On the other hand, propionate production might be linked to the presence of Bacteriodes 
spp. and Clostridium spp. in the 2nd microbial communities.  Previously, Bacteroides 
eggerthii, Bacteroides fragilis, and Eubacterium dolichum were reported to associate with 
propionate production in human intestine [269]. However, we did not observe positive 
correlation in propionate production with the Bacteriodes spp. and Clostridium spp. in LNT 
fermentations with B. infantis.  
In LNnT fermentation, Bifidobacterium spp. and Lactobacillales (specific genus 
could not be identified) were dominant members regardless of B. infantis addition. 
Bifidobacterium spp. increased over time in both fermentations (from 50 % to 74 % in 
microbiomes without B. infantis, from 52 % to 62 % with B. infantis) (Figure 4.5B). 
Interestingly, Lactobacillales showed a decreased pattern for both fermentations (from 47 
% to 26 % in microbiomes without B. infantis and from 47 % to 27 % with B. infantis). 
Clostridium spp. appeared at 20th hour and disappeared in the communities without B. 
infantis addition. Similarly, it disappeared after 12th hour in communities with B. infantis. 
We did not observe Bacteriodes spp. in the fermentations without B. infantis whereas it 
appeared at the 48th h of fermentation in LNnT fermentations with B. infantis (10 %). We 
did not observe any positive correlation with any metabolite production in LNnT 
fermentations with B. infantis.  
In lactose fermentations, the dynamics of species was distinct between the two 
microbiomes (Figure A4.5). In the 1st microbiomes, we observed decreased abundance of 
Bifidobacterium sp., and species such as Streptococcus that we did not observe either of 
the HMO fermentation (Figure A4.5A). That is not surprising that lactose is more available 
for most of the bacteria. In the 2nd microbiomes, Lactobacillales dominated the 
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fermentations regardless of B. infantis presence which is different than the LNnT 
fermentations (Figure A4.5B).  
4.4 Discussion 
In this study, we demonstrate the HMO utilization in modeled microbiomes using 
an in vitro bioreactor system. This system allowed us to simultaneously control pH, 
anaerobiosis and optical density as well as sample from numerous timepoints in order to 
monitor SCFA concentrations and microbial abundance. Within the infant gut microbiome, 
the B. infantis genome contains 40-kb gene cluster dedicated to the use of oligosaccharides 
in the milk [11]. This provides an advantage to survival in the infant gut microbiome during 
nursing. B. infantis utilizes oligosaccharides in their intact form; therefore, does not 
degrade tetrasaccharides to mono- or di-saccharides which are available for other members 
of the microbiome. Instead, B. infantis secrete metabolites, mainly acetate and lactate in 
the infant gut. These metabolites might be directly used by the infant gut epithelial cells or 
used by the other members of the gut microbiome [75]. Our previous results indicated that 
human milk tetrasaccharides LNT and LNnT are differentially utilized by B. infantis strains 
[229]. In addition, the inefficient utilization of LNnT by B. infantis ATCC 15697 shifts 
towards microbial metabolism towards formate production [229]. To this point, our 
knowledge about the influence of increased formate production is limited. Elevated 
formate concentrations in the gut were found to be related with inflammation-associated 
dysbiosis and increased abundance of  formate utilizing E.coli [255]. On the other hand, 
formate cross-feeding are of interest for cooperative interactions within the gut bacterial 
metabolism. Methanogenic microbes were reported to utilize formate and facilitate the 
syntrophic interactions in anaerobic environmental conditions [270]. Acetogen Blautia 
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hydrogenotrophica was identified to utilize formate and produce acetate in return [267, 
271]. Due to differential utilization of HMOs and our interest on syntrophic interactions 
and role of formate production, we conducted an infant fecal derived modeled microbiome 
in bioreactor systems, in order to identify the microbial interactions during HMO utilization 
in regard to the absence and presence of B. infantis.  
 In this study, we used two baby fecal samples for microbiome modelling. The fecal 
samples from different weeks on same baby were pooled and grew before inoculation into 
bioreactors containing lactose, LNT and LNnT. These inoculums either supplemented with 
B. infantis or not at the time of inoculation. According to B. infantis specific qPCR results 
on fecal samples, B. infantis was not present; therefore, this allowed us to identify the 
manipulations that occur during the microbial interactions due to B. infantis.  
 The two fecal sources structure initially regardless of the B. infantis addition were 
not distinct from each other at phyla level. At genus level, similar genera occur in the fecal 
microbiomes, but the abundances were different. However, during fermentation they 
responded HMOs differentially. In the 1st microbiome communities, elevated butyrate 
production and propionate production were observed regardless of carbohydrate source 
whereas there were no butyrate production and propionate concentrations remained steady 
during the fermentations of 2nd microbiomes.  
 It was previously found that LNT abundance in infant fecal samples were positively 
correlated with Bacillales and negatively correlated with Bifidobacteriales [272]. It is also 
noted Bifidobacteria levels increased over time when the most fecal HMO compositions 
have dropped dramatically. We observed that Bifidobacterium sp. levels increased over 
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time and Bacillus sp. levels dropped during the fermentations with LNnT in 1st 
microbiomes with B. infantis and B. infantis counts increased accordingly.  
The clear distinction was abundant occurrence of Clostridium spp. in the both 
HMOs with B. infantis, increased abundance of Eubacterium spp. over time in all 1st 
microbiome fermentations. These two genera are associated with butyrate production. In 
fact, our correlation analysis showed that Eubacterium spp. was strongly correlated with 
butyrate production in both HMOs regardless of addition of B. infantis. Accordingly, 
Eubacterium spp. showed correlation with lactate concentrations in LNT fermentations. 
Lactate concentrations decreased in all fermentations of 1st microbiomes later hours of 
fermentation. This indicates that lactate is utilized by the other members of microbiome. 
In a previous study, Eubacterium hallii was reported to produce butyrate in mono-cultures 
and use lactate in co-cultures with B. infantis during fucose fermentation [273]. 
Eubacterium spp. has been reported to utilize lactate and produce butyrate in co-cultures 
with other bifidobacteria [245, 249]. In the 2nd microbiome fermentations, lactate 
concentrations remained similar after 24th hour and no Eubacterium spp. and butyrate 
production were observed regardless of carbohydrate source and B. infantis addition. This 
might mean that presence of Eubacterium spp. facilitates the lactate utilization as well as 
the butyrate production. Increased abundance of lactate utilizing bacteria was associated 
with colic in infants [274], however, butyrate is an energy source for the colon epithelial 
cells, contributes to the maintenance of the gut barrier functions, and has 
immunomodulatory and anti-inflammatory properties [192].   
  Propionate production in the gut was previously suggested to associate with 
interleukin (IL)10-producing regulatory T (Treg) cell differentiation [275]. We observed 
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increased production of propionate in 1st microbiome fermentations and it has been linked 
to Phascolarctobacterium spp. Similarly, we did not observe this genus in the 2nd 
microbiomes; but observed unchanged propionate productions. This genus has been 
identified to utilize succinate and produce propionate [268]; however, we did not identify 
succinate presence in our study. 
 As observed in pure cultures [229], LNnT fermentations in both fecal microbiomes 
revealed elevated amounts of formate production when B. infantis added. This might 
indicate that B. infantis preference between these tetrasaccharides manipulated the 
microbial interactions in the complex infant gut derived communities. In both 
microbiomes, formate showed at first increase and then decrease. This indicates that 
formate becomes an energy source for the other members of the community. We see an 
increase in the acetate concentrations that might be related with formate decrease. 
However, we did not observe any known acetogens that are formate utilizers in the both 
microbiomes. In LNT fermentations, formate production was correlated with 
Bifidobacterium spp. Clostridium spp., and Eubacterium spp. abundance; however, these 
correlations were not found in the LNnT fermentations with B. infantis. Previously, E. 
limosum and E. acidaminophilum were identified to require formate under certain 
conditions [276, 277]. On the other hand, the bacteria that elevate formate production in 
LNnT fermentations and result in its utilization were not clear. Since inefficient utilization 
of LNnT by B. infantis elevates formate production, there might be inverse relationship 
between B. infantis and formate.  
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4.5 Conclusions 
This study constitutes a tool for the investigation of various microbe-microbe and 
microbe-human milk oligosaccharides interactions in vitro. In this study we demonstrated 
a hallmark of a syntrophic interaction with heterologous members of the modeled 
community. This indicates that the specific microbiome architecture may decrease the 
competitive advantage experienced by B. infantis through HMO utilization. This study 
provides characterization of the structure-function relationships between specific HMO 
isomers and their activity on the composition of the infant microbiome, therefore, ascribing 
a microbiologically-active function to human milk that potentially impacts infant health 
through its microbiome. 
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Table 4.1 Pearson correlation between genus-level taxa and metabolite production in 1st microbiomes 
 
      Lactate Acetate Formate Butyrate Propionate 
Bifidobacteriaceae;Bifidobacterium 
LNT 
without 
BI 0.4443 0.01687 0.2065 0.2413 0.5364* 
with BI 0.01341 0.8168* 0.6544* 0.5818* 0.1701 
LNnT 
without 
BI 0.4804 0.08768 0.3199 0.1343 0.04192 
with BI 0.6346* 0.3967 0.4535 0.2555 0.9086* 
Bacteroidaceae;Bacteroides 
LNT 
without 
BI 0.4577 0.3485 0.3884 0.6107* 0.8596* 
with BI 0.399 0.2953 0.294 0.507 0.8383* 
LNnT 
without 
BI NA NA NA NA NA 
with BI 0.4191 0.3807 0.2968 0.2156 0.9753* 
Bacillaceae;Bacillus 
LNT 
without 
BI NA NA NA NA NA 
with BI 0.0113 0.9931* 0.439 0.6391* 0.4421 
LNnT 
without 
BI NA NA NA NA NA 
with BI 0.03463 0.8402* 0.01415 0.9132* 0.1577 
Lactobacillales 
LNT 
without 
BI 0.1408 0.6633* 0.3659 0.5819* 0.3575 
with BI 0.04726 0.7602* 0.228 0.2896 0.1279 
LNnT 
without 
BI 0.1395 0.5484 0.0033 0.06404 0.0808 
with BI 0.372 0.5107 0.3394 0.3329 0.9724* 
Clostridiaceae;Clostridium LNT without BI NA NA NA NA NA 
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with BI 0.156 0.8784* 0.7804* 0.8779* 0.504 
LNnT 
without 
BI 0.281 0.0003 0.386 0.1039 0.0688 
with BI 0.4473 0.3529 0.3139 0.1935 0.9652* 
Eubacteriaceae;Pseudoramibacter_Eubacterium 
LNT 
without 
BI 0.5979* 0.5487 0.7584* 0.9579* 0.5583 
with BI 0.6045* 0.5121 0.7624* 0.9679* 0.7705* 
LNnT 
without 
BI 0.2998 0.4847 0.7641* 0.9998* 0.4765 
with BI 0.4977 0.4332 0.3687 0.2698 0.9769* 
Veillonellaceae;Phascolarctobacterium 
LNT 
without 
BI 0.265 0.226 0.2096 0.3518 0.9985* 
with BI 0.6151* 0.3733 0.4811 0.8068* 0.9322* 
LNnT 
without 
BI 0.1447 0.2438 0.2798 0.5044 0.9859* 
with BI 0.3323 0.3103 0.207 0.1547 0.9427* 
The asterisk means (*) that the correlation is significant (p<0.05). the bold color means that the R2 is above 0.7.  
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Figure 4.1 Microbial metabolites produced during the growth of infant fecal 
inoculated microbiomes with and without B. infantis addition on LNT and LNnT 
within a modeled system. Absolute concentrations of lactate (A), acetate (C), formate 
(E), butyrate (G), and propionate (H) of 1st microbiomes and lactate (B), acetate (D), 
formate (F) of 2nd microbiomes  All panels represent fecal bacterial communities with or 
without supplementation of B. infantis ATCC15697 growing on colon medium 
containing 1% (wt/v) lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT). The values 
for organic acid production are expressed in millimolar (mM). 
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Figure 4.2 B. infantis levels as determined by qPCR represented as log (cfu/ml). (A) 
microbiomes derived from 1st baby fecal and (B) microbiomes derived from 2nd baby 
fecal. B. infantis initially inoculated at 104 cfu/ml at time 0.   
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Figure 4.3 Principal-coordinate score plot of 16S rRNA gene amplicon sequence 
reads using Jaccard distance metrics on beta diversities. The dots represent each time 
point in three fermentations (LNT, LNnT, lactose) of 1st (blue) and 2nd (orange) fecal 
derived microbiomes regardless of addition of B. infantis. 
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Figure 4.4 Phyla composition (as determined by 16S rRNA gene amplicon 
sequencing) of in vitro modeled microbiomes with or without addition of B. infantis 
during LNT and LNnT fermentation. (A) microbiomes derived from 1st baby fecal and 
(B) microbiomes derived from 2nd baby fecal.  
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Figure 4.5 Relative abundances of bacterial genera during LNT and LNnT 
fermentations of in vitro modeled microbiomes with and without addition of B. 
infantis. (A) microbiomes derived from 1st baby fecal and (B) microbiomes derived from 
2nd baby fecal. 
  
137 
 
CHAPTER 5 
A HUMAN GUT COMMENSAL FERMENTS CRANBERRY 
CARBOHYDRATES TO PRODUCE FORMATE 
 
Ezgi Özcan1, Jiadong Sun2, David C. Rowley2, and David A. Sela1, 3 
 
1Department of Food Science, University of Massachusetts, Amherst, Massachusetts 
01003, United States 
2College of Pharmacy, University of Rhode Island, Kingston, RI 02881, United States 
3Department of Microbiology & Physiological Systems, University of Massachusetts 
Medical School, Worcester, MA 
 
5.1 Abstract 
Commensal bifidobacteria colonize the human gastrointestinal tract and catabolize 
glycans that are impervious to host digestion. Accordingly, Bifidobacterium longum 
typically secretes acetate and lactate as fermentative end products. This study tested the 
hypothesis that B. longum utilizes cranberry-derived xyloglucans in a strain-dependent 
manner. Interestingly, the B. longum strain that efficiently utilizes cranberry xyloglucans 
secretes 2.0 to 2.5 mol of acetate-lactate. The 1.5 acetate:lactate ratio theoretical yield 
obtained in hexose fermentations shifts during xyloglucan metabolism. Accordingly, this 
metabolic shift is characterized by increased acetate and formate production at the expense 
of lactate. α-L-Arabinofuranosidase, an arabinan endo-1,5-α-L-arabinosidase, and a β-
xylosidase with a carbohydrate substrate binding protein and carbohydrate ABC 
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transporter membrane proteins are upregulated (2-fold change), which suggests carbon flux 
through this catabolic pathway. Finally, syntrophic interactions occurred with strains that 
utilize carbohydrate products derived from initial degradation from heterologous bacteria. 
5.2 Introduction 
Microbial commensals colonize the mammalian gut and interact with their host 
through various interwoven metabolic networks. A well-characterized operation performed 
by microbiota is energy liberation from dietary polysaccharides. These complex 
carbohydrates are impervious to host digestion and thus available for microbial populations 
to utilize. In turn, gut microorganisms produce metabolites sequestered by the host, 
including short chain fatty acids (SCFAs) [49, 75, 77, 243]. Briefly, gut microorganisms 
compete for food, with metabolites secreted by one member often utilized by a secondary 
microbial population [74]. This syntrophic metabolism is extended towards interactions 
with their host. For instance, microbial SCFAs (i.e. acetate, propionate, butyrate, and 
valerate) are substrates for specific host tissues. This includes butyrate that provides a 
primary energy source for enterocytes [75–77]. 
Bifidobacterium longum as taxon is often dominant in the infant gut and colonizes 
adults at lower concentrations [10]. Whereas B. longum subsp. infantis colonizes the infant 
gut, B. longum subsp. longum tends to populate adult microbiomes. As with all 
bifidobacteria, B. longum catabolizes carbohydrates via their fructose-6-phosphate 
phosphoketolase pathway, which is characteristic of the genus and termed the bifid shunt. 
This ATP generating pathway results in acetate and lactate secretion to recycle cofactors 
required in substrate-level phosphorylation [189, 190]. The theoretical yield is 3:2 moles 
of acetate to lactate produced for every 2 moles hexose that enters the bifid shunt. 
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Bifidobacteria encode an assortment of glycosyl hydrolases (GH) in order to utilize dietary 
glycans as fermentative substrates [215, 278, 279]. Oligosaccharide utilization phenotypes 
are often consistent with the ecological niche that the bifidobacterial strain occupies (e.g. 
adult vs. infant gut)[183]. The B. longum subsp. longum genome, for example, encodes a 
large number of GHs dedicated to arabinose and xylose utilization [280]. In contrast, the 
phylogenetic near-neighbor and infant-colonizing Bifidobacterium longum subsp. infantis 
chromosome encodes genes to enable human milk oligosaccharide utilization within the 
nursing infant gut [11, 186, 187, 197]. In general, B. longum subsp. infantis varies in its 
ability to utilize plant-derived carbohydrates [183].  
Xyloglucans are a cross-linking oligosaccharide found in type 1 plant cell walls 
[281] and exhibit a β(1→4)-glucan primary backbone with α(1→6)-linked xylosyl 
residues as substituents. Depending on the plant species and tissue of origin, xyloglucan 
branches may be extended by galactose, fucose, or arabinose residues [282, 283]. The 
predominant cranberry xyloglucan structure was previously characterized as SSGG (S, β-
D-glucose with α-L-Ara-(1−2)-α-D-Xyl at the O-6 position; G, β(1→4)-glucan main 
chain) [284].  
Oligosaccharides isolated from the cranberry cell wall (Vaccinium macrocarpon) 
prevent adhesion of uropathogenic Escherichia coli and may limit biofilm production [285, 
286]. With regards to xyloglucan metabolism, certain gut microorganisms produce 
enzymes to degrade tamarind seed xyloglucans in their extracellular environment [287]. 
However, the structure-function relationship between the xyloglucan and specific 
populations of commensal bacteria remains unresolved. Thus, we evaluated B. longum 
strains in their capacity to utilize cranberry-derived xyloglucans as a sole carbon source. In 
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order to further understand in vitro metabolism, organic acids produced during 
fermentation were profiled. In addition, few lactobacilli strains that are recognized as 
probiotics [288], and potentially used as synbiotics, were subjected to growth on
xyloglucans as the sole carbohydrate source.
5.3 Materials and Methods 
5.3.1 Isolation of xyloglucans from the cranberry cell wall 
Cranberry hulls were degraded with pectinase (Klerzyme 150, DSM Food 
Specialties, South Bend, IN, USA) and fractionated as previously described [286] with 
modifications. Briefly, 2 g of the cranberry pectinase treated powder was dissolved in 20 
ml distilled water and loaded onto a RediSep GOLD C18 Reverse-phase column (Teledyne 
ISCO, Inc., Lincoln, NE, USA) and connected to a CombiFlash Rf purification system 
(Teledyne ISCO, Inc.) The column was eluted sequentially with 500 ml deionized water, 
500 ml 15% methanol/water and 500 ml methanol. Fractions from each gradient were 
individually pooled and lyophilized to obtain three major fractions, Cranf1W (761 mg, 
38.1%) eluted with 100% deionized water, Cranf1b (476 mg, 23.8%) eluted with 15% 
methanol/water, and Cranf1M (562 mg, 28.1%) eluted with 100% methanol. 100 mg of 
Cranf1b was then dissolved in 2 ml distilled water and further purified by a size-exclusion 
column Hiprep Sephacryl S-100 HR 16/60 (GE healthcare Life Sciences, Pittsburgh, PA, 
USA). The column was isocratically eluted with deionized water at 0.5 ml/min. Eluates 
were collected every 5 ml and evaluated for their total carbohydrate content by phenol 
sulfuric acid assay [289]. The total carbohydrate content was assessed in a 96-well 
microtiter plate as previously reported [289]. Briefly, in each well of a 96-well microtiter 
plate, 30 µl of each fraction was mixed with 100 µl concentrated sulfuric acid and 20 µl 
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5% phenol solution. The microtiter plates were than incubated at 90 °C for 5 min and 
recorded for absorbance at 490 nm using a Spectramax M2 microplate reader (Molecular 
Devices, Sunnyville, CA, USA).  
5.3.2 Xyloglucan structural analysis 
Oligosaccharide fractions were pooled and freeze-dried to obtain 59.5 mg of 
cranberry xyloglucans, which were then chemically verified by a combination of Matrix-
assisted Laser Desorption/Ionization-Time of Flight-Mass Spectrometry (MALDI-TOF-
MS) and 1H Nuclear Magnetic Resonance (1H-NMR) spectroscopy. Briefly, 1 µl of 
xyloglucan (1 mg/ml in H2O) was mixed with 1 µl of 2, 3-dihydrobenzoic acid (DHB) 
matrix solution. 2 µl of this mixture was analyzed by MALDI-TOF-MS (Axima 
Performance, Shimadzu, Kyoto, Japan) in positive reflectron mode. 500 profiles were 
collected for each experiment. Furthermore, the cranberry xyloglucans were dissolved in 
D2O (99.96%, Cambridge Isotope Laboratories Inc., Tewksbury, MA, USA). The 1H 
spectrum was obtained on a 500 MHz NMR spectrometer (Varian VNMR, Agilent 
Technologies, Santa Clara, CA, USA) at 25 °C. 
5.3.3 Bacterial strains and propagation 
Bacterial strains used in this study are summarized in Table 5.1. Bifidobacterial 
strains were propagated in Bifidobacterial Selective Media (BSM) or De Man Rogosa 
Sharp (MRS, Oxoid, Hampshire, England) medium supplemented with 0.05% (wt/v) L-
cysteine (Sigma-Aldrich, St. Louis, MO) [201] at 37 °C under anaerobic conditions (Coy 
Laboratory Products, Grass Lake, MI). Lactobacillus cultures were propagated in MRS 
supplemented with 0.05% (wt/v) L-cysteine as a reducing agent at 37 °C under anaerobic 
conditions. Bacterial strains were routinely verified using the bifidobacterial-specific 
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phosphoketolase assay [202],  and through microscopy. The strains used in this study have 
previously confirmed by multilocus sequence typing (MLST), and urease assay to 
distinguish infantis/longum (urease+/urease-) [197]. In addition, a PCR-based 
Bifidobacterium longum/infantis ratio analysis (BLIR) were performed to differentiate B. 
longum subspecies as previously described [204].  
5.3.4 Microplate growth assay  
In order to evaluate growth phenotypes in a 96 well format, overnight cultures were 
centrifuged and washed with phosphate buffer solution that was inoculated (1% (v/v)) into 
modified MRS (mMRS, without acetate and carbohydrate substrate). The sole carbon 
source was defined as purified xyloglucans at a final concentration of 2% (wt/v). The 
growth assay was conducted anaerobically at 37 °C for 72 h by assessing optical density at 
600 nm (OD600nm) in an automated PowerWave HT microplate spectrophotometer (BioTek 
Instruments, Inc. Winooski, VT). Each strain was evaluated in biological triplicates with 
three technical replicates. Negative and positive controls consisted of inoculated medium 
in the absence of substrate and presence of glucose (2% wt/v), respectively. Bacterial 
growth kinetics were calculated using Wolfram Mathematica 10.3 Student Edition with the 
equation below as described in Dai et al [205].  
!"#(%) = !"#()*+{ 11 + exp[3%4 − %] − 11 + exp[3%4]} 
ΔODasym is the growth level at stationary phase with k representing the growth rate and tc 
is the inflection point indicating the time to reach the highest growth rate. 
5.3.5 Modeled syntrophic interactions 
In order to determine if degradative or secreted metabolites are utilized by a 
heterologous strain, supernatants from the microplate growths were analyzed. Accordingly, 
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800 µl of the conditioned supernatant was dissolved in 1200 µl of mMRS medium. 
Bacterial strains were washed with PBS once in order to remove the residual carbohydrates 
from initial propagation and were inoculated 1% (v/v) and evaluated for growth in a 96 
well format as described. Bacterial growth kinetics were calculated, and the supernatant 
obtained after the secondary growth was analyzed by HPLC. 
5.3.6 Xyloglucan profiling following bacterial fermentation  
Following in vitro fermentation, filtered bacterial culture supernatants were 
derivatized with 2-aminobenzamide (2-AB) for oligosaccharide purification. Briefly, 50 μl 
of cell-free supernatants were diluted with 2 ml deionized water and loaded onto Porous 
Graphitized Carbon (PGC) cartridge (1 g, Thermo Scientific, Waltham, MA, USA). The 
cartridge was pre-washed with 5 ml 50% (v/v) acetonitrile/H2O and equilibrated with three 
times of 5 ml deionized water. First, the cartridges were eluted with 5 ml deionized water 
three times with oligosaccharide fractions eluted with 30% (v/v) acetonitrile/H2O with 
0.1% trifluoroacetic acid (TFA) three times. The resulting fractions were spiked with 0.036 
mg glucose as an internal standard and freeze-dried. 7 mg/ml of 2-AB and 3.2 mg/ml of 2-
picoline borane were prepared in 10% (v/v) acetic acid/H2O and 200 μl was added into 
each mixture. The solutions were held at 40 °C for 4 h, centrifuged and dried in vacuo. The 
derivatized oligosaccharide mixtures were re-dissolved in 400 μl deionized water for FL-
HPLC and LC-MS analyses. 
5.3.7 FL-HPLC and LC-MS analyses 
The 2-AB labeled xyloglucans were analyzed by FL-HPLC and LC-MS. FL-HPLC 
analysis performed on a Hitachi Elite LaChrom HPLC system (Hitachi, Tokyo, Japan) 
connected to a fluorescence detector (L-2485, Hitachi). The samples were analyzed on a 
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Kinetex RP-C18 column (150 mm × 3 mm, 2.6 μm, Phenomenex, Torrance, CA, USA) at 
40 °C. The column was first eluted with isocratic 10% (v/v) methanol in H2O (with 0.1% 
TFA) for 10 min at 0.2 ml/min, followed with a linear gradient of 10%-20% methanol in 
H2O for 90 min, and then a linear gradient of 20% to 100% methanol in H2O for 15 min 
and stayed at 100% for 30 min. The elution was monitored by fluorescence detector with 
an excitation wavelength of 330 nm and emission wavelength at 420 nm. The LC-MS 
analysis was performed on a Shimadzu Prominence UFLC system (Shimadzu, Kyoto, 
Japan) coupled to an AB sciex Qtrap 4500 mass spectrometer (AB sciex, Framingham, 
MA, USA) with electrospray ionization source. The LC-MS analysis was performed with 
the same column and same HPLC program as aforementioned for FL-HPLC. The mass 
spectrometer was operated in positive mode and ions at m/z 200 to m/z 2000 were scanned. 
Quantification of extracted ions was normalized by 2-AB derivatized glucose. 
5.3.8 Characterization of bacterial organic acid production 
Endproducts from bacterial fermentation were quantitated by HPLC. Bacterial 
strains were initially propagated as described above. Cell-free supernatants from 
microcentrifuge tubes were obtained at early stationary phase and filtered through a 0.22 
µm filter following centrifugation and stored at -80 °C until analysis. Organic acids were 
quantified using an Agilent 1260 Infinity HPLC (Agilent Technologies, Santa Clara, CA) 
system equipped with a Wyatt Optilab T-rEX detector (Refractive Index detector, Wyatt 
Technology Corp, Santa Barbara, CA). Separation was carried out using an Aminex HPX-
87H column (7.8 mm ID x 300 mm, Bio Rad Laboratories, Hercules, CA) at 50 °C in a 
mobile phase of 5 mM H2SO4 at flow rate of 0.6 ml/min with 50 µl of injection volume. 
Organic acids (i.e. acetic acid, lactic acid, formic acid) were acquired from Sigma-Aldrich 
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Co. (St. Louis, MO). Metabolite concentrations were calculated from standard curves 
derived from external standards for six different concentrations (0.05, 0.1, 0.5, 1, 5, and 10 
mg/ml) and converted to millimolar (mM). Metabolite profiling was carried out in triplicate 
and each measurement was performed in duplicate.  
5.3.9 Gene expression by quantitative real-time PCR 
Relative gene expression was performed by qRT-PCR. Four ml samples were 
collected at mid-exponential phase and pelleted at 12,000 x g for 2 min and stored in 1 ml 
Ambion RNAlater (Life Technologies, Carlsbad, CA). Total RNA was extracted using 
Ambion RNAqeous-Mini kit (Life Technologies, Carlsbad, CA) according to the 
manufacturer’s instructions. The cells were placed in lysis buffer to be transferred to MP 
Bio Matrix E tubes and were subjected to bead-beating using FastPrep 24 instrument (MP 
Biomedicals, Santa Ana, CA) (2 X 5.5 m/sec for 30 sec). Total RNA was eluted in 50 µL 
of EB solution and immediately subjected to DNase treatment with the Ambion Turbo 
DNase-free (Life Technologies, Carlsbad, CA) using 1 µL of DNase I for half-hour. Total 
RNA was converted to cDNA using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Carlsbad, CA) according to manufacturer's instructions. cDNA 
concentrations were measured by a Nanodrop 2000 Spectrophotometer (Thermo Fisher 
Scientific Inc., Agawam, MA). qRT-PCR analysis was performed using a 7500 Fast Real-
Time PCR System (Applied Biosystems, Singapore) with PowerUP SYBR Green Master 
Mix (Applied Biosystems, Foster City, CA) using parameters suggested by the 
manufacturer. Primers were designed using Primer3 (Table 5.2; http:// frodo.wi.mit.edu). 
The gene Blon_0393 was used as an endogenous control as previously validated [184]. 
Gene expression levels while growing on glucose (2 % w/v) was used as a reference. 
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Results were expressed as fold change relative to control. Bacterial growths were 
performed in triplicates with triplicate measurements by qRT-PCR.  
5.3.10 Statistical Analysis 
Bacterial growth kinetics were subjected to two-way ANOVA and Tukey’s HSD 
test for multiple comparisons of strains within treatment compared with the positive 
control. Metabolite concentrations were subjected to two-way ANOVA and the Sidak’s 
correction was used to account for multiple comparisons. Significant differences in 
modeled syntrophic interactions were determined by paired-t test for bacterial growth 
kinetics. The fold change gene expression was analyzed by paired t-test compared to 
control. 
5.4 Results  
5.4.1 The cranberry cell wall contains xyloglucans 
Oligosaccharides were purified from a cranberry derivative through reverse-phase 
C18 and size exclusion chromatography (see Figure A5.1 in the supplemental material). 
The chemical properties of the purified oligosaccharides were subsequently assessed by 
matrix-assisted laser desorption ionization (MALDI-TOF) mass spectrometry (MS) 
(Figure 5.1) and 1H nuclear magnetic resonance (NMR) spectroscopy (Figure A5.2). 
Consistent with previous studies [284, 286], the purified oligosaccharides were identified 
as xyloglucans with degrees of polymerization (DPs) ranging from 6 to 9. MALDI-TOF 
MS analysis identified sodium adduct ions at 923, 953, 1,055, 1,085, 1,217, 1,247, and 
1,379, which were interpreted as xyloglucan compositions of hexose3-pentose3 (H3P3), 
H4P2, H3P4, H4P3, H4P4, H5P3, and H5P4, respectively. Putative cranberry xyloglucan 
oligosaccharide structures were provisionally assigned as reported in Table A5.1.  
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5.4.2 B. longum xyloglucan utilization is strain dependent  
Among the bifidobacterial strains tested (Table 5.1), B. longum subsp. longum 
UCD401 exhibits the most growth on the purified xyloglucans, achieving a final optical 
density at 600 nm (OD600) of 0.15±0.02 (Figure 5.3). The growth rate of B. longum subsp. 
longum UCD401 while utilizing xyloglucans does not significantly differ from that during 
glucose utilization (p>0.05) (Table 5.3). This indicates that B. longum subsp. longum 
UCD401 does not have a metabolic preference for glucose relative to xyloglucans. As 
expected, while fermenting xyloglucans, B. longum subsp. longum UCD401 achieves a 
modest biomass relative to that achieved on glucose (p<0.05) and no growth was observed 
on the negative control. This indicates that UCD401 does not utilize these carbohydrates 
with similar efficiency. Bifidobacteria that utilize both plant and milk oligosaccharides 
have exhibited similar growth profiles [242, 290]. Despite similar growth rates on glucose 
and xyloglucans, B. longum subsp. longum UCD401 ferments xyloglucans more slowly 
than glucose to achieve maximal growth (tc) (p<0.05) (Table 5.3). In contrast to UCD401, 
B. longum subsp. infantis ATCC 15697 and JCM1260 did not metabolize cranberry 
xyloglucans. 
Lactobacillus strains were evaluated to test if other fermentative bacteria could 
harness cranberry xyloglucan carbon. Lactobacillus plantarum ATCC BAA-793 and 
Lactobacillus johnsonii ATCC 33200 were subjected to growth on xyloglucans as a sole 
carbohydrate source as depicted in Figure 5.2 with growth kinetics displayed in Table 5.3. 
L. johnsonii ATCC 33200 did not utilize cranberry-derived oligosaccharides. In contrast, 
L. plantarum ATCC BAA-793 achieved a final OD600 of 0.29±0.03, which is higher than 
that of all of the B. longum strains tested (p<0.05) (Figure 5.2). This Lactobacillus strain 
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does prefer glucose, as it has a significantly lower growth rate while consuming 
xyloglucans (p<0.05, Table 5.3). Its maximal growth (tc) did not vary between xyloglucan 
and glucose utilization (p>0.05), despite the lower growth rate during xyloglucan 
utilization. Interestingly, L. plantarum has a lower growth rate than B. longum subsp. 
longum UCD401 while fermenting purified xyloglucans despite achieving a higher 
biomass (p<0.05). The time required to achieve maximum growth (tc) while utilizing 
xyloglucan is significantly shorter for L. plantarum than for B. longum subsp. longum 
UCD401 (p<0.05). This suggests that L. plantarum does not prefer these complex 
carbohydrates, despite having a higher utilization efficiency than the B. longum strain. 
5.4.3 B. longum consumes xyloglucans from the growth medium.  
The extent to which UCD401 utilizes xyloglucans was determined by profiling 
spent fermentation medium from growth conducted in microcentrifuge tubes. Interestingly, 
degraded glycans were not detected in spent medium compared with the control (i.e., 
preinoculated medium) (Figure A5.3 and A5.4). The extracted ion counts for each 
xyloglucan were quantitated as percentages of the baseline control (t=0) (Figure A5.5 and 
A5.6). Of interest, detectable xyloglucans with DPs of 6 to 9 exhibited 120% of the 
extracted ion counts of the baseline (t=0). Thus, there was an extensive accumulation of 
xyloglucans with all DPs following fermentation by B. longum subsp. longum UCD401. 
Significantly, xyloglucans with DPs of <7 did not accumulate to the same extent. This is 
indicative of an ability to utilize the short-chain oligosaccharides. Accordingly, we did not 
detect monosaccharide accumulation in the spent fermentation medium. A similar 
observation has been reported previously with bifidobacterial metabolism of human milk 
oligosaccharides [198, 199]. As previously postulated, B. longum is able to transport only 
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lower molecular-weight oligosaccharides across its envelope. This suggests that a dynamic 
equilibrium has been achieved between the import of lower-DP molecules and the 
extracellular hydrolysis of higher-DP molecules. This is consistent with higher-DP 
oligosaccharide accumulation in the growth medium. A similar glycan distribution was 
observed in L. plantarum qualitatively, along with corresponding degradation phenotypes 
(Figure A5.3). It is important to note that glycoprofiling was performed with bacteria 
grown in microcentrifuge tubes. 
5.4.4 Bifidobacteria metabolize xyloglucans via the bifid shunt  
Metabolite end products secreted while utilizing xyloglucans were quantified by 
high-performance liquid chromatography (HPLC) of cell-free supernatants. The absolute 
concentrations of acetate, lactate, and formate secreted by B. longum subsp. longum 
UCD401 in the early stationary phase of xyloglucan or glucose utilization are depicted in 
Figure 5.3. B. longum subsp. longum UCD401 secretes significantly lower lactate and 
acetate concentrations while utilizing xyloglucans (4.08±0.16 and 8.78±0.10 mM, 
respectively) than when subsisting on glucose (37.60±9.41 and 54.11±13.40 mM, 
respectively). This is expected and consistent with the lower biomass achieved (p<0.05). 
In addition, less metabolic investment is required to catabolize glucose in the bifid shunt. 
The absolute concentrations were normalized with respect to the OD600 reached in 
microcentrifuge tubes. UCD401 exhibited higher acetate concentrations in xyloglucan 
metabolism (172.54±10.52 mM) than in glucose metabolism (124.56±22.70 mM), whereas 
the lactate concentrations were similar (80.31±6.76 and 86.50±15.98 mM). Interestingly, 
and despite a lower biomass, B. longum subsp. longum UCD401 secretes high 
concentrations of formate while metabolizing cranberry xyloglucans (10.01±0.86 mM). 
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This is significantly higher than during glucose utilization (1.62±1.30 mM) (p<0.05), 
indicating a shift in metabolism to harvest energy more efficiently from this substrate. 
The bifid shunt catabolizes hexose sugars to yield a theoretical acetate:lactate ratio 
of 1.5. As expected, UCD401 achieved this while utilizing glucose (1.44±0.01); however, 
xyloglucan fermentation shifted the ratio significantly toward acetate at the expense of 
lactate (2.15±0.08) (p<0.05) (Figure 5.3d). When normalizing the absolute concentrations 
with respect to biomass, more acetate production from xyloglucan metabolism than from 
glucose metabolism occurred. This has been observed in a previous study, as more ATP is 
produced by flux through acetate-producing pathways [193]. Accordingly, formate 
secretion was significantly increased with a formate:lactate ratio of 2.50±0.28 while 
fermenting xyloglucans, in contrast to 0.05±0.01 during glucose metabolism (Figure 5.3e). 
Organic acids produced while lactobacilli ferment xyloglucans were subsequently profiled 
(Figure 5.3). In addition to comparative physiology, this approach may inform future 
mixed-culture probiotics (i.e., lactobacilli and bifidobacteria), as well as synbiotic 
strategies that incorporate xyloglucans with one or more probiotic strain. Lactate was 
produced at significantly lower concentrations (5.27±0.19 mM, p<0.05) by L. plantarum 
ATCC BAA-793 than during glucose consumption. In addition, acetate secretion was 
observed with an acetate:lactate ratio of 1:1 when L. plantarum ATCC BAA-793 utilized 
cranberry xyloglucans (Figure 5.3d). While fermenting glucose, L. plantarum exhibited an 
acetate:lactate ratio of 0.05±0.01 (p<0.05) (Figure 5.3d). We expected L. plantarum, as a 
heterofermentative species, to secrete acetate. Interestingly, formate production was 
detected during xyloglucan consumption, although it was not detected following glucose 
151 
 
fermentation. The secretion of acetate and formate has been previously observed when 
inefficient substrate utilization yielded less biomass [291, 292].  
5.4.5 Bacterial commensals exhibit differential growth phenotypes while consuming 
oligosaccharide extracts containing secondary plant material 
In addition to purified xyloglucans, crude cranberry cell wall extracts were 
evaluated as a growth substrate. These fractions are more crudely enriched for 
oligosaccharides and thus more closely mimic what would be encountered by the 
microbiota following the ingestion of cranberries. Moreover, prebiotic formulations would 
likely use a crude cranberry extract for functional or processing reasons. We tested two 
crude fractions, termed A2, which retains a pink color and is extracted from whole 
cranberries, and A6, which is derived from the primary A2 fraction. Both of these 
preparations have been previously reported [284]. However, the precise distribution of 
glycans and noncarbohydrate molecules in A2 is not fully characterized.  
Accordingly, B. longum strains achieved more pronounced growth phenotypes 
while consuming A2 and A6. Cellular growth (Figure 5.4) and kinetics varied by the 
particular strain tested (Table 5.4). A2 was most vigorously utilized by B. longum subsp. 
infantis JCM7007 (OD600 of 0.58±0.34), B. longum subsp. infantis JCM1272 (OD600 of 
0.38±0.10), and B. longum subsp. longum UCD401 (0.37±0.07) (Figure 5.4a; Table 5.4). 
With the exception of UCD401, these strains did not grow on purified xyloglucans. 
Interestingly, there are two B. longum subsp. infantis strains that utilize A2 as a substrate. 
This is significant, as B. longum subsp. infantis is predicted not to utilize xyloglucans; thus, 
other components of the A2 fraction were fermented or cofermented. In addition, B. 
longum subsp. infantis JCM1272 achieved moderate growth on A2 (OD600 of 0.17±0.08), 
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whereas growth on purified xyloglucans was not observed. In contrast, the more purified 
A6 fraction was utilized only by B. longum subsp. longum UCD401 and B. longum subsp. 
infantis JCM 1260, with final OD600s of 0.27±0.03 and 0.08±0.02, respectively (Figure 
5.4b). Clearly, the A6 fraction is not as efficiently utilized as the cruder and likely 
polyphenol-containing A2 fraction (Table 5.4; Figure A5.7). UCD401 exhibited a gradual 
decline in growth efficiency while utilizing the crudest extract to the most purified form 
(Figure A5.7b) (P<0.05). This mirrors the general trend that the majority of bifidobacterial 
strains tested do not metabolize highly purified xyloglucans. This includes all B. longum 
subsp. infantis strains (Figure A5.7c). B. longum subsp. longum UCD401 utilizes A6, 
leading to an increase in the acetate: lactate ratio (1.90±0.16) and absolute formate 
production (8.87±2.63 mM) relative to those achieved with glucose, despite the lower 
biomass (p<0.05) (Figure 5.5). Formate production by UCD401 is greater than that by B. 
longum subsp. infantis JCM1260 when catabolizing A6 (p<0.05). This is consistent with 
formate secretion while utilizing highly purified xyloglucans and suggests that UCD401 is 
specifically consuming this substrate in the mixed-purity preparation. Interestingly, B. 
longum subsp. infantis JCM1260 exhibits an acetate:lactate ratio of 2.44±0.32 and 
6.39±0.57 mM formate secreted (Figure 5.5c). Glucose flux through the bifid shunt was 
metabolized, as expected, to approximate the theoretical yield of 1.5 (1.82±0.15 and 
1.43±0.01) (p<0.05) (Figure 5.5d). Again, this is consistent with utilization of the 
carbohydrate constituents of the A6 fraction.  
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5.4.6 Expression of arabinose utilization genes while utilizing the A6 cranberry 
xyloglucan fraction 
The expression of four GH family genes in the UCD401 chromosome while 
metabolizing A6 was evaluated. This includes an a-L-arabinofuranosidase gene 
(BL_0405), two arabinan endo-1,5-a-L-arabinosidase genes (BL_0404, BL_0403), and a 
b-xylosidase gene (BL_0402). We observed that BL_0405, BL_0404, and BL_0402 were 
significantly upregulated, with a minimum of a 2-fold increase during exponential phase 
(Figure 5.6a, p<0.05). This indicates that the expression of these genes and their products 
is modulated during the utilization of the A6 xyloglucan fraction. Interestingly, BL_0403 
expression did not significantly change relative to that of the glucose control (p>0.05). This 
indicates that the adjacent BL_0404 gene is responsible for xyloglucan hydrolysis. 
Moreover, differential regulation of these paralogs potentially reflects divergent enzymatic 
functions. Fermentation of the A6 fraction induces UCD401 to express transport-related 
proteins that may be involved in xyloglucan transport across the membrane. Upregulated 
transport genes, including those for a carbohydrate ABC transporter substrate-binding 
protein (BL_0398) and carbohydrate ABC transporter membrane proteins (BL_0397, 
BL_0396) exhibit >2-fold induction relative to the control (Figure 5.6b, p<0.05). This 
suggests recognition and a potential uptake of arabinose and xylose backbone motifs across 
the cell envelope.  
5.4.7 Modeled bidirectional syntrophic interactions 
 Conditioned spent medium from xyloglucan fermentations was used to assess in 
vitro bidirectional syntrophic interactions in microplate growth. This occurs when 
fermentation by a primary strain provides hydrolysis products to be used by a heterologous 
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secondary strain that is incapable of utilizing the initial substrate. Since L. johnsonii does 
not grow on xyloglucans on a microplate, we included this strain as a negative control. 
Interestingly, B. longum subsp. infantis ATCC 15697 does not utilize purified xyloglucans 
as a sole carbon source; however, conditioned supernatants from L. plantarum and L. 
johnsonii enabled growth to final OD600s of 0.066±0.008 and 0.093±0.008 with growth 
rates of 0.940±0.106 h-1 and 0.801±0.077 h-1, respectively (Table 5.5). We interpret this as 
moderate growth because of the characteristic sigmoidal response curve produced during 
fermentation. In contrast, supernatant harvested from B. longum subsp. longum UCD401 
did not enable B. longum subsp. infantis ATCC 15697 to grow (Figure 5.7). This is likely 
due to the inability of B. longum subsp. infantis ATCC 15697 to utilize arabinosyl-reducing 
ends, as predicted by comparative genomics (15). UCD401 may potentially sequester and 
metabolize molecules that would otherwise be utilized by other bifidobacterial strains. 
Furthermore, it is possible that the lactobacilli secreted other products to enhance B. 
longum subsp. infantis growth (e.g., exopolysaccharides) (34). B. longum subsp. infantis 
ATCC 15697 utilization of carbohydrates liberated from lactobacilli and UCD401 primary 
fermentations were analyzed by liquid chromatography (LC)-MS (Figure A5.8). Of 
interest, ATCC 15697 grew on the spent medium from lactobacillus primary fermentations, 
albeit with a stronger peak intensity observed by LC-MS. This may be due to hydrolysis 
of higher-molecular-weight xyloglucans or the production of exopolysaccharides, as 
hypothesized with primary fermentations. In addition, we determined that ATCC 15697 is 
incapable of utilizing the spent medium from UCD401 in a secondary fermentation.  
When B. longum subsp. longum UCD401 was grown on the L. plantarum 
supernatant, it achieved a lower final OD600 (0.096±0.005) than when it was grown on 
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purified xyloglucans in a primary fermentation (p<0.05), although the growth rates are 
similar regardless of whether UCD401 is conducting a primary or a secondary fermentation 
(Table 5.5). Conversely, the growth rate of L. plantarum on conditioned medium from B. 
longum subsp. longum UCD401 was significantly higher whereas its biomass production 
(final OD600 of 0.115±0.009) was significantly lower than that of purified xyloglucans 
(final OD600 of 0.29±0.03) (p<0.05) (Table 5.5). This may indicate the production of 
inhibitory compounds or a preference for intact oligosaccharides.  
5.5 Discussion 
It has been established that genotypic and phenotypic variations contribute to 
bifidobacterial preferences for carbon sources [215]. For the former, the B. longum subsp. 
infantis genome has evolved to enable milk oligosaccharide utilization at the expense of 
plant carbohydrates. Bifidobacteria deploy transporters to capture intact oligosaccharides 
or their derivatives from the extracellular milieu [183, 293]. Thus, the inability of B. 
longum subsp. infantis strains to utilize xyloglucans may be due to absence of specific 
transporters. This is consistent with B. longum subsp. infantis ATCC15697 utilization of 
lactobacilli hydrolysis products. These lactobacilli perform extracellular digestion to 
provide ATCC15967 with fermentable substrates. In contrast, UCD401 internalizes intact 
oligosaccharides to withhold potential growth substrates from ATCC15697. 
It is likely that B. longum subsp. longum UCD401 utilize xyloglucans from the 
terminal arabinose positioned at the reducing end. This is consistent with expression of 
arabinose utilization genes within the UCD401 genome (Figure A5.9). This arabinose 
utilization cluster is conserved in B. longum subsp. longum strains with an araC 
transcriptional family operon upstream of α-L-arabinofuranosidase and β-xylosidase genes 
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adjacent to an ABC transporter cassette. Importantly, B. longum subsp. longum 
ATCC15707 does not grow on xylose but metabolizes arabinose as a sole carbohydrate 
source [294]. Accordingly, B. longum subsp. longum UCD401 utilizes arabinose more 
efficiently in comparison to other B. longum subsp. longum strains tested (Figure A5.10). 
It is noteworthy that this B. longum strain was isolated from an infant stool sample and the 
stronger utilization phenotype may reflect recent isolation and limited passages.  
Bifidobacterial xyloglucan utilization requires transport of arabinose following 
extracellular hydrolysis of higher DP oligosaccharides. β-D-glucopyranosyl and α-D-
xylopyranosyl residues are not metabolized extracellularly. This likely causes the 
accumulation of lower DP xyloglucans. Arabinose metabolism has been linked to genes 
encoding extracellularly secreted α-arabinofuranosidases, which is encoded within the 
UCD401 genome (Figure A5.4) [295]. As we predicted, B. longum subsp. longum UCD401 
utilizes xyloglucan within the crude A6 fraction likely using an extracellular 
arabinofuranosidase (BL_0405). Arabinose liberated from xyloglucans was completely 
sequestered, as it was not detected in spent medium. It has been posited that bifidobacterial 
strains cannot use xylose backbones longer than xylotetraose (DP=4) [295]. The B. longum 
subsp. longum arabinose cluster encodes predicted intracellular xylosidases, which 
supports the hypothesis that transport is essential for catabolism of higher (DP>4) 
xylooligosaccharides (Figure A5.4). The up-regulation of solute binding transport proteins 
(BL_0398) and permeases (BL_0397 and BL_0396) suggest that uptake of arabinose and 
lower DP xyloglucans including xylose and glycosyl residues occur after releasing 
arabinose moieties.  
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 In bifidobacterial carbohydrate metabolism, pyruvate is converted to lactate via 
lactate dehydrogenase which does not produce additional ATP but recycles NAD+ [191]. 
Pyruvate-formate lyase (pfl; EC: 2.3.1.54) catalyzes formate and acetyl-coA production 
from pyruvate. Acetyl-coA is subsequently metabolized to acetate or ethanol secretion 
[191]. This results in increasing the acetate to lactate ratio and correspondingly higher ATP 
production [191, 193]. We predicted increased acetate secretion during UCD401 
xyloglucan fermentation, although the lower biomass on this substrate hinders comparisons 
in absolute concentrations. However, formate and ethanol secretion was previously 
determined to impact the acetate:lactate ratio in bifidobacteria [191]. Thus, the shift 
towards formate production coincides with an increased need for ATP while metabolizing 
xyloglucans. Bifidobacterial secretion of formate while utilizing certain oligosaccharides 
has been previously observed [188, 222, 296]. Under certain conditions bifidobacterial 
oligosaccharide metabolism is characterized by high levels of lactate produced initially, 
with a shift occurring towards formate production later in the fermentation [214, 216, 222]. 
This suggests that formate production benefits the cell by generating additional ATP when 
oligosaccharides are catabolized slowly. In general, bifidobacteria secrete secondary 
products such as formate, succinate, and ethanol when achieving lower biomass 
concentrations (OD600nm<0.5) and when the carbohydrate consumption rate is diminished 
[188, 193, 216, 222]. Our results are consistent in that formate production increases while 
utilizing xyloglucans slowly, ostensibly to bolster ATP production under these conditions. 
Crude oligosaccharide extracts were tested as this is of interest for preparation of 
cranberry xyloglucans for prebiotic applications. The cranberry cell wall does not contain 
appreciable quantities of monosaccharides [297] and is not expected to influence growth 
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[284]. As the A2 fraction retains a pink color there is likely small quantities of phenolic 
compounds that may contribute to differential growth observed between A2 and the highly 
purified xyloglucans. Furthermore, the most abundant oligosaccharides within the A6 
fraction are identical to the xyloglucans purified in this study [284]. However, XSGGG-
Ac and XSGGG-Ac2 structures (i.e. acetylated xyloglucan oligosaccharides) have been 
identified in the A6 fractions and did not remain in the highly purified xyloglucans. Thus, 
these oligosaccharides may be responsible for promoting L. johnsonii and B. longum subsp. 
infantis JCM1260 growth. B. longum typically consumes short-chain oligosaccharides, 
likely subsequent to intracellular transport [183, 298]. Thus, it is possible that differential 
phenotypes may be due to variation in xyloglucan DP.  
Lactobacilli are natural inhabitants of the human gastrointestinal tract and may be 
used as probiotics and in concert with prebiotics in synbiotic applications [288, 299]. 
Lactobacilli strains may utilize carbohydrates as well as bifidobacteria [300]. It is likely 
that L. plantarum uses the phosphoketolase pathway while consuming xyloglucans to 
secrete formate and acetate with lactate being reduced. This was previously observed in L. 
plantarum VTT E 79098 fermentation of arabino-xylooligosaccharide [292, 301, 302].  
Our experiments suggest that syntrophic interactions following xyloglucan 
degradation may occur between other members of the gut consortium. The interactions 
between lactobacilli, bifidobacteria, and oligosaccharides are of interest in engineering 
synbiotic interventions. Moreover, lactobacilli-mediated cleavage of xyloglucans within 
the small intestine would impact substrates available to bifidobacterial commensals of the 
lower gastrointestinal tract. Syntrophic interactions during bifidobacterial in vitro co-
fermentations on various carbohydrate sources has been previously described which 
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includes members of the genus Bifidobacterium [215, 247, 298]. Cooperative or cross-
feeding between strains that colonize the gastrointestinal tract may contribute to 
competitive exclusion of sensitive taxa and maintain diversity through specialist adaptation 
to colonize unique niches [303]. Such syntrophic interactions under in vivo conditions 
might prompt a shift in the gut microbiome towards metabolism of plant-derived 
carbohydrates with a metabolome characteristic of saccharolytic activities [304]. We did 
not detect monosaccharides in spent media by HPLC leading to the hypothesis that 
liberated monosaccharides would be sequestered thus rendering them undetectable. 
Furthermore, it is possible that the transfer of conditioned media from the primary 
fermentation introduced endproducts to the secondary fermentation although at very low 
concentrations with minimal impacts to growth.  
5.6 Conclusions 
Among the bifidobacterial strains tested, B. longum subsp. longum UCD401 
utilizes cranberry xyloglucans as a sole energy and carbon source. This is potentially 
significant as it was recently isolated from an infant and subjected to limited passages. This 
may be due to conserving phenotypic function, as genomic or regulatory features likely 
remained intact in the limited generations since isolation [305]. Furthermore, it hints at the 
potential for strain variation within infants and adults in their capacity to utilize cranberry 
xyloglucans. B. longum subsp. longum colonizes both infants and post-weaning 
individuals. The phenotypic versatility underlying the broad host range to subsist on a 
substrate encountered in the adult diet suggests a post-weaning strategy. It is notable that 
xyloglucan catabolism prompts a shift in the central fermentative pathway to obtain more 
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ATP. The significance of the altered metabolic profile to microbiome function or host 
health remains an outstanding question. 
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Table 5.1 List of strains used in this study a 
Strain Species Origin 
ATCC 15697 B. longum subsp. infantis Feces of human infant 
JCM 1260 B. longum subsp. infantis Feces of human infant 
JCM 1272 B. longum subsp. infantis Feces of human infant 
JCM 7007 B. longum subsp. infantis Feces of human infant 
JCM 11347 B. longum subsp. longum Feces of human 
ATCC 15708  B. longum subsp. longum Feces of human 
UCD 401 B. longum subsp. longum Feces of human 
ATCC BAA-793 Lactobacillus plantarum Saliva- human oral cavity 
ATCC 33200 Lactobacillus johnsonii Human blood 
a UCD: University of California Davis Culture Collection, ATCC: American Type 
Culture Collection, JCM: the Japanese Collection of Microorganism 
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Table 5.2 Primers used in this study. 
Primer Sequence (5’ – 3’) 
Blon_0393F CCATGTCCCACCGTTACCT 
Blon_0393R CCAGCGACTTCGACATCTTC 
BL_0405F AACCGCTTCCAGCAGATTTT 
BL_0405R TGGTAGGAATGCTCGTCCAC 
BL_0404F CAACGGCTGGTGGTATCTGT 
BL_0404R GGTCTGATTGTCGGGGATTT 
BL_0403F ACGATCCATCCATCGTCAAG 
BL_0403R CGACCAGTTGGTCCAGATGT 
BL_0402F ATCTACTCCGGATCGCTCGT 
BL_0402R TATCGCCCGTTGTCGTACTC 
BL_0398F GACGGCACCTACAAGTACGC 
BL_0398R AGGGACCACTTCACCTGGTT 
BL_0397F GCTCCTTCCAGGTCTTCGAT 
BL_0397R TGATGAGCAGCACGTACGAC 
BL_0396F GGTCACGATCATCTCCGTGT 
BL_0396R CCGAGGTAGCTGTTGACGAG 
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Table 5.3 Analysis of bacterial growth kinetics calculated with Wolfram Mathematica 10.3 
Strain 2 % xyloglucans 2 % Glucose k (h-1) ΔODasym tc(h) k (h-1) ΔODasym tc(h) 
B infantis JCM 1260 NDa ND ND ND ND ND 
B. infantis ATCC 15697 ND ND ND ND ND ND 
B. longum UCD 401 0.555±0.055 0.15±0.02b 19.7±2.5c 0.614±0.048 1.25±0.09b 13.7±0.6c 
L. plantarum ATCC BAA-793 0.386±0.049d 0.29±0.03b 2.3±0.60c 0.569±0.005 1.48±0.02b 5.3±0.60c 
L. johnsonii ATCC 33200 ND ND ND ND ND ND 
aND, not determined. 
bSignificant difference in the asymptotic OD value of each strain compared to each other and to the positive control, glucose (p< 0.05). 
cSignificant difference in the inflection point (tc) of each strain compared to each other and to the positive control, glucose (p< 0.05). 
dSignificant difference between the growth rate (k) of L. plantarum on xyloglucans and that of other strains on xyloglucans and 
glucose (p< 0.05). 
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Table 5.4 Kinetic analysis of bacterial growth on A2 and A6 fractions xyloglucans calculated using Wolfram Mathematica 10.3. 
Strain A2 fraction xyloglucans A6 fraction xyloglucans k (h-1) ΔODasym tc(h) k (h-1) ΔODasym tc(h) 
B infantis JCM 1260 0.464±0.280 0.17±0.08 6.4±3.3 1.188±0.79 0.08±0.02b 3.3±1.8 
B infantis JCM 1272 0.427±0.039 0.38±0.10 12.4±0.6 ND ND ND 
B infantis JCM 7007 0.215±0.137 0.58±0.34 17.6±6.1 ND ND ND 
B. infantis ATCC 15697 NA NA NA ND ND ND 
B. longum JCM 11347 ND ND ND ND ND ND 
B. longum ATCC 15708 ND ND ND ND ND ND 
B. longum UCD 401 0.438±0.152 0.37±0.08 11.3±3.0 0.270±0.084 0.27±0.03a 16.3±0.6 
L. plantarum ATCC BAA-793 NA NA NA 0.513±0.061 0.25±0.02a 2.9±0.5 
L. johnsonii ATCC 33200 NA NA NA 0.944±0.166 0.12±0.01b 1.4±0.3 
aSignificant difference between asymptotic OD values of strains in A6 fraction treatment (p< 0.05). 
bND, not determined. 
cNA, not available. 
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Table 5.5 Growth kinetics of strains during syntrophic interaction 
Strain 
Supernatant from B. longum UCD 401 Supernatant from L. plantarum ATCC BAA-793 Supernatant from L. johnsonii ATCC 33200 
k (h-1) ΔODasym tc(h) k (h-1) ΔODasym tc(h) k (h-1) ΔODasym tc(h) 
B. infantis 
ATCC 15697 ND
e ND ND 0.940±0.106a 0.066±0.008 10.3±0.6 0.801±0.077 0.093±0.008 10.3 ±0.6 
B. longum UCD 
401 NA
f NA NA 0.632±0.120b 0.096±0.005d 12.8±0.6 0.468±0.070d 0.162±0.007c 11.0±0.0 
L. plantarum 
ATCC BAA-
793 
0.890±0.158d 0.115±0.009d 2.1±0.9 NA NA NA NA NA NA 
aSignificant difference between the growth rates of B. infantis ATCC 15697 in different conditioned media determined by paired t test 
(p<0.05). 
bSignificant difference between the growth rates of B. longum UCD401 in different conditioned media determined by paired t test 
(p<0.05). 
cSignificant difference between the asymptotic OD values of B. longum UCD401 in different conditioned media determined by paired 
t test (p<0.05). 
dSignificant difference in the growth kinetics of each strain in different conditioned media and its growth kinetics in xyloglucans alone 
(shown in Table 5.3) determined 
by paired t test (p<0.05). 
eND, not determined. 
fNA, not available. 
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Figure 5.1 Purified cranberry xyloglucan putative structures. Positive reflectron 
mode MALDI-TOF-MS spectrum of cranberry xyloglucan obtained from Hiprep 
Sephacryl S-100 HR size exclusion column. The voltage was set at 80kV and 500 
profiles were collected. Major peaks at m/z 923, 953, 1055, 1085, 1217, 1247 and 1379 
represent sodium adducts ([M+Na]+) of xyloglucan with degrees of polymerization (DP) 
ranging from 6-9 and sugar compositions as follows: [Hexose3Pentose3+Na]+, m/z 923; 
[Hexose4Pentose2+Na]+, m/z 953; [Hexose3Pentose4+Na]+, m/z 1055; 
[Hexose4Pentose3+Na]+, m/z 1085; [Hexose4Pentose4+Na]+, m/z 1217; 
[Hexose5Pentose3+Na]+, m/z 1247; [Hexose5Pentose4+Na]+, m/z 1379. 
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Figure 5.2 Bacterial growth while utilizing cranberry xyloglucans. Growth curves of 
B. longum subsp. longum UCD 401, Lactobacillus plantarum ATCC BAA-793, 
Lactobacillus johnsonii ATCC 33200, B. longum subsp. infantis ATCC 15697 and B. 
longum subsp. infantis JCM 1260 for growth on modified MRS containing 2 % (w/v) 
xyloglucans. The curves are drawn from average of three independent experiments. 
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Figure 5.3 Bacterial fermentative endproducts while utilizing the cranberry 
xyloglucans. Production of lactate (a), acetate (b), formate (c). Acetate to lactate ratio 
(d), formate to lactate ratio (e). Strains are shaded as follows: B. longum subsp. longum 
UCD 401 (black) and Lactobacillus plantarum ATCC BAA-793 (grey). Averages from 
independent biological triplicates are shown and bars represent standard deviations of the 
means. The values for organic acid production are expressed in millimolar absolute 
concentration. Asterisks represent the significant difference evaluated by two-way 
ANOVA and Sidak’s multiple comparison test (p<0.05).  
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Figure 5.4 Bacterial growth on additional fractions of cranberry xyloglucans. 
Growth curves represent B. longum subsp. infantis ATCC 15697, B. longum subsp. 
infantis JCM 1260*, B. longum subsp. infantis JCM 1272, B. longum subsp. infantis JCM 
7007*, B. longum subsp. longum JCM 11347*, B. longum subsp. longum ATCC 15708*, 
B. longum subsp. longum UCD 401, Lactobacillus plantarum ATCC BAA-793 and 
Lactobacillus johnsonii ATCC 33200 for growth on modified MRS containing (a) 2 % 
(w/v) A2 fractions xyloglucans, and (b) 2 % (w/v) A6 fractions xyloglucans. The curves 
are drawn from average of at least three independent experiments with the exception of 
strains labeled with asterisks which are based on duplicates in (a). 
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Figure 5.5 Bifidobacterial fermentative endproducts while utilizing the cranberry 
A6 fraction. Lactate (a), acetate (b), formate (c) production while B. longum subsp. 
infantis JCM 1260 and B. longum subsp. longum UCD 401 utilizes the A6 xyloglucan 
fraction collected at early stationary phase. Panel d also depicts the acetate to lactate ratio 
after fermentation. Averages from independent biological triplicates are shown and bars 
represent standard deviations of the means. Asterisks represent the significant difference 
evaluated by two-way ANOVA and Sidak’s multiple comparison test (p<0.05).  
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Figure 5.6 Gene expression of B. longum subsp. longum UCD 401 while utilizing the 
cranberry A6 fraction as a sole carbon source. Genes in arabinose cluster of B. longum 
subsp. longum UCD 401 predicted to participate in xyloglucan metabolism are depicted 
in the x-axis. The levels of expression of (a) four glycosyl hydrolase family genes, α-L-
arabinofuranosidase, C-terminal (BL_0405), arabinan endo-1,5-α-L-arabinosidase 
(BL_0404, BL_0403), β-xylosidase (BL_0402) and (b) carbohydrate ABC transporter 
substrate-binding protein (BL_0398) and carbohydrate ABC transporter membrane 
proteins (BL_0397, BL_0396)  are expressed in fold change relative to control (glucose). 
Averages from independent biological triplicates are shown and bars represent standard 
deviations of the means. Asterisks represent the significant difference evaluated by 
paired-t test (p<0.05).  
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Figure 5.7 Bacterial syntrophic interactions after growth on cranberry xyloglucans. 
Growth curve of B. longum subsp. infantis ATCC 15697 on modified MRS containing 
xyloglucans (green), supernatants from B. longum subsp. longum UCD 401 (orange), 
Lactobacillus plantarum ATCC BAA-793 (blue) and Lactobacillus johnsonii ATCC 
33200 (yellow) growth after xyloglucan fermentation. The curves are drawn from 
average of three independent experiments. 
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6.1 Introduction 
Polyphenols are known to be bioactive antioxidant compounds with  
epidemiological evidence of their anti-inflammation, anti-cancer, anti-bacterial effects in 
both humans and animals [306–309] and in vitro [80]. The bioavailability of polyphenols 
has been found to be largely dependent on hydrolysis of polyphenols by gut microbiome 
such as reduction, decarboxylation, ring fussion, and demethylation [310, 
311]. Cranberries contain polyphenols mainly proanthocyanidins (PACs) and 
anthocyanidins as well as flavanols and phenolic acids [312]. Proanthocyanidins (PACs) 
are condensed tannins comprised mainly of epicatechin units [313]. Polyphenol enriched 
cranberry products were found to be effective on obesity, inflammation and cardiovascular 
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disease [314–319]. The metabolism of PACs by human gut microbiome and their influence 
on the gut microbiome have been studied in vitro and in vivo [108, 109, 136, 319–324]. 
Lactic acid bacteria present in many vegetable and fruits, mostly facilitate the 
fermentation in fermented foods, and they have been previously studied for their 
association with polyphenols [325–329]. They are also probiotics and commensals in the 
human gut. Polyphenols might enhance the growth of intestinal microbes and probiotics 
due to favored sugar uptake and cell transport mechanism [330], or the degradation of 
PACs which provides additional energy for the cell growth (i.e., prebiotic effects)[331].  
 Lactobacillus plantarum IFPL935 was capable of modifying the phenolic profile 
of the cranberry extract, mainly due to catabolism of hydroxycinnamic and hydroxybenzoic 
acids not A-type or B-type dimers [325]. Adversely, catechin (100 mg/l) added to 0.5 % 
galactose containing media promoted the growth of L. plantarum RM71 by extending the 
sugar utilization, and sugar uptake without getting degraded by the bacteria [332]. L. 
plantarum IFPL935 was able to metabolize the polyphenols studied by means of galloyl-
esterase, decarboxylase and benzyl alcohol dehydrogenase activities that led to the 
formation of gallic acid, pyrogallol and catechol, respectively [326]. There were also other 
lactobacillus strains which are capable of utilizing polyphenols. For example, grape 
pomace phenolic extract (1 mg/ml) induced a significant biomass of L. acidophilus grown 
in MRS broth [329]. Similarly, the mammalian intestinal commensal L. johnsonii N6.2 can 
degrade common dietary phytophenols (ferulic, caffeic, p- coumaric acid) as a mode of 
self-protection [333].  
The synergetic effect of combination of polyphenols and probiotics are under 
investigation. For instance, proanthocyanidins derived from cranberries and probiotics 
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were tested on reducing the invasiveness of extra-intestinal pathogenic Escherichia coli 
(ExPEC) in a cell culture model [334]. Similarly, the effect of cranberry extracts on 
Lactobacillus plantarum’s anti-inflammatory activity on colon cancer cells was also 
investigated [335]. However, there was not much of evidence on tripartite relationship of 
oligosaccharides, polyphenols and gut microbes, e.g. L. plantarum.  
 We previously observed that B. longum UCD401 and Lactobacillus plantarum 
ATCC BAA-793 grow on xyloglucans (cranberry oligosaccharides) with a moderate 
biomass and produce formic acid [221]. In addition, secondary molecules in xyloglucan 
fractions boosted the growth of B. infantis and B. longum strains when these fractions are 
only carbon source in the environment [221]. Therefore, we hypothesize that 
oligosaccharide uptake inside the cells was favored and biomass was increased by addition 
of the secondary molecules. These secondary molecules are likely to be polyphenols 
present in cranberries. In this study, we will investigate the effect of polyphenol fractions 
extracted from cranberry (PACs) on the growth of Lactobacillus plantarum ATCC BAA-
793 in the presence of different oligosaccharides such as cranberry oligosaccharides 
(xyloglucans, XG), fructooligosaccharides (FOS) and human milk oligosaccharides 
(HMOs). We will show that the mechanism underlying the effects of PACs on the L. 
plantarum physiology. We also hypothesize that L. plantarum deploys differential 
mechanism to utilize polyphenols in different fractions of cranberry PACs, depending on 
the carbohydrate source. 
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6.2 Material and Methods 
6.2.1 The growth promotion assay and phenotypic response 
The growth promotion assay was evaluated in a 96-well microplate. Lactobacillus 
plantarum ATCC BAA-793 was propagated in De Man Rogosa Sharp (MRS, Difco) 
medium supplemented with 0.05 % (wt/v) L-cysteine hydrochloride (Across Organics, 
New Jersey, USA) at 37 °C under anaerobic conditions (Coy Laboratory Products, Grass 
Lake, MI). Overnight cultures were centrifuged and resuspended in modified MRS 
(mMRS, without acetate and carbohydrate substrate), and then were used to inoculated (1% 
(v/v)) into mMRS with glucose (Sigma-Aldrich Co. St. Louis, MO), cranberry 
oligosaccharide fraction (xyloglucans, XG, Ocean Spray Inc, MA), fructooligosaccharides 
from chicory (FOS, Sigma-Aldrich Co. St. Louis, MO), pooled human milk 
oligosaccharides (HMOs, donated from Barile Lab at UC Davis) at a final concentration of 
1% (wt/v, 10 mg/ml) as the sole carbohydrate source. Two different PAC fractions (Ocean 
Spray Inc, MA) were initially dissolved in absolute dimethylsulfoxide (DMSO) at 100 
mg/ml concentration, then diluted in mMRS at the final concentration of 1 mg/ml for each 
carbohydrate source. This makes DMSO concentration 1 % (v/v) which is a concentration 
that does not affect the growth. The dose dependent response was conducted by diluting 1 
mg/ml of PACs to 500, 250 and 125µl/ml concentrations. In addition, to investigate if PAC 
fractions involves in carbon metabolism, PAC fractions were also added in modified MRS 
as the same concentration without any carbon source. The growth assay was conducted 
anaerobically at 37 °C for 48 h by assessing optical density at 600 nm (OD600nm) in an 
automated PowerWave HT microplate spectrophotometer (BioTek Instruments, Inc. 
Winooski, VT) placed in anaerobic chamber. Each experiment was evaluated in biological 
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triplicates with technical triplicates. Negative control consisted of inoculated medium in 
the absence of carbohydrate substrate and PAC fraction. For each carbohydrate and PAC 
combination, blanks were added into the respective wells and color change and degradation 
of polyphenols independent from bacterial fermentation were observed. The bacterial 
growth curves were represented by the subtraction of OD600nm values of blanks of PAC 
fractions from respective OD600nm values of bacterial growths. Growth characteristics were 
determined using growthcurver package in R [231], the obtained kinetics data were 
subjected to one-way ANOVA with Tukey’s HSD test for multiple comparisons.   
In addition to L. plantarum strain, other lactobacilli strains, Lactobacillus johnsonii 
ATCC 33200, Lactobacillus reuteri B-14171, Lactobacillus pentosus B-227, Lactobacillus 
plantarum ATCC 14914 while growing on glucose, HMOs and xyloglucans with PACs 
and bifidobacterial strains Bifidobacterium longum subsp. infantis ATCC 15697, B. 
longum subsp. longum UCD401 and ATCC 15707 while growing on lactose with PACs. 
The strains were acquired from ARS Culture Collection (NRRL) unless stated as ATCC. 
The propagation of other lactobacilli and bifidobacteria cells and microplate growth assay 
were performed as described above.  
6.2.2 Metabolic end product determination  
Cell-free supernatants from microplate growths were obtained at stationary phase 
and filtered through a 0.22 µm filter (Corning Costar Spin-X) following centrifugation and 
stored at -20 °C until further analysis. The secreted metabolites from bacterial fermentation 
were quantitated using an Agilent 1260 Infinity HPLC system (Agilent Technologies, 
Santa Clara, CA) equipped with a Wyatt Optilab T-rEX refractive-index detector (Wyatt 
Technology Corp., Santa Barbara, CA). Separation was carried out using an Aminex HPX-
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87H column (7.8 mm ID x 300 mm, Bio Rad Laboratories, Hercules, CA) at 30 °C in a 
mobile phase of 5 mM H2SO4 at flow rate of 0.6 ml/min with 20 µl of injection volume. 
Standards including organic acids (i.e. acetic acid, lactic acid, formic acid), ethanol were 
acquired from Sigma-Aldrich Co. (St. Louis, MO). Metabolite concentrations were 
calculated from standard curves derived from external standards for six concentrations (0.5, 
1, 5, 10, 20 and 50 mM). Metabolite profiling was carried out in triplicate and each 
measurement was performed in duplicate. 
6.2.3 Determination of phenolic metabolites from cranberry PACs 
 The phenolic metabolites after Lactobacillus plantarum fermentation with PACs 
were determined using UPLC system coupled to an Acquity UV detector and an Acquity 
TQD tandem quadrupole mass spectrometer equipped with Z-spray electrospray interface 
(UPLC/Xevo TQD QQQ-MS, Waters, Milford, MA). We followed the protocol for 
separation as previously published [324, 325, 336]. Briefly, separation was done on a 
Waters BEH C18 column (100 x 1.0 mm id., Waters, Milford, MA) at 40 °C with aqueous 
phase A (2 % acetic acid in water (v/v) and an organic phase B (2% acetic acid in 
acetonitrile v/v) at a flow rate of 0.5 ml/min. The gradient was applied as: 0 min, 0.1% B; 
1.5 min, 0.1% B; 11.17 min, 16.3% B; 11.5 min, 18.4% B; 14 min, 18.4% B; 14.1 min, 
99.9% B; 15.5 min, 99.9% B; 15.6 min, 0.1% B with total run time 18 min. The UV was 
set to 280 nm wavelength. The ESI parameters were as follows: The ESI was operated in 
negative mode with the parameter as: capillary voltage, 3 kV; source temperature, 130 °C; 
desolvation temperature, 400 °C; desolvation gas (N2) flow rate, 750 l/ h; cone gas (N2) 
flow rate, 60 L/h. The MS/MS parameters (cone voltage and collision energy) of for 
analytes were optimized by direct infusion using 10 μg/ml solutions at a flow rate of 5 
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μl/min. The MS/MS conditions for each standard were given in Table A6.1. For 
quantification purposes, 3 groups of standards were prepared for separating their elusion 
times and mass spectra using the multiple reaction monitoring (MRM) mode. Data 
acquisition and processing was carried out by the MassLynx 4.1 software. 
6.2.4 Preparation of transcriptome libraries of L. plantarum growing on PACs by 
RNA-seq 
The cells were grown cells to their mid exponential stage in culture tubes up to 3 
ml and collected approximately after 5 to 6 hours of incubation by measuring their OD in 
nanodrop (Thermo Scientific, Waltham, MA). The OD values differs according to their 
growth on each substrate measured by microplate. The pellets were obtained by 
centrifugation at 16,000 x g for 2 min and resuspended in 500 μl RNAlater solution after 
removal of supernatants. The samples were stored 4 °C overnight and transferred -80 °C. 
For RNA extraction, cells from -80 °C were centrifuged at 12,000 × g for 2 min to collect 
the cell pellet from RNAlater and the pellet washed twice with PBS buffer to remove 
residual RNAlater by centrifuging at 12,000 × g for 2 min. The total RNA was extracted 
using Ambion RNAqeous kit (LifeTechnologies, Carlsbad, CA) according to the 
manufacturer’s instructions with slight modifications. Briefly, the cells were suspended 
with lysis buffer in Lysing Matrix E tubes (MP Biomedicals LLC, Solon, Ohio) to disrupt 
cell walls through beadbeating at 5.5 m/s for 30 s twice using FastPrep 24 bead beader (MP 
Biomedicals, Santa Ana, CA) with 5-min incubation on ice. Total RNA eluted in 50 µl of 
EB solution. After measuring RNA concentration in nanodrop, we proceeded with DNase 
treatment using the Ambion Turbo DNA-free (Invitrogen, Vilnius, Lithuania) using 1 µl 
of DNase I for 30 min. An aliquot of RNA was evaluated for genomic DNA contamination 
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by quantitative pcr using PowerUp Syber Green kit with primers targeted rpoD (Forward: 
5’-GCT TAC GGT TCG GAC TTG ATG-3’ and Reverse: 5’-GCC TTG GCT TCG ATT 
TGG-3’) region in L. plantarum19. For samples with high levels of DNA contamination, 
DNase treatment repeated as same conditions. Another aliquot of RNA was quantified 
RNA using Qubit High Sensitivity RNA Assay Kit and RNA like integrity (RINe) were 
determined on TapeStation 2200 system using High Sensitivity RNA screen tapes and 
reagents (Agilent Technologies, Santa Clara, CA) following the manufacturer’s protocol. 
The samples with RNA like integrity (RINe) more than 7.0 were proceeded with depletion 
of ribosomal RNA with Ribo-zero magnetic kit, bacteria (Illumina). Subsequently, the 
mRNA purification was performed using Qiagen RNaesy Minelute Cleanup according to 
instructions on Illumina protocol. RNA was quantified using the Qubit High Sensitivity 
RNA Assay (Life Technologies, Carlsbad, CA, USA) and rRNA depletion (the presence 
of 16S and 23S peaks) was checked on TapeStation 2200 system. The depleted RNAs (with 
RIN* approximately 1.0) were proceeded with NEBNext Ultra II Directional Library 
preparation kit (New England Biolabs, Inc, Ipswich, MA) following the instructions. The 
purification steps were done following the kit instructions using AmPure XP beads 
(Beckman Coulter, Brea, CA). The samples were indexed using NEBNext® Multiplex 
Oligos for Illumina (Dual Index Primers Set 1, New England Biolabs Inc, Ipswich, MA) 
indexes with PCR cycles of 10. The libraries were quantified using the Qubit double-
stranded DNA (dsDNA) HS assay (Life Technologies, Carlsbad, CA, USA). The quality 
of library products was measured by DNA analysis ScreenTape assay on the TapeStation 
2200 system (Agilent Technologies, Santa Clara, CA). The libraries were pooled in 
equimolar concentration (0.5 nM) and denatured immediately prior to sequencing 
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following Illumina library pool instructions. Sequencing was performed on an Illumina 
NextSeq platform (paired-end, NextSeq reagent kit v3, mid output, 5% Phi-X) at the 
Genomics Resource Laboratory, University of Massachusetts Amherst.  
6.2.5 RNA-seq Analysis 
Transcriptomic data (i.e. raw reads) of from Illumina BaseSpace was uploaded to 
the Massachusetts Green High-Performance Computing Cluster (MGHPCC) that was used 
for all computational/statistical analyses unless specifically noted. The RNA-seq reads 
were aligned to the reference Lactobacillus plantarum WCFS-1 genome (AL935263). 
Coding regions of the L. plantarum genome were used for alignments with bowtie 2. Total 
and unique gene reads aligning to a specific genomic locus (i.e. locus tag), as well as 
calculated raw counts (ht-seq count) was obtained for differential expression analysis.  
6.2.6 Differential gene expression 
In order to identify and quantify the magnitude of differentially expressed genes, 
the R package DESeq2 was used to analyze the raw count data [208]. Genes with a sum 
count < 200 was removed from analysis by pre-filtering. DESeq2 applies the Wald test for 
statistical analysis. Adjusted p-values ≤ 0.05 were defined as statistically significant.  
6.2.7 Functional Enrichment Analysis 
Gene feature fasta file of L. plantarum ATCC BAA793 (AL935263) was used as 
queries in BlastX from the National Center for Biotechnology Information (NCBI). L. 
plantarum protein sequencing database was used for blasting database. The resulting 
BlastX hits files were used to retrieve the functional annotations with OmicsBox (version 
1.1.164) with default settings. For each substrate group, genes were ranked by their 
log2foldchange for gene expression relative to glucose.  The ranked gene lists were 
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analyzed using Gene Set Enrichment Analysis (GSEA) for enrichment with functional 
annotations towards the top of the list (e.g. those most differentially expressed) using 
OmicsBox. Custom scripts were developed to create GSEA input files for different 
functional annotations as GO terms.  
6.3 Results 
6.3.1 High cranberry PAC fractions promotes the growth of L. plantarum on dietary 
oligosaccharides  
We tested different concentrations of PAC fractions on the growth of L. plantarum 
during glucose (Figure A6.1). This showed that different doses of PAC did not significantly 
affect the growth on glucose. Therefore, we chose 1000 mg/ml concentration for the rest 
of the experiments. The growth curves for L. plantarum while growing on glucose, FOS, 
HMOs, and xyloglucans (XG) with two PAC fractions (1000 mg/ml) and PAC fractions 
(1000 mg/ml) alone as carbon source were shown in Figure 6.1 and the growth kinetics 
demonstrated as Table A6.1. While growing in glucose, PAC1 induced the growth of L. 
plantarum (OD600nm=1.48±0.02) compared to glucose only (OD600nm=1.21±0.03) and 
glucose with PAC2 (OD600nm=1.07±0.01) (Figure 6.1A, p<0.05); however it did not grow 
different rate (p>0.05, Table A6.2). Glucose with 1 % DMSO did not show any detrimental 
effect on growth (p>0.05). While L. plantarum showed no growth on FOS (p>0.05 
compared to negative control), addition of PAC1 and PAC2 significantly induced its 
growth (OD600nm=1.02±0.01 and OD600nm=0.25±0.04, Figure 6.1B, p<0.05) and changed 
their growth rate in both PACs (p<0.05, Table A6.2). While PAC1 elevated the L. 
plantarum growth on HMOs (OD600nm=0.59±0.02, p<0.05), growth with PAC2 was not 
significantly different than the HMO only (p>0.05, Figure 6.1C). On the other hand, both 
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PAC1 and PAC2 induced the growth while growing xyloglucans (Figure 6.1D). It is also 
observed that PAC1 alone as carbon source promoted the growth (OD600=0.40±0.02, Figure 
6.1E) but PAC2 was not significantly different than the corresponding negative control 
(p>0.05). In all fermentation conditions except xyloglucans, PAC1 resulted in more 
biomass than PAC2 (p<0.05). This indicates that both PACs depending on the carbohydrate 
source, they enter the carbon-energy conversion in the cell metabolism and promote the 
growth.  
6.3.2 High cranberry PAC fractions alters the fermentative end product formation 
during the growth on oligosaccharides 
End products formed from central carbohydrate metabolism of L. plantarum were 
shown in Figure 6.2. L. plantarum produced mainly lactic acid (140.4±2.7 mM) and small 
amounts of acetic acid (16.2±0.7 mM) when growing on glucose (Figure 6.2A). It has been 
observed that PAC1 and PAC2 did not change both lactic acid (148.4±2.2 mM and 
144.9±8.2 mM) and acetic acid (16.1±0.4 mM and 17.2±1.2 mM) concentrations in glucose 
fermentation (p>0.05, Figure 6.2A). Unlike glucose fermentation, L. plantarum produced 
formic acid, in addition to lactic and acetic acids during oligosaccharide fermentations. 
This phenomenon was observed previously when L. plantarum was growing on cranberry 
oligosaccharides [221]. FOS with PAC2 increased lactic acid concentration (6.2±0.3 mM) 
compare to FOS (4.8±0.5 mM) and FOS with PAC1 (4.5±0.6 mM) fermentations (p<0.05); 
but not formic acid and acetic acid (Figure 6.2B). It is interesting that despite the increased 
growth on FOS with PAC1, it did not favor the carbon metabolism. Decreased 
concentrations of lactic acid were observed in HMO with PAC1 (15.4±0.4 mM) compared 
to HMO (19.6±1.5 mM), HMO with PAC2 (18.9±0.3 mM) (p<0.05, Figure 6.2C) and in 
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PAC1 alone (5.6±0.3 mM) compared to PAC2 alone (7.9±0.9 mM) (p<0.05, Figure 6.2D). 
Similarly, XG with PAC2 significantly increased acetic acid (21.6±1.6 mM) and formic 
acid (4.6±0.4 mM) concentrations compared to XG alone (11.2±0.7 mM and 2.4±0.3 mM) 
and XG with PAC1 (10.3±0.9 mM and 2.7±0.1 mM) (p<0.05, Figure 6.2E). This means 
that PAC2 involves in the central carbon metabolism of L. plantarum; however, the 
metabolites facilitated differ between oligosaccharides fermentations.  
6.3.3 L. plantarum involves in polyphenol degradation and produces phenolic 
metabolites depending on oligosaccharide type 
Phenolic degradation products were profiled by mass spectrometry from the 
supernatants of L. plantarum growing on glucose, FOS, HMOs, xyloglucans (XG) with 
both PACs (Table 6.1). Among 13 metabolites, we observed 11 of them in our samples. 
The composition of two PAC fractions were displayed in Table A6.4. According to Ocean 
Spray method, PAC concentrations were higher in PAC1 fractions. We observed that the 
concentrations of procyanidin dimer B2, epicatechin and procyanidin dimer A2 in pre-
fermentations varies depending on the type of oligosaccharides. It is possible that higher 
degree PACs might be degraded into these compounds variably due to their interaction 
with oligosaccharides during the set-up of the experiment. High amounts of procyanidin 
B2 was observed in pre-fermentations of HMO involving PAC2 and PAC2 alone. Bacterial 
fermentation resulted in degradation of procyanidin dimer B2 more than its simultaneous 
degradation over time, concomitantly production of 3-(3,4-dihydroxyphenyl) propionic 
acid. This metabolite was observed previously as a product of B2 bacterial metabolism 
[337]. This compound also observed in FOS and xyloglucans involving PAC2; however, 
185 
 
no B2 degradation occurred in those samples. This might be due to degradation of higher 
degree PACs into B2 simultaneously.    
Formation of 3-(4-hydroxyphenyl) propionic acid, a product of procyanidin A2 
degradation, was detected in all PAC2 fermentations. This degradation metabolite was not 
observed in no-fermentations. Procyanidin A2 was degraded in both bacterial and no-
fermentations except HMOs. During HMOs, we did not observe degradation of A2. This 
means that although A2 tends to degrade over time, L. plantarum involves in conversion 
to phenolic metabolites.   
Both 4-hydroxyphenylacetic acid and syringic acid were found in all fermentations 
and no-fermentations indicating these metabolites occurs with simultaneous degradation 
of PACs. In addition, there were p-coumaric acid in the pre-fermentations of PAC2; not in 
PAC1. This coincides with the composition of PAC fractions (Table A6.4), that PAC2 
contains higher concentrations of phenolic acids. p-coumaric acid was degraded in PAC2 
bacterial fermentations regardless of carbohydrate source while its concentration stayed 
similar in no-fermentations. This is potentially due to phenolic acid decarboxylation [338].  
In pre-fermentations, epicatechin existed as trace amounts in PAC1 and relatively 
higher amounts in PAC2. After fermentation, we observed a degradation of epicatechin in 
PAC2 bacterial fermentations, but this was also observed in PAC2 no-fermentation 
samples. This means that this precursor compound degraded during fermentation 
conditions.  
Catechol increased in all PAC fermentation while we have seen a decrease in 
protocatechuic acid in all PAC2 fermentations and HMO+PAC1 and XG+PAC1.  
Protocatechuic acid is precursor of catechol formation This also means that L. plantarum 
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involves in protocatechuic acid degradation with simultaneous catechol formation by 
means of alcohol dehydrogenase activity. Adversely, protocatechuic acid increased in 
PAC1 alone and FOS+PAC1. This means that the degradation of another compound 
resulting protocatechuic acid was faster than the conversion of protocatechuic acid to 
catechol formation; therefore, we observed an accumulation. These results showed that L. 
plantarum uses phenolic compounds depending on the type and carbohydrate source.  
6.3.4 Whole transcriptome of L. plantarum differentially responds PAC fractions 
To profile the transcriptional response of L. plantarum to major PACs with 
oligosaccharides, samples were extracted from duplicate cultures at mid exponential phase 
of their growth and glucose was used as a reference. RNAs extracted from samples were 
depleted of ribosomal RNA and used to quantify absolute transcript concentrations using 
RNA sequencing (RNA-seq). RNA-seq experiments were generated over 200 million reads 
in total, with each sample averaging 9.1 million reads. Reads were removed from 16S 
contamination using Silva 16S reference sequence, then were aligned to reference genome 
with NCBI accession number AL935263.  
The alignment rates of reads to genome and coding genes were summarized in 
Table A6.3. Aligned reads to genes were counted using ht-seq count on Massachusetts 
Green High-Performance Computing Cluster (MGHPCC). Then, the raw counts were 
subjected to differential expression analysis using DESeq2 in R.   
We first compared the whole transcriptomes of L. plantarum on every substrate 
with sample to sample distance matrices using hierarchical clustering (Figure 6.3). 
Biological replicates of samples with PACs showed dissimilarities to each other. PAC1 
with oligosaccharides showed similarities with their corresponding oligosaccharide 
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combinations but not PAC2 samples. This might be due to L. plantarum switch the 
metabolism quickly between oligosaccharides to polyphenol.   
Certain genes were highly expressed regardless of the growth conditions (Figure 
6.4, Table A6.5). Genes include ribosomal proteins and elongation factors used in protein 
synthesis were expressed, which provides insights into lactobacillus physiology. One of 
the most transcribed loci across all samples was RNase P, which is a catalytic RNA that 
participates in post-transcriptional modification of tRNA molecules [339]. Interestingly, 
several key enzymes of central metabolic pathway (glycolysis), fructose-bisphosphate 
aldolase (lp_0330), glyceraldehyde-3-phosphate dehydrogenase (lp_0789), pyruvate 
kinase (lp_1897) and formate C-acetyltransferase (lp_3313) were highly expressed among 
all the samples.  
6.3.5 Specific physiological networks are enriched during PAC metabolism  
A Gene Ontology (GO) enrichment analysis was performed to determine biological 
processes, metabolic function, or cellular components responding to PAC fractions. The 
first comparison was made between cells growing on oligosaccharides with PACs and 
glucose as control. The most highly expressed GO terms with normalized enrichment 
scores for each differential expression of log2foldchange were shown in Figure 6.5. Among 
general GO terms nitrogen compound metabolic process was the most enriched network 
on both carbohydrate metabolism of HMOs (Figure A6.2G) and XGs (Figure A6.2J).  L. 
plantarum differentially increased nucleic acid metabolic process, oxidoreductase activity 
and oxidation reduction process during both PAC1 and PAC2 metabolism (Figure 6.5A, 
B). PAC1 differentially increased metal ion bonding, organonitrogen compound 
biosynthetic process and nitrogen compound transport whereas these was not observed in 
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PAC2 metabolism. With HMO carbohydrate metabolism, PAC1 gene expression did not 
change compared to its PAC1 alone. (Figure 6.5D). HMO PAC2 increased hydrolase 
activity (Figure 6.5E) and FOS with PAC2 and XG with PAC2 differentially increased 
carboxylic acid metabolic process (Figure 6.5C, H). Decarboxylation and hydrolases are 
the processes involved in polyphenol metabolism.  
6.3.6 High cranberry polyphenols change the growth phenotype of other lactobacilli 
and bifidobacterial strains on oligosaccharides 
Other lactobacilli and bifidobacterial strains were tested to expand the 
characterization of synergistic effects of oligosaccharides with PACs. The growth curves 
of other lactobacilli while growing on glucose, HMOs and xyloglucans were shown in 
Figure 6.6 and Figure A.6.3. Among 4 additional strains, Lactobacillus johnsonii and 
Lactobacillus plantarum ATCC 14917 showed significant response with PACs. Addition 
of PAC1 significantly induced the growth of L. johnsonii when growing on glucose 
(OD600nm= 0.72±0.01) and xyloglucans (OD600nm= 0.48±0.02) compared to their 
corresponding carbohydrate source alone (Figure 6.6A, p<0.05). In contrast, PAC2 
significantly increased the growth of L. johnsonii on HMO (OD600nm= 0.22±0.02, p<0.05). 
Similarly, PAC2 induced the growth of ATCC 14917 on HMOs (OD600nm= 0.49±0.04, 
p<0.05) whereas PAC1 promoted the growth on xyloglucans (OD600nm= 0.50±0.01, p<0.05) 
(Figure 6.6B). 
PACs did not significantly influence the growth of L. reuteri when growing on 
glucose, xyloglucans and HMOs (Figure A6.3A, p>0.05). PAC1 decreased the growth of 
L. pentosus on glucose (p<0.05) whereas PAC2 did not affect the growth (Figure A6.3B). 
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Both PACs had no impact to the growth of L. pentosus on HMO and xyloglucans (Figure 
A6.3B). 
Unlike lactobacilli strains, the addition of both PACs into the growing media had 
detrimental effect on the growth of Bifidobacterium longum subsp. longum UCD401, 
ATCC 15707 while growing on lactose (Figure A6.4A, B). Only PAC2 diminished the 
growth of B. longum subsp. infantis ATCC 15697 while growing on lactose (Figure 
A6.4C).  
6.4 Discussion 
Both polyphenols and oligosaccharides benefit hosts through their microbiome. 
Commensal bacteria and probiotics use these dietary components to generate energy and 
release metabolites. The synergistic effect of cranberry components needs characterization 
to better target the benefits to host. The role of gut microflora in the catabolism of 
proanthocyanidins and plant oligosaccharides were separately explored using a static 
anaerobic incubation system with freshly collected human colonic fecal bacteria [135, 
139]. A combination of xylooligosaccharides and a polyphenol blend was investigated for 
their effect on microbial composition and activity in a distal colon model [340]. However, 
the catabolic capacity of individual bacteria, that would be a probiotic candidate, is 
understudied. We posit the added effect of cranberry components with the oligosaccharides 
to contribute microbial metabolism within the human gut.   
In the absence of carbohydrate, L. plantarum is usually unable to grow, however, 
both PAC1 and PAC2 increased the growth of L. plantarum in the absence of any 
carbohydrate source. This indicates that both polyphenol fractions involved in energy and 
carbon cycle. In addition, PAC2 increased lactic acid production compared to PAC1 
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metabolism and cell division functions and ATP binding were increased during PAC2 
alone fermentations according to GO terms. During PAC1 fermentations, nitrogen related 
metabolic functions were enriched the most. This might indicate that polyphenol fractions 
involve not just in carbon metabolism but also nitrogen metabolism, which increase the 
growth of L. plantarum. 
PAC1 addition increased the growth during all tested oligosaccharides whereas 
PAC2 only increased during xyloglucan growth. This means that PAC1 facilitates the 
cellular function. Cellular macromolecular biosynthetic processes were enriched during 
PAC1 alone and PAC1 with HMO (Figure 6.5), however PAC1 did not impact the 
metabolite production. Although growth mostly facilitated by the carbohydrate 
metabolism, since nitrogen compound related metabolic processes were enriched in PAC1 
alone and HMO with PAC1 (Figure A6.2), this might indicate that the growth can be also 
facilitated by the nitrogen metabolism. Therefore, there were no carbon metabolite related 
enhancement.  
PAC2 shows growth promotion effect during PAC2 alone, glucose, FOS and 
xyloglucans compared to their corresponding carbon source. In the metabolite production, 
we also observed that lactic acid productions with PAC2 metabolism increased compared 
to their corresponding FOS, HMOs and PAC2 alone. This indicates that PAC2 might 
extend sugar utilization. This was observed previously with catechin added to galactose 
during L. plantarum RM71 [328]. Besides, PAC2 fractions although they are rich in 
proanthocyanidins, it contains 15X higher total anthocyanins. Anthocyanins in plants and 
foods do not exist in free form, all occurring anthocyanins are O-glycosylated with sugar 
substitutes forms of anthocyanidins and when the sugar substitute number is higher than 
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three they can be attached to basic molecules with sugar and acyl linkages [341]. Therefore, 
these sugar linkages can be broken during L. plantarum growth and those sugar can become 
available for central metabolic pathway. This concept coincides with the increased lactic 
acid production. In addition, catechin addition extended sugar uptake [328] and polyphenol 
metabolism might favor cell transport mechanism [330]. During FOS with PAC2 
metabolism, we observed that transmembrane transport activities were enriched.  
During xyloglucan fermentation with PAC2, we observed an increase in formic and 
acetic acid production (Figure 6.2D). When the biomass is low, L. plantarum requires 
heterofermentation to produce more ATP [221]. Similarly, organic acid biosynthesis was 
enriched during XG+PAC2 fermentation (Figure 6.5H).  
L. plantarum incorporate PAC fractions into its both carbon and nitrogen 
metabolism and these activities might be due to degradation of phenolic compounds in 
PAC fraction. Previously, the microbial metabolism of polymeric procyanidins in a static 
batch culture system with fresh fecal inocula resulted in products: 3-(3’hydroxyphenyl) 
propionic acid, 4-hydroxyphenyl acetic acid, 3-(4’-hydroxyphenyl) propionic acid, 3-
pheylpropionic acid [342]. In our current study, L. plantarum metabolism of cranberry 
PACs resulted in occurrence of only 3-(4’-hydroxyphenyl) propionic acid in all PAC2 
fermentations and trace amounts in PAC1 fermentations except XG+PAC1. 4-
hydoxyphenyl acetic acid simultaneously occurred without fermentation except 
xyloglucans. 3-(3’-hydroxyphenyl) propionic acid did not appear in any fermentations. 
This means that L. plantarum is capable of deploying different pathways for degrading 
polyphenols. The theoretical pathway for B2 dimers microbial metabolism was 
demonstrated previously [68, 337] based on the findings on in vitro batch culture fecal 
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fermentations. Cleavage of the C-ring of epicatechin at C2 position or of interflavan bond 
to form epicatechin and oxidization of the A-ring are the initial functions. These 
metabolites are further degraded to valerolactone and valeric acid as intermediate 
metabolites and if the incubation continues, further dehydroxylation and alpha or beta 
oxidation occur to form various forms of phenyl propionic and acetic acids. Since we 
collect the samples at the stationary phase, we do not expect to see the intermediate 
products whereas we expect production of phenyl propionic and acetic acids. According to 
in vitro batch culture fermentations, 3-(3-4’-dihydroxyphenyl) propionic acid and 3-
(3’hydroxyphenyl) propionic acid forms from microbial metabolism of epicatechin, 
procyanidin B2, and procyanidin A2 whereas only A2 leads to 3-(4’-hydroxyphenyl) 
propionic acid formation. 2-(3’,4’-dihydroxyphenyl) acetic acid forms from metabolism of 
both B2 and A2 dimers. On the other hand, L. plantarum catabolized only epicatechin-O-
gallate and resulting in formation of 1-(3′,4′-dihydroxyphenyl)-3-(2″,4″,6″-
trihydroxyphenyl)propan-2-ol. This compound would arise from the reductive cleavage of 
the heterocyclic C-ring of flavan-3-ols [325]. However, in our study, we observed only 
catabolism of procyanidin B2. This means that depending on the type of strain L. plantarum 
deploys different mechanisms to utilize PACs.   
Catabolism of cranberry extract resulted in a decrease in hydroxycinnamic acids, 
including p-coumaric acid as well as hydroxybenzoic acids, including protocatechuic acids, 
an increase in catechol fermentation but not diphenylpropan-2-ol [325]. This coincides 
with our findings. PAC2 fractions contains higher amounts of phenolic acids initially and 
pre-fermentation samples with PAC2 contains higher amounts of p-coumaric acid. The 
degradation of this phenolic acid contains decarboxylation and L. plantarum contains 
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decarboxylases [343, 344]. Although all PAC2 fermentations showed decrease in p-
coumaric acid, only FOS with PAC2 and XG with PAC2 showed carboxylic acid metabolic 
process.  
We observed that the synergistic L. plantarum metabolism on PAC fractions in 
presence of oligosaccharides can be extended to other lactobacilli, such as L. johnsonii and 
L. plantarum ATCC 14917. While PAC2 showed only increase in L. johnsonii growth with 
xyloglucans, this can be extended to HMOs in L. plantarum ATCC 14917. L. johnsonii 
was previously found to degrade ferulic, caffeic, p- coumaric acid as a mode of self-
protection [333]. However, specific mechanisms involved in these activities for these 
species were not studied fully. 
Although B. infantis strains showed promoted growth during cranberry 
oligosaccharide utilization when secondary molecules present, in this study, purified PAC 
fractions decreased their growth. This indicates that we cannot extend the synergistic 
metabolism of PAC with oligosaccharides to phylogenetically close neighbors of 
lactobacilli.  
In conclusion, the development of new prebiotics, with added functionality, is one 
of the most serious challenges shared not only by the scientific community but also by the 
food industry. In this study we showed an added value of cranberry fractions within 
oligosaccharide fermentation of L. plantarum. This study provided detailed interrogation 
of the mechanism underlying the effects of PACs on the L. plantarum physiology. We 
observed that L. plantarum deploys differential mechanism to utilize polyphenols in 
different fractions of cranberry PAC and this is dependent on carbohydrate source.  
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Table 6.1 Phenolic degradation products profiled by mass spectrometry from the supernatants of L. plantarum growing on glucose, 
FOS, HMOs, xyloglucans (XG) with both PACs  
  Alone 
  pre-fermentation post-fermentation no-fermentation 
  P1 P2 P1 P2 P1 P2 
Protocatechuic acid 1.49 7.21 1.93±0.59 2.90±0.37 3.31 9.22 
3,4-dihydroxyphenylacetic acid 0.12 0.12 0.00±0.00 0.09±0.09 0.12 0.18 
4-hydroxyphenylacetic acid 0.46 0.46 0.37±0.17 0.46±0.17 0.53 0.66 
Syringic acid 0.10 0.05 0.10±0.00 0.22±0.08 0.15 0.25 
3-(4-hydroxyphenyl) propionic acid 0.06 0.06 0.12±0.12 49.06±7.34 0.06 0.00 
catechol 0.00 0.00 0.36±0.31 4.61±0.92 0.00 0.00 
3-(3,4-dihydroxyphenyl) propionic acid 0.00 0.00 0.00±0.00 7.93±2.98 0.00 0.00 
 p-coumaric acid 0.06 29.45 0.00±0.00 0.18±0.00 0.00 32.74 
Procyanidin B2 0.00 6.00 0.87±1.52 2.95±2.88 1.75 3.89 
epicatechin 0.66 2.69 0.72±0.09 1.84±±0.33 0.55 1.76 
Procyanidin A2 8.64 6.04 2.61±0.67 4.33±0.60 1.73 3.40 
  Fructo-oligosaccharides 
  pre-fermentation post-fermentation no-fermentation 
  P1 P2 P1 P2 P1 P2 
Protocatechuic acid 1.36 6.17 2.12±0.37 2.60±0.28 7.79 9.74 
3,4-dihydroxyphenylacetic acid 0.12 0.12 0.04±0.07 0.14±0.15 0.00 0.12 
4-hydroxyphenylacetic acid 0.33 0.39 0.37±0.14 0.55±0.10 0.33 0.46 
Syringic acid 0.10 0.00 0.10±0.05 0.19±0.03 0.40 0.66 
3-(4-hydroxyphenyl) propionic acid 0.00 0.06 0.04±0.03 55.32±2.83 0.00 0.00 
catechol 0.00 0.00 0.03±0.05 2.52±0.61 0.00 0.00 
3-(3,4-dihydroxyphenyl) propionic acid 0.00 0.00 0.00±0.00 6.58±2.89 0.00 0.00 
 p-coumaric acid 0.06 30.24 0.00±0.00 0.41±0.04 0.06 31.22 
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Procyanidin B2 0.00 0.05 0.06±0.03 0.22±0.38 0.03 0.02 
epicatechin 0.10 0.38 0.31±0.03 0.97±0.17 0.17 0.45 
Procyanidin A2 0.00 0.05 0.01±0.01 0.07±0.03 0.00 0.09 
  Xyloglucans (Cranberry oligosaccharides) 
 pre-fermentation post-fermentation no-fermentation 
 P1 P2 P1 P2 P1 P2 
Protocatechuic acid 0.23 1.32 0.01±0.00 0.00±0.00 0.32 1.44 
3,4-dihydroxyphenylacetic acid 0.00 0.00 0.00±0.00 0.00±0.00 0.00 0.00 
4-hydroxyphenylacetic acid 0.00 0.00 0.33±0.00 0.33±0.00 0.00 0.00 
Syringic acid 0.03 0.06 0.05±0.02 0.05±0.02 0.03 0.04 
3-(4-hydroxyphenyl) propionic acid 0.00 0.90 0.00±0.00 1.04±0.05 0.00 0.89 
catechol 0.16 0.00 0.39±0.12 1.34±0.11 0.00 0.00 
3-(3,4-dihydroxyphenyl) propionic acid 0.00 0.12 0.12±0.02 1.33±0.14 0.00 0.00 
 p-coumaric acid 0.00 3.91 0.26±0.01 0.44±0.05 0.02 4.02 
Procyanidin B2 0.41 0.44 0.18±0.16 0.35±0.03 0.14 0.28 
epicatechin 0.04 0.09 0.04±0.00 0.07±0.01 0.00 0.03 
Procyanidin A2 2.55 3.96 0.25±0.04 1.90±0.49 0.08 0.55 
 Human milk oligosaccharides 
 pre-fermentation post-fermentation no-fermentation 
 P1 P2 P1 P2 P1 P2 
Protocatechuic acid 1.23 7.79 0.17±0.04 0.28±0.04 2.53 11.88 
3,4-dihydroxyphenylacetic acid 0.12 0.18 0.08±0.07 0.16±0.14 0.00 0.18 
4-hydroxyphenylacetic acid 1.64 1.25 2.50±0.37 1.91±0.34 2.70 2.30 
Syringic acid 0.05 0.05 0.07±0.03 0.27±0.03 0.20 0.20 
3-(4-hydroxyphenyl) propionic acid 0.00 0.06 0.14±0.15 48.94±1.78 0.00 0.06 
catechol 0.00 0.00 2.03±0.52 9.12±2.77 0.00 0.00 
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3-(3,4-dihydroxyphenyl) propionic acid 0.00 0.00 0.00±0.00 6.06±1.34 0.00 0.00 
 p-coumaric acid 0.00 24.94 0.00±0.00 0.16±0.04 0.06 28.54 
Procyanidin B2 0.00 7.02 0.88+0.79 1.18±0.99 0.00 2.99 
epicatechin 0.66 2.55 0.47±0.10 1.14±0.07 0.48 1.66 
Procyanidin A2 5.93 6.82 4.08±0.25 5.77±0.14 7.15 6.63 
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Figure 6.1 L. plantarum growth while utilizing cranberry PACs with 
oligosaccharides. Growth curves of Lactobacillus plantarum ATCC BAA-793 on 
modified MRS containing 1 % (w/v) glucose (A), fructooligosaccharides (FOS) (B), 
human milk oligosaccharides (HMO) (C), xyloglucans (XG) (D) and proantocyanidins 
(PACs) alone (D) and 1 mg/ml PAC fractions. The curves are drawn from average of 
three independent experiments.   
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Figure 6.2 L. plantarum fermentative endproducts while utilizing the cranberry 
xyloglucans. Production of lactic acid, acetic acid, and formic acid during the growth of 
L. plantarum with PAC fractions on glucose (A), fructooligosaccharides (B), human milk 
oligosaccharides (C), xyloglucans (D) and PACs alone (D). Averages from independent 
biological triplicates are shown and bars represent standard deviations of the means. The 
values for organic acid production are expressed in millimolar absolute concentration. 
Asterisks represent the significant difference evaluated by two-way ANOVA and Sidak’s 
multiple comparison test (p<0.05).  
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Figure 6.3 Whole transcriptome distances in substrate responses of L. plantarum. 
The heatmap shows the distances between the L. plantarum whole transcriptomes in 
response to glucose (GLC), cranberry proanthocyanidins (PACs) alone,  
fructooligosaccharides (FOS) with PACs, human milk oligosaccharides (HMOs) with 
PACs and xyloglucans (XG) with PACs The distances calculated are Euclidian distances 
of the regularized log transformation of counts with biological duplicates. The darkness 
of the blue color in the heatmap indicates the degree of similarity, from white (dissimilar) 
to dark blue (most similar). Likewise, the dendograms also show the distances with larger 
branch lengths indicating greater distances.  
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Figure 6.4 Most highly transcribed genes in all datasets in L. plantarum. The heatmap 
shows differential expressions of the L. plantarum whole transcriptomes in response to 
glucose (GLC), cranberry proanthocyanidins (PACs) alone, fructooligosaccharides (FOS) 
with PACs, human milk oligosaccharides (HMOs) with PACs and xyloglucans (XG) with 
PACs The distances calculated are Euclidian distances of the regularized log 
transformation of counts with biological duplicates. The darkness of the red color in the 
heatmap indicates the degree of highly transcribed genes. Likewise, the dendrograms also 
show the distances with larger branch lengths indicating greater distances between the 
whole transcriptomes.  
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Figure 6.5 GO enrichment analysis in response to oligosaccharides with PACs. The 10 most specific GO term differential 
expression are considered through normalized enrichment score (NES) using OmicsBox tools. Higher scores indicate higher 
proportion of up-regulated genes in the pooled PAC1 alone (A), PAC2 alone (B), FOS+PAC2 (C), HMO+PAC1 (D), HMO+PAC2 
(E), HMO (F), XG+PAC1 (G), XG+PAC2 (H), and XG (I) compared to the glucose control. 
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Figure 6.6 Bacterial growth while utilizing oligosaccharides with cranberry PACs. 
Growth curves of Lactobacillus johnsonii (A) and Lactobacillus plantarum ATCC 14917 
(B) on modified MRS containing 1mg/ml PAC fractions and 1 % (w/v) glucose, human 
milk oligosaccharides, xyloglucans and PACs alone. The curves are drawn from average 
of three independent experiments.  
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APENDICIES 
1. SUPPLEMENTARY TABLES 
Table A2.1 Primers used in this study. 
Primer Sequence (5’ – 3’) 
Blon_0393F CCATGTCCCACCGTTACCT 
Blon_0393R CCAGCGACTTCGACATCTTC 
Blon_0881F TCGACAACGACATCAACCAG 
Blon_0881R AGTAGTCCTTGTGGCGCAGA 
Blon_0882F TGGGAGAAGAGCTTCGATGA 
Blon_0882R GAACGGGCCTTCCAGATG 
Blon_0883F TCCAAGAAGATCGAGGACGA 
Blon_0883R CGTAGGGGTTGGTGTACAGG 
Blon_0884F GTCGATCCGAACTTCATCCA 
Blon_0884R ACCGAGGGCACATAGAGGAT 
Blon_0885F GGACTTCTTCGCCTCCATTC 
Blon_0885R GGTCATGAGGGTCATGGAGA 
Blon_2175F ACCAACACGATGCTCTCGAT 
Blon_2175R CCACGAACAGGAACAGGAAG 
Blon_2176F CGTCGTGGCATCGATTATCT 
Blon_2176R TGTTGTAGCCGGTGAAGGTC 
Blon_2177F CGACTACTTCAGCGGACAGG 
Blon_2177R ACGGACAGACCGAGGTTCTT 
Blon_2344F ACCGGTGAGCACGAATACAC 
Blon_2344R TGTAGTCCTTGACGGGATCG 
Blon_2345F CTGAACTCGGTGTGGGTGTT 
Blon_2345R CCAAGCCAGTGAAGAAGTCG 
Blon_2346F GTGGACCTGTCCCTGTACGA 
Blon_2346R CCAAGCCAGTGAAGAAGTCG 
Blon_2347F GTCCCGAGGCAAGTCCTACT 
Blon_2347R AGCTGTCGAGCTTCCTGATG 
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Table A2.2 Function of genes described in Figure 2.5 
Locus_tag Annotation Function 
Blon_0248 alpha-L-fucosidase, GH, family 29 (EC 3.2.1.51) Fucose metabolism 
Blon_0268 GH, family 2 Enzymatic degradation 
Blon_0282 GH, family 13, (EC 3.2.1.1) Starch and sucrose 
metabolism 
Blon_0417 glucose-6-phosphate isomerase (EC 5.3.1.9) Sugar metabolism 
Blon_0426 alpha-L-fucosidase, GH, family 29 Fucose metabolism 
Blon_0459 beta-N-acetylhexosaminidase, GH, family 20 Enzymatic degradation 
Blon_0538 galE, UDP-glucose-4-epimerase (EC 5.1.3.2) Leloir pathway 
Blon_0621 glucan 1,3-beta-glucosidase, GH family 5 Starch and sucrose 
metabolism 
Blon_0625 beta-glucosidase, GH, family 3 Starch and sucrose 
metabolism 
Blon_0645 nanE N-acylglucosamine-6-phosphate 2-epimerase (EC 
5.1.3.9) 
Amino sugar metabolism 
Blon_0732 beta-N-acetylhexosaminidase, GH, family 20 Enzymatic degradation 
Blon_0840 ldh, lactate dehydrogenase, (EC 1.1.1.37) F6PPK pathway 
Blon_0881 nagB, glucosamine-6-P isomerase (EC 3.5.99.6) Amino sugar metabolism 
Blon_0882 nagA, GlcNAc-6-P deacetylase (EC 3.5.1.25) Amino sugar metabolism 
Blon_0883 extracellular solute-binding protein, family 1 ABC transporter 
Blon_0884 binding-protein-dependent transport systems inner 
membrane component 
ABC transporter 
Blon_0885 binding-protein-dependent transport systems inner 
membrane component 
ABC transporter 
Blon_0900 type I glyceraldehyde-3-phosphate dehydrogenase (EC 
1.2.1.12) 
F6PPK pathway 
Blon_1095 tal, transaldolase (EC 2.2.1.2) F6PPK pathway 
Blon_1096 tkt, transketolase (EC 2.2.1.1) F6PPK pathway 
Blon_1100 GH, family 25 Enzymatic degradation 
Blon_1368 ribulose phosphate-3 epimerase (EC 5.1.3.1) F6PPK pathway 
Blon_1654 GH, family 25 Enzymatic degradation 
Blon_1714 pfl, pyruvate formate lyase (EC 1.97.1.4) F6PPK pathway 
Blon_1715 pfl, formate acetyl transferase (EC 2.3.1.54) F6PPK pathway 
Blon_1722 xfp, fructose-6-phosphoketolase (EC 4.1.2.22) F6PPK pathway 
Blon_1731 ack, acetate kinase (EC 2.7.2.1) F6PPK pathway 
Blon_1740 GH, family 13 Starch and sucrose 
metabolism 
Blon_1745 pyk, pyruvate kinase (EC 2.7.1.40) F6PPK pathway 
Blon_1836 eno, enolase (EC 4.2.1.11) F6PPK pathway 
Blon_1843 beta-N-acetylhexosaminidase, GH, family 3 Amino sugar metabolism 
Blon_1905 beta-glucosidase, GH, family 1 Starch and sucrose 
metabolism 
Blon_2016 beta-galactosidase, GH, family 42 Galactose metabolism 
Blon_2062 galK, galactokinase (EC 2.7.1.6) Leloir pathway 
Blon_2063 galT, galactose-1-phosphate uridyltransferase 
(EC:2.7.7.12) 
Leloir pathway 
Blon_2123 beta-galactosidase, GH, family 42 Galactose metabolism 
Blon_2171 galE, UDP-glucose-4-epimerase (EC 5.1.3.2) Leloir pathway 
Blon_2172 galT, galactose-1-phosphate uridyltransferase (EC 
2.7.7.10) 
Leloir pathway 
Blon_2173 nahK, N-acetylhexosamine-1-kinase (EC:2.7.1.162) LNB metabolism 
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Blon_2174 1,3-galactosyl N-acetylhexosamine phosphorylase (EC 
2.4.1.211) 
LNB metabolism 
Blon_2175 binding-protein-dependent transport systems inner 
membrane component 
ABC transporter 
Blon_2176 binding-protein-dependent transport systems inner 
membrane component 
ABC transporter 
Blon_2177 extracellular solute-binding protein, family 1 ABC transporter 
Blon_2184 pgm, phosphoglucomutase, alpha-D-glucose phosphate-
specific (EC 5.4.2.2) 
Amino sugar metabolism 
Galactose metabolism 
Blon_2191 rpi, ribose-5-phosphate isomerase EC 5.3.1.6) F6PPK pathway 
Blon_2334 lacZ, beta-galactosidase, GH, family 2 Galactose metabolism 
Blon_2335 alpha-L-fucosidase 2, GH, family 65 Other glycan degradation 
Blon_2336 alpha-L-fucosidase, GH, family 29 Other glycan degradation 
Blon_2342 binding-protein-dependent transport systems inner 
membrane component 
ABC transporter 
Blon_2344 extracellular solute-binding protein, family 1 ABC transporter 
Blon_2347 extracellular solute-binding protein, family 1 ABC transporter 
Blon_2348 exo-alpha-sialidase Other glycan degradation 
Blon_2350 extracellular solute-binding protein, family 1 ABC transporter 
Blon_2351 extracellular solute-binding protein, family 1 ABC transporter 
Blon_2352 extracellular solute-binding protein, family 1 ABC transporter 
Blon_2354 extracellular solute-binding protein, family 1 ABC transporter 
Blon_2355 beta-N-acetylhexosaminidase, GH, family 20 Enzymatic degradation 
Blon_2411 GH, family 43 Enzymatic degradation 
Blon_2416 beta-galactosidase, GH, family 42 Galactose metabolism 
Blon_2453 GH, family 13 Galactose metabolism 
Blon_2460 GH, family 36 Galactose metabolism 
Blon_2468 endo-beta-N-acetylglucosaminidase, GH, family 20 Enzymatic degradation 
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Table A2.3. Growth kinetics of B. infantis strains while utilizing milk carbohydrates 
calculated with Wolfram Mathematica 10.3a 
Strains/ 
Carbohydrat
e source 
UMA299 UMA300 UMA301 
OD600nm, asym k (h-1) OD600nm, asym k (h-1) OD600nm, asym k (h-1) 
Glucose 0.955±0.083B 0.553±0.005B 0.949±0.055
A 
0.580±0.026A
B 
0.779±0.066C 0.301±0.038C 
Galactose 1.033±0.021A
B 
0.590±0.021A
B 
1.184±0.209
A 
0.753±0.056A 1.224±0.045A
B 
0.625±0.060A 
GlcNAc 0.423±0.092D 0.160±0.007C 0.293±0.080
B 
0.154±0.006C ND ND 
Lactose 1.161±0.024A 0.513±0.009B 0.525±0.161
B 
0.503±0.110B 1.285±0.050A 0.561±0.054AB 
LNT 0.693±0.091C 0.567±0.053B 0.998±0.196
A 
0.719±0.083A 1.006±0.167B
C 
0.443±0.057AB
C 
LNnT 0.708±0.060C 0.680±0.057A 1.300±0.118
A 
0.507±0.049B 0.861±0.042C 0.395±0.138BC 
aThe letters indicate significant differences observed between carbohydrates using one-
way ANOVA and Tukey’s test (p<0.05). ND - not determined.  
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Table A3.1. Growth kinetics of B. infantis strains while utilizing milk carbohydrates 
calculated with growthcurver package in R. 
*The letters represent the significant difference between strains within the same column 
(p<0.05)  
  pooled HMO lactose 2´FL 
  
OD600nm, 
asym Rate (k, h-1) 
OD600nm, 
asym Rate (k, h-1) OD600nm, asym Rate (k, h-1) 
ATCC 
15697 0.55±0.06a  0.76±0.05a 1.33±0.03 0.34±0.03c 0.41±0.11b 0.38±0.06 
UMA299 0.49±0.04a 0.46±0.02c 1.31±0.04 0.35±0.01bc 0.79±0.08a 0.29±0.06 
UMA300 0.34±0.05b 0.23±0.03d 1.14±0.14 0.53±0.03a 0.62±0.06ac 0.32±0.03 
UMA301 0.62±0.08a 0.63±0.01b 1.15±0.28 0.40±0.01b 0.54±0.07bc 0.35±0.00 
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Table A5.1 MALDI-TOF Mass Spectrometry of cranberry xyloglucans with sodium 
adduct ions, composition and tentative assignmentsa 
[M+Na]+ Composition Assigned structure 
923 H3P3 SXG, XSG 
953 H4P2 SGGG 
1055 H3P4 SSG, GSS 
1085 H4P3 GSXG 
1217 H4P4 SSGG 
1247 H5P3 SXGGG 
1379 H5P4 SSGGG 
aH: hexose, P: pentose, G: β-D-glucopyranosyl (β-D-Glcp), X: β-D-Glcp substituted at 
O-6 position with α-D-xylopyranosyl (α-D-Xylp), S: X substituted at O-2 position of α-
D-xylp with α-D-arabinofuranosyl (α-D-Araf). 
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Table A6.1 MS/MS conditions for phenolic metabolites detection[336] 
Compound Retention 
time 
(min) 
[M-H]- 
(m/z) 
m/z Cone 
voltage 
Collision 
Energy 
(V) 
Pyrogallol 1.1 125 79 36 16 
Protocatechuic acid 1.8 153 109 30 12 
Catechol/pyrocatechol 2.6 109 81 44 14 
3,4-dihydroxyphenylacetic acid 2.7 167 123 20 12 
4-hydroxyphenylacetic acid 4.3 151 107 24 6 
3-(3,4-Dihydroxyphenyl)-
propionic acid 
4.4 181 137 32 12 
3-hydroxybenzoic acid 4.5 137 93 30 18 
3-hydroxyphenyl acetic acid 5.0 151 197 25 16 
Syringic acid 5.7 197 182 30 12 
3-(4-hydroxyphenyl)-propionic 
acid 
6.3 165 121 33 12 
p-coumaric acid 6.7 163 119 30 14 
3-(3-hydroxyphenyl)-propionic 
acid 
7.6 165 121 32 12 
Epicatechin 6.31 289 245 34 16 
Procyanidin A2 10.17 575 285 44 24 
Procyanidin A2 10.17 575 449 44 20 
Procyanidin B2 5.26 577 289 36 22 
Procyanidin B2 5.26 577 425 36 12 
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Table A6.2. Growth kinetics of L. plantarum in response to carbohydrates with PACs 
calculated with growthcurver package in R. 
 
*The letters indicate significant differences observed between carbohydrates using one-
way ANOVA and Tukey’s test (p<0.05). 
a: if it is different than corresponding carbon source   
b: if it is different than corresponding PAC alone   
c: if it is different between the two pac within same carbon source  
d: if PAC alone different than negative control  
 
 
 
 
  
  OD600nm, asym RATE   
Glucose 1.21±0.03 0.74±0.03   
Glucose+PAC1  1.48±0.02abc 0.44±0.00b   
Glucose+PAC2 1.07±0.01ab 0.73±0.01b   
FOS 0.10±0.00 2.77±0.26   
FOS+PAC1 1.02±0.01abc 0.23±0.00abc   
FOS+PAC2 0.25±0.04ab 1.05±0.14ab   
HMO 0.34±0.01 0.51±0.01   
HMO+PAC1 0.59±0.02abc 0.66±0.01b   
HMO+PAC2 0.38±0.04b 0.70±0.07b   
XG 0.27±0.02 1.12±0.11   
XG+PAC1 0.48±0.04a 0.83±0.12b   
XG+PAC2 0.50±0.06ab 0.55±0.10ab   
PAC1 alone 0.40±0.02cd 1.78±0.18   
PAC2 alone 0.11±0.01 1.99±0.25   
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Table A6.3. General features of the RNA-seq experiments 
Sample 
Number of 
reads* 
% reads 
aligning to 
genome 
% counts 
mapped to 
genes 
number of 
no feature 
reads 
% counts 
unmapped 
to genes 
LP_GLC_1 9221438 98.79 84.9 1445048 15.7 
LP_GLC_2 12093346 98.77 85.4 1849639 15.3 
LP_PAC1_1 8624612 97.14 63.2 3010386 34.9 
LP_PAC1_2 6599974 96.42 60.9 2399896 36.4 
LP_PAC2_1 6588582 91.35 55.0 2437166 37.0 
LP_PAC2_2 7572692 96.68 62.2 2676866 35.3 
LP_FOSP1_1 6596108 98.43 49.0 3287733 49.8 
LP_FOSP1_2 10096652 99.24 29.6 7214820 71.5 
LP_FOSP2_1 9920768 96.85 57.9 3950811 39.8 
LP_FOSP2_2 7836120 82.17 48.7 2671105 34.1 
LP_HMO_1 2924134 96.4 70.5 786543 26.9 
LP_HMO_2 8705044 99 72.1 2449899 28.1 
LP_HMOP1_1 7736134 93.15 65.2 2249911 29.1 
LP_HMOP1_2 8763882 90.77 67.2 2159683 24.6 
LP_HMOP2_1 8963566 98.55 76.0 2210053 24.7 
LP_HMOP2_2 9104024 98.55 72.4 2496786 27.4 
LP_XG_1 8440096 96.82 62.9 2946760 34.9 
LP_XG_2 8055766 82.13 54.0 2321634 28.8 
LP_XGP1_1 8364220 82.97 71.7 1077865 12.9 
LP_XGP1_2 6524084 55.62 36.3 1290991 19.8 
LP_XGP2_1 8609078 98.17 66.8 2793281 32.4 
LP_XGP2_2 9826372 93.66 66.3 2800076 28.5 
*After 16S cleanup            
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Table A6.4. The composition of Cranberry PAC fractions obtained from Ocean Spray, Inc. 
 
  
Test Unit 
8498 
(PAC2) 
120814 
(PAC1) 
Note 
Total Organic Acid % 2.9 ND   
Total Sugar % 7 2   
Total Phenolic acid mg/kg 134,600 2,500 HPLC method 
Total flavonol mg/kg 60,300 59,200 HPLC method 
PACs-BL DMAC mg/kg 190,500 194,000 
with A2 Dimer as 
standard 
PACs -OSC 
DMAC* 
mg/kg 535,000 832,000 
Ocean Spray 
internal method 
Total Anthocyanin mg/kg 16,300 1,300 HPLC method 
* use PAC from whole fruit as standard 
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Table A6.5. Function of genes associated to highly expressed genes in L. plantarum 
described in Figure 6.4 
 
  
Locus_tag Annotation 
lp_RNA03 misc_RNA 
lp_RNA02 Rnase P RNA 
lp_3170 pm9, phosphoglycerate mutase family protein, EC_number 5.4.2.1 
lp_0330 fba, fructose-bisphosphate aldolase, EC_number 4.1.2.13 
lp_1229 msa, mannose-specific adhesin, LPXTG-motif cell wall anchor 
lp_0789 gapB, glyceraldehyde 3-phosphate dehydrogenase 
lp_3581 lamC, two-component system histidine protein kinase; sensor, EC_number 2.7.3.- 
lp_3580 lamA, two-component system response regulator; accesory gene 
lp_2119 tuf, translation elongation factor Tu 
lp_0737 sigma 54 modulation protein/ribosomal protein S30EA 
lp_1274 ptsI, phosphoenolpyruvate-protein phosphotransferase 
lp_1879 hbsU, DNA-binding protein 
lp_1897 pyk, pyruvate kinase 
lp_rRNA14 23S ribosomal RNA 
lp_rRNA02 23S ribosomal RNA 
lp_rRNA05 23S ribosomal RNA 
lp_3313 pflB, formate C-acetyltransferase 
lp_rRNA11 23S ribosomal RNA 
lp_rRNA08 23S ribosomal RNA 
lp_1230 transcription regulator, MarR family 
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2. SUPPLEMENTARY FIGURES 
 
 
 
Figure A2.1 Consumption of mono- and di-saccharides by B. longum subsp. infantis 
strains. The mono- and di-saccharides consumption in percentages (A) and amount of 
carbon recovered in metabolites in percentages (B) of B. infantis strains subsisting on 
mMRS medium containing 2% (wt/v), glucose (purple), galactose (red), N-
acetylglucosamine (GlcNAc, blue) and lactose (yellow). The data depicts mean ±SD of 
three independent experiments. The asterisks indicate the significant differences between 
strains evaluated by one-way ANOVA and Tukey’s multiple comparison. Single asterisk 
(*) indicates p<0.05, double asterisks (**) p<0.005, triple asterisks (***) p<0.0005. For 
glucose and GlcNAc, the comparison was made between strains consuming those 
carbohydrate sources.  
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Figure A3.1 B. longum subsp. infantis strains fermentative end products while 
utilizing HMOs through the F6PPK pathway. Absolute concentrations of lactic acid 
(A), formic acid (B), acetic acid (C), and 1, 2-propanediol (D). All panels represent B. 
infantis ATCC15697 growing on mMRS medium containing 2% (wt/v) human milk 
oligosaccharides. Averages from independent biological triplicates are shown with bars 
representing standard deviations of the means. The values for organic acid production are 
expressed in millimolar (mM) absolute concentrations. A single asterisk (*) denotes 
significant differences between strain evaluated by one-way ANOVA and Tukey’s 
multiple comparison test (p<0.05). 
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Figure A3.2 B. longum subsp. infantis strainsfermentative end products while 
utilizing HMOs through the F6PPK pathway. Absolute concentrations of lactic acid 
(A), formic acid (B), acetic acid (C), ethanol (D), and 1, 2-propanediol (E) and acetic acid 
to lactic acid ratio (F). All panels represent B. infantis ATCC15697 growing on mMRS 
medium containing 2% (wt/v) 2’fucosyllactose. Averages from independent biological 
triplicates are shown with bars representing standard deviations of the means. The values 
for organic acid production are expressed in millimolar (mM) absolute concentrations. A 
single asterisk (*) denotes significant differences between strains evaluated by one-way 
ANOVA and Tukey’s multiple comparison test (p<0.05). 
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Figure A3.3 HPLC chromatograms of monosaccharides produced after whole cells 
and cell free lysates fermentations of B. infantis strains on LNT and 2 fucosyllactose. 
(A) peaks of glucose and N-acetylglucosamine after LNT fermentation of cell free lysates 
of ATCC 15697 (UMA272) and UMA300. (B) peaks of glucose and N-
acetylglucosamine after LNT fermentation of whole cells of ATCC 15697 (UMA272) 
and UMA300. (C) peaks of glucose and fucose after 2’fucosyllactose fermentation of cell 
free lysates of ATCC 15697 (UMA272) and UMA300. (D) peaks of glucose and fucose 
after 2’fucosyllactose fermentation of whole cells of ATCC 15697 (UMA272) and 
UMA300.  
  
218 
 
 
Figure A4.1 Fermentation parameters (redox potential (mV), pH and absorbance 
unit (AU) monitored over time. Parameters for each set of bioreactors inoculated with 
1st microbiomes derived from baby fecal samples with B. infantis (A) and without B. 
infantis (B) and with 2nd microbiomes derived from baby fecal with B. infantis (C) and 
without B. infantis (D). 
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Figure A4.2 Microbial metabolites produced during the growth of infant fecal 
inoculated microbiomes with and without B. infantis addition on lactose as control 
within a modeled system. Absolute concentrations of (A) lactate, (B) acetate, (C) 
formate, (D) butyrate and (E) propionate in millimolar (mM).  
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Figure A4.3 B. infantis levels during the lactose fermentations. The levels were 
determined by qPCR represented as log (cfu/ml) on microbiomes derived from 1st baby 
fecal and from 2nd baby fecal. B. infantis initially inoculated at 104 cfu/ml at time 0.  
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Figure A4.4 Relative abundances of bacterial phyla (A) and genera (B) of 
microbiomes derived from baby fecal samples which are inoculated into bioreactors 
before B. infantis addition. M1+BI: 1st microbiomes that inoculated into bioreactors 
with B. infantis M1-BI: 1st microbiomes that inoculated into bioreactors without B. 
infantis M2+BI: 2nd microbiomes that inoculated into bioreactors with B. infantis M2-BI: 
2nd microbiomes that inoculated into bioreactors without B. infantis. 
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Figure A4.5 Relative abundances of bacterial phyla (A) and genera (B) during 
lactose fermentations of in vitro modeled microbiomes with and without addition of 
B. infantis.  
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Figure A5.1 Elution profile of cranberry xyloglucans on a sephacryl S-100 HR 16/60 
column, eluted with deionized water. 
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Figure A5.2 1H NMR spectra of cranberry xyloglucan (500 MHz, D2O). The inset 
blue box shows an expanded anomeric region of the 1H NMR spectrum. 
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Figure A5.3 LC-MS analysis of xyloglucans (A) before fermentation and remaining 
post-fermentation by (B) B. longum subsp. longum UCD 401 and (C) Lactobacillus 
plantarum ATCC BAA-793. Shown in the upper left section are the full scan MS of the 
blank control along with the corresponding xyloglucan structures between DP=6-9.  
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Figure A5.4 FL-HPLC chromatograms of xyloglucans (A) before fermentation 
(control) and remaining post fermentation by (B) B. longum subsp. longum UCD 
401.  
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Figure A5.5 LC-MS analysis for specific xyloglucan structures by B. longum subsp. 
longum UCD 401 fermentation. The extracted ion chromatograms (EIC) of xyloglucans 
(A) before incubation (control) and (B) after incubation with B. longum subsp. longum 
UCD 401.   
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Figure A5.6 Abundance of xyloglucan glycoprofiles LC-MS analysis of B. longum 
subsp. longum UCD 401 grown on a medium supplemented with 2 % (w/v) 
cranberry xyloglucans. The quantity of xyloglucans is represented as the percentage of 
extracted ion counts compared to control (t=0) (see Figure A5.5 and Table A5.1 for full 
scan MS and detailed structure of xyloglucans) 
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Figure A5.7 Comparison of utilization of different xyloglucan fractions. (a) the 
growth curve of B. longum subsp. longum UCD 401 on modified MRS containing 2% 
(w/v) A2 fraction (yellow), A6 fraction (blue), purified xyloglucans (green). (b) 
Asymptotic OD (OD600 nm at the stationary level) of B. longum subsp. longum UCD 
401 on A2 and A6 fractions and purified xyloglucans. (c) Asymptotic OD (OD600 nm at 
the stationary level) of B. longum subsp. infantis JCM 1260, B. longum subsp. infantis 
JCM 1272, B. longum subsp. infantis JCM 7007 and B. longum subsp. longum UCD 401 
on A2 and A6 fractions and purified xyloglucans. 
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Figure A5.8. LC-MS analysis of xyloglucans remaining after syntropic interactions 
of B. longum subsp. infantis ATCC 15697 between (A) Lactobacillus plantarum 
ATCC BAA-793, (B) Lactobacillus plantarum ATCC BAA-793 and (C) B. longum 
subsp. longum UCD 401. (see Figure A5.5 for full scan MS and detailed structure of 
xyloglucans remaining after fermentation of three strains).  
231 
 
 
 
Figure A5.9 Genomic regions putatively linked with xyloglucan/arabinoxylose 
utilization in B. longum strains. Gene orthologous annotations for B. longum subsp. 
longum UCD 401 were obtained from genomic sequence available as draft in the Joint 
Genome Institute Integrated Microbiome Genomes and Microbiome platform (IMG). 
Genes are represented by arrows and are colored according to predicted function (not 
depicted according to scale). 
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Figure A5.10 Growth curves of B. longum subsp. infantis JCM 1260, B. longum 
subsp. infantis JCM 1272, B. longum subsp. infantis JCM 7007, B. longum subsp. 
longum JCM 11347, B. longum subsp. longum ATCC 15708, B. longum subsp. 
longum UCD 401 on modified MRS containing 2 % (w/v) arabinose with triplicates. 
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Figure A6.1 Dose-dependent L. plantarum growth while utilizing glucose with 
cranberry PACs. Growth curves of Lactobacillus plantarum ATCC 1BAA793 on 
modified MRS containing 1000-0.125 mg/ml PAC1 (A) and PAC2 (B) fractions with 1 
% (w/v) glucose. The curves are drawn from average of three independent experiments.  
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Figure A6.2 GO enrichment analysis in response to oligosaccharides with PACs. The GO term differential expression is 
considered through normalized enrichment score (NES) using OmicsBox tools. Higher score indicates higher proportion of up-
regulated genes in the pooled PAC1 alone (A), PAC2 alone (B), FOS+PAC2 (C) HMO+PAC1 (D). HMO+PAC2 (E), HMO (F), 
XG+PAC1 (G), XG+PAC2 (H), and XG (I) compared to the glucose control. 
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Figure A6.3 Bacterial growth while utilizing oligosaccharides with cranberry PACs. 
Growth curves of Lactobacillus reuteri (A) and Lactobacillus pentosus (B) on modified 
MRS containing 1000mg/ml PAC fractions and 1 % (w/v) glucose, human milk 
oligosaccharides, xyloglucans and PACs alone. The curves are drawn from average of 
three independent experiments.  
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Figure A6.4 Bacterial growth while utilizing lactose with cranberry PACs. Growth 
curves of Bifidobacterium longum UCD401 (A) and Bifidobacterium longum subsp. 
infantis (B) and Bifidobacterium longum ATCC 15707 on modified MRS containing 
1000mg/ml PAC fractions and 1 % (w/v) lactose. The curves are drawn from average of 
three independent experiments.  
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